1	BACKGROUND	I
2	:	I
3	Ischemic	I
4	heart	I
5	disease	B
6	is	B
7	the	B
8	primary	B
9	cause	B
10	of	B
11	morbidity	B
12	and	B
13	mortality	I
14	among	B
15	diabetics	B
16	,	B
17	especially	B
18	those	O
19	who	O
20	became	B
21	ill	B
22	at	B
23	a	B
24	young	O
25	age	B
26	.	I

1	More	I
2	importantly	I
3	,	B
4	this	I
5	fusion	I
6	converted	I
7	a	B
8	less	B
9	effective	B
10	vaccine	B
11	into	B
12	one	B
13	with	B
14	significant	B
15	potency	B
16	against	I
17	established	I
18	E7	I
19	-	I
20	expressing	I
21	metastatic	B
22	tumors	I
23	.	I

1	Reverse	B
2	transcription	B
3	-	I
4	PCR	B
5	analysis	B
6	of	B
7	mRNA	B
8	from	O
9	patients	B
10	shows	O
11	that	B
12	each	I
13	of	I
14	these	I
15	five	B
16	mutations	B
17	results	B
18	in	B
19	aberrant	B
20	splicing	B
21	.	B

1	Using	I
2	the	I
3	postural	I
4	and	I
5	force	B
6	data	B
7	as	B
8	input	I
9	to	I
10	a	I
11	3	I
12	-	I
13	D	I
14	biomechanical	B
15	model	B
16	,	B
17	the	B
18	lumbosacral	B
19	spinal	I
20	compression	I
21	was	I
22	calculated	B
23	.	B

1	Sequence	B
2	analysis	B
3	revealed	B
4	significant	B
5	differences	B
6	between	B
7	the	B
8	5	B
9	'	B
10	region	B
11	of	B
12	the	B
13	beta	B
14	subunit	O
15	gene	O
16	and	O
17	the	B
18	corresponding	I
19	regions	B
20	of	B
21	the	B
22	homologous	B
23	GlyR	B
24	alpha	B
25	subunit	B
26	genes	O
27	;	B
28	it	B
29	also	B
30	identified	B
31	a	B
32	novel	B
33	exon	B
34	(	B
35	exon	B
36	0	B
37	)	B
38	that	B
39	encodes	B
40	most	I
41	of	I
42	the	I
43	5	I
44	'-	I
45	untranslated	B
46	portion	B
47	of	B
48	the	B
49	GlyR	I
50	beta	B
51	mRNA	B
52	.	O

1	Therefore	I
2	,	B
3	we	B
4	suggested	B
5	that	B
6	both	B
7	proteins	B
8	might	B
9	belong	B
10	to	O
11	the	I
12	PLTP	I
13	family	I
14	.	I

1	Influence	I
2	of	I
3	compression	I
4	therapy	I
5	on	I
6	symptoms	B
7	following	B
8	soft	B
9	tissue	B
10	injury	B
11	from	I
12	maximal	I
13	eccentric	B
14	exercise	B
15	.	B

1	STAT5A	B
2	mutations	B
3	in	B
4	the	B
5	Src	B
6	homology	B
7	2	B
8	(	B
9	SH2	B
10	)	B
11	and	B
12	SH3	I
13	domains	I
14	did	B
15	not	B
16	alter	B
17	the	I
18	BTK	I
19	-	I
20	mediated	I
21	tyrosine	B
22	phosphorylation	B
23	.	I

1	In	B
2	the	B
3	present	B
4	work	B
5	,	B
6	the	B
7	complete	B
8	genome	I
9	sequences	I
10	of	B
11	Pyrococcus	B
12	horikoshii	B
13	and	B
14	Pyrococcus	B
15	abyssi	B
16	,	B
17	two	B
18	species	B
19	in	B
20	a	B
21	genus	B
22	of	O
23	hyperthermophilic	B
24	archaeon	O
25	(	I
26	archaebacterium	B
27	),	B
28	were	B
29	compared	B
30	to	B
31	detect	I
32	large	I
33	genome	I
34	polymorphisms	I
35	linked	I
36	with	I
37	restriction	I
38	-	I
39	modification	I
40	gene	I
41	homologs	B
42	.	B

1	In	B
2	addition	B
3	,	B
4	these	B
5	patients	B
6	show	B
7	both	B
8	quantitative	B
9	and	B
10	qualitative	B
11	differences	B
12	in	B
13	their	B
14	infectious	B
15	microbiological	B
16	spectrum	B
17	,	B
18	mainly	O
19	in	O
20	clean	O
21	-	O
22	contaminated	B
23	,	O
24	contaminated	O
25	and	O
26	dirty	B
27	surgical	B
28	procedures	B
29	.	I

1	p42MAPK	O
2	signalings	O
3	are	O
4	required	O
5	for	O
6	the	O
7	HBx	O
8	-	O
9	induced	O
10	Sp1	O
11	-	O
12	mediated	B
13	IGF	I
14	-	O
15	II	O
16	P4	O
17	transcriptional	O
18	activity	O
19	since	O
20	(	O
21	i	O
22	)	O
23	PKC	O
24	activation	O
25	by	O
26	PMA	B
27	or	I
28	PKC	O
29	expression	O
30	vector	O
31	increases	O
32	Sp1	O
33	phosphorylation	B
34	and	O
35	P4	O
36	activity	O
37	in	O
38	HBx	O
39	-	O
40	transfected	O
41	HepG2	O
42	cells	O
43	;	O
44	(	O
45	ii	O
46	)	O
47	PKC	O
48	inhibition	O
49	by	O
50	PKC	O
51	inhibitor	O
52	Go6976	O
53	reduces	O
54	Sp1	O
55	phosphorylation	O
56	,	O
57	P4	O
58	activity	O
59	,	O
60	and	O
61	IGF	O
62	-	O
63	II	O
64	mRNA	O
65	in	O
66	HBx	O
67	-	O
68	transfected	O
69	HepG2	O
70	cells	O
71	;	O
72	and	O
73	(	O
74	iii	O
75	)	O
76	the	O
77	inhibition	O
78	of	O
79	MEK	O
80	activation	O
81	by	O
82	U0126	O
83	reduces	O
84	Sp1	O
85	phosphorylation	O
86	,	O
87	P4	O
88	activity	O
89	and	O
90	IGF	O
91	-	O
92	II	O
93	mRNA	O
94	in	O
95	HBx	O
96	-	O
97	transfected	O
98	HepG2	O
99	cells	O
100	.	O
1	We	B
2	show	B
3	that	B
4	p73	B
5	can	B
6	transcriptionally	B
7	inhibit	B
8	a	B
9	number	B
10	of	B
11	cellular	B
12	and	B
13	viral	B
14	promoters	B
15	.	I

1	Similarly	B
2	,	B
3	curcumin	B
4	(	B
5	diferuloylmethane	B
6	),	B
7	an	B
8	anti	B
9	-	B
10	inflammatory	B
11	agent	B
12	,	B
13	suppressed	B
14	OSM	B
15	-	B
16	stimulated	B
17	STAT1	O
18	phosphorylation	O
19	,	B
20	DNA	B
21	-	O
22	binding	B
23	activity	O
24	of	O
25	STAT1	O
26	,	O
27	and	O
28	c	I
29	-	I
30	Jun	I
31	N	I
32	-	I
33	terminal	I
34	kinase	I
35	activation	B
36	without	B
37	affecting	B
38	JAK1	B
39	,	B
40	JAK2	O
41	,	B
42	JAK3	B
43	,	B
44	ERK1	B
45	/	B
46	2	B
47	,	B
48	and	B
49	p38	B
50	phosphorylation	I
51	.	I

1	The	I
2	effects	B
3	of	B
4	the	B
5	transfected	B
6	receptors	B
7	were	B
8	associated	B
9	with	B
10	antagonism	I
11	of	I
12	activator	B
13	protein	B
14	1	B
15	(	B
16	AP	B
17	-	B
18	1	B
19	)	B
20	activity	B
21	.	O

1	Furthermore	I
2	,	I
3	the	I
4	soluble	I
5	forms	I
6	of	I
7	ATF6	B
8	and	B
9	the	B
10	G13	B
11	gene	B
12	product	B
13	are	B
14	unable	B
15	to	I
16	bind	I
17	to	I
18	several	I
19	point	I
20	mutants	I
21	of	B
22	the	B
23	cis	I
24	-	I
25	acting	I
26	ER	I
27	stress	B
28	response	B
29	element	B
30	in	B
31	vitro	B
32	that	B
33	hardly	B
34	respond	B
35	to	I
36	ER	I
37	stress	I
38	in	B
39	vivo	I
40	.	I

1	PURPOSE	I
2	:	I
3	The	I
4	objective	I
5	of	I
6	this	I
7	study	B
8	was	B
9	to	B
10	assess	I
11	first	B
12	embryo	B
13	cleavage	B
14	(	B
15	FEC	B
16	)	B
17	25	I
18	-	I
19	27	I
20	h	B
21	after	B
22	intracytoplasmic	B
23	sperm	B
24	injection	B
25	(	I
26	ICSI	B
27	)	B
28	as	B
29	a	B
30	parameter	B
31	for	B
32	the	B
33	embryo	B
34	selection	B
35	process	I
36	.	I

1	RESULTS	B
2	:	I
3	A	I
4	significant	I
5	correlation	I
6	(	B
7	p	B
8	<	B
9	0	B
10	.	I
11	001	I
12	)	I
13	was	B
14	observed	I
15	for	B
16	mean	I
17	wall	B
18	thickness	B
19	and	I
20	vessel	I
21	wall	B
22	area	I
23	between	I
24	MRI	I
25	and	I
26	histopathology	I
27	(	I
28	r	B
29	=	B
30	0	I
31	.	I
32	87	I
33	and	I
34	r	I
35	=	I
36	0	I
37	.	I
38	85	I
39	,	B
40	respectively	B
41	).	B

1	Molecular	I
2	cloning	B
3	,	B
4	genomic	B
5	mapping	B
6	,	B
7	and	I
8	expression	I
9	of	B
10	two	B
11	secretor	B
12	blood	B
13	group	O
14	alpha	B
15	(	B
16	1	B
17	,	B
18	2	B
19	)	B
20	fucosyltransferase	B
21	genes	O
22	differentially	I
23	regulated	I
24	in	I
25	mouse	I
26	uterine	B
27	epithelium	B
28	and	B
29	gastrointestinal	B
30	tract	I
31	.	I

1	We	B
2	show	B
3	that	B
4	several	B
5	heme	B
6	-	I
7	responsive	I
8	mechanisms	B
9	combine	B
10	to	B
11	regulate	I
12	DAN	I
13	/	B
14	TIR	B
15	gene	B
16	expression	B
17	.	I

1	No	B
2	'	B
3	TATA	B
4	'	B
5	motif	B
6	was	O
7	identified	O
8	near	O
9	either	O
10	the	O
11	GABPalpha	O
12	or	O
13	ATPsynCF6	B
14	transcription	O
15	start	O
16	sites	O
17	.	O

1	These	B
2	results	B
3	indicate	B
4	the	B
5	presence	B
6	of	B
7	TATA	B
8	-	B
9	unified	B
10	transcription	B
11	systems	I
12	in	I
13	contemporary	I
14	eukaryotes	B
15	and	I
16	provide	I
17	insight	I
18	into	I
19	the	I
20	residual	I
21	need	I
22	for	I
23	TBP	B
24	by	I
25	all	B
26	three	B
27	Pols	B
28	in	B
29	other	B
30	eukaryotes	B
31	despite	B
32	a	B
33	lack	B
34	of	B
35	TATA	B
36	elements	B
37	in	B
38	their	B
39	promoters	B
40	.	I

1	Different	B
2	thermoluminescent	B
3	detectors	B
4	(	B
5	TLD	B
6	)	B
7	have	B
8	been	B
9	used	B
10	to	I
11	measure	I
12	the	I
13	contribution	I
14	of	B
15	the	B
16	low	B
17	linear	B
18	energy	B
19	transfer	B
20	component	B
21	(	B
22	LET	B
23	<	B
24	10	O
25	keV	O
26	/	O
27	micrometer	O
28	)	O
29	and	O
30	plastic	B
31	nuclear	B
32	track	B
33	detectors	B
34	(	O
35	PNTD	O
36	)	O
37	for	O
38	the	O
39	high	O
40	linear	O
41	energy	O
42	tranfer	O
43	(	O
44	LET	O
45	)	O
46	component	O
47	.	O

1	However	B
2	,	B
3	the	B
4	beta5L	B
5	splice	B
6	variant	B
7	was	B
8	found	B
9	only	B
10	in	B
11	the	B
12	retina	B
13	.	B

1	This	B
2	analysis	B
3	supports	B
4	the	B
5	use	B
6	of	B
7	fluticasone	B
8	propionate	I
9	88	B
10	microg	I
11	twice	I
12	daily	I
13	as	I
14	first	I
15	-	I
16	line	B
17	treatment	B
18	in	I
19	patients	B
20	with	B
21	persistent	I
22	asthma	I
23	previously	B
24	treated	B
25	with	B
26	short	B
27	-	B
28	acting	I
29	beta2	I
30	-	I
31	agonist	I
32	alone	B
33	.	B

1	The	I
2	mice	I
3	are	I
4	phenotypically	I
5	normal	B
6	and	I
7	do	B
8	not	B
9	develop	B
10	spontaneous	I
11	tumors	I
12	at	I
13	an	I
14	early	I
15	age	I
16	,	B
17	in	B
18	contrast	B
19	to	I
20	knock	I
21	-	I
22	out	I
23	(	B
24	p53	B
25	(-/-))	B
26	strains	I
27	with	I
28	a	B
29	defective	B
30	p53	B
31	gene	B
32	.	I

1	Furthermore	I
2	,	I
3	stable	I
4	expression	B
5	of	B
6	a	B
7	constitutively	B
8	active	I
9	form	I
10	of	I
11	chicken	B
12	Notch1	I
13	or	I
14	Notch2	I
15	in	I
16	a	I
17	B	B
18	cell	B
19	line	B
20	results	B
21	in	B
22	a	B
23	down	B
24	-	I
25	regulation	I
26	of	B
27	surface	B
28	IgM	I
29	expression	I
30	,	B
31	which	B
32	is	B
33	accompanied	B
34	by	I
35	the	I
36	reduction	I
37	of	I
38	IgH	I
39	gene	I
40	transcripts	I
41	.	I

1	On	I
2	Cox	B
3	proportional	B
4	hazards	B
5	regression	B
6	adenocarcinoma	B
7	(	B
8	P	I
9	=	I
10	0	I
11	.	I
12	006	I
13	),	I
14	the	I
15	development	B
16	of	B
17	BPF	B
18	(	B
19	P	I
20	=	I
21	0	I
22	.	I
23	003	I
24	),	B
25	older	B
26	age	B
27	(	B
28	P	I
29	=	I
30	0	I
31	.	I
32	03	I
33	)	I
34	and	I
35	higher	I
36	pathological	B
37	stage	B
38	(	B
39	P	I
40	=	I
41	0	I
42	.	I
43	02	I
44	)	B
45	were	B
46	independent	B
47	adverse	B
48	predictors	B
49	of	B
50	survival	B
51	.	B

1	We	B
2	found	I
3	that	B
4	RhoA	B
5	can	B
6	initiate	I
7	a	B
8	linear	I
9	kinase	B
10	cascade	B
11	leading	I
12	to	I
13	the	I
14	activation	I
15	of	B
16	ERK6	B
17	(	B
18	p38	B
19	gamma	B
20	),	B
21	a	B
22	recently	B
23	identified	B
24	member	I
25	of	I
26	the	I
27	p38	B
28	family	B
29	of	B
30	MAPKs	B
31	.	B

1	Twenty	I
2	-	I
3	six	I
4	(	I
5	55	I
6	%)	I
7	(	I
8	95	B
9	%	B
10	CI	B
11	,	B
12	41	B
13	-	B
14	69	B
15	%)	B
16	patients	B
17	experienced	B
18	>	B
19	or	I
20	=	I
21	grade	I
22	3	I
23	acute	I
24	toxicity	I
25	(	I
26	RTOG	I
27	).	B

1	We	B
2	hypothesize	B
3	that	B
4	proprioception	B
5	may	B
6	be	B
7	used	B
8	to	I
9	calibrate	I
10	the	I
11	efference	B
12	copy	B
13	during	B
14	development	B
15	and	B
16	in	B
17	response	I
18	to	I
19	perturbations	I
20	by	I
21	signaling	I
22	potential	B
23	mismatches	B
24	between	B
25	eye	B
26	movement	I
27	information	I
28	derived	I
29	from	I
30	the	I
31	efferent	I
32	command	I
33	and	I
34	the	I
35	actual	I
36	motion	B
37	of	B
38	the	B
39	eye	B
40	transduced	B
41	by	B
42	the	B
43	proprioceptive	I
44	organs	I
45	.	I

1	Thus	B
2	,	B
3	BALB	I
4	/	B
5	c	I
6	mice	I
7	appear	I
8	to	I
9	be	I
10	the	I
11	most	I
12	appropriate	I
13	strain	B
14	of	B
15	mice	I
16	to	I
17	perform	I
18	studies	I
19	on	B
20	the	B
21	possible	I
22	connection	I
23	between	I
24	infection	I
25	with	I
26	T	B
27	.	B
28	canis	I
29	and	I
30	allergic	I
31	asthma	B
32	.	B

1	They	B
2	correspond	B
3	to	I
4	nucleotides	I
5	equivalent	I
6	to	I
7	base	I
8	-	I
9	pair	I
10	C1	B
11	-	B
12	G72	I
13	and	I
14	discriminator	I
15	base	B
16	A73	B
17	in	B
18	the	I
19	amino	I
20	acid	B
21	-	I
22	acceptor	B
23	branch	B
24	of	B
25	the	B
26	molecule	B
27	.	B

1	Our	B
2	results	B
3	suggest	I
4	that	I
5	the	I
6	central	I
7	role	I
8	of	I
9	the	I
10	Notch	I
11	-	I
12	CBF1	I
13	/	B
14	RBP	B
15	-	I
16	Jkappa	B
17	signaling	B
18	pathway	B
19	in	B
20	cell	B
21	fate	B
22	decisions	B
23	renders	B
24	it	B
25	susceptible	B
26	to	B
27	pathways	I
28	of	I
29	viral	B
30	replication	B
31	and	B
32	oncogenic	I
33	conversion	B
34	.	I

1	High	B
2	-	B
3	affinity	B
4	binding	B
5	of	B
6	NF	B
7	-	B
8	1	B
9	to	I
10	PSE	I
11	-	I
12	B	I
13	,	B
14	but	B
15	not	B
16	to	I
17	PSE	I
18	-	I
19	A	I
20	,	B
21	was	B
22	confirmed	B
23	by	B
24	competition	B
25	of	B
26	DNA	B
27	-	B
28	protein	B
29	interactions	B
30	by	I
31	using	I
32	NF	I
33	-	I
34	1	B
35	DNA	B
36	elements	B
37	and	B
38	antibodies	B
39	.	I

1	The	I
2	first	B
3	case	B
4	of	B
5	HCV	B
6	seroconversion	B
7	in	B
8	Portugal	B
9	after	B
10	the	B
11	introduction	B
12	of	B
13	HCV	B
14	NAT	B
15	screening	B
16	.	I

1	Substitutions	B
2	in	B
3	the	B
4	YFV	B
5	Ag	B
6	-	B
7	binding	B
8	region	B
9	(	B
10	ABR	B
11	)	B
12	occur	B
13	at	B
14	four	B
15	of	O
16	the	O
17	eight	B
18	highly	O
19	conserved	O
20	residues	O
21	that	O
22	are	O
23	essential	O
24	for	O
25	binding	O
26	of	O
27	peptide	O
28	-	O
29	Ag	O
30	in	O
31	the	O
32	class	O
33	Ia	O
34	molecules	B
35	.	I

1	The	I
2	Novacor	I
3	Left	I
4	Ventricular	B
5	Assist	B
6	System	B
7	(	B
8	LVAS	B
9	)	B
10	(	B
11	Novacor	B
12	Corp	I
13	,	B
14	Oakland	B
15	,	B
16	CA	B
17	)	B
18	was	B
19	initially	O
20	console	B
21	-	I
22	based	B
23	and	I
24	has	B
25	been	B
26	available	I
27	since	I
28	1993	I
29	in	I
30	a	I
31	wearable	B
32	configuration	B
33	.	I

1	Ileal	B
2	digestibilities	B
3	of	B
4	DM	B
5	,	B
6	OM	B
7	,	B
8	CP	B
9	,	B
10	total	B
11	dietary	O
12	fiber	B
13	(	B
14	TDF	B
15	),	B
16	fat	I
17	and	I
18	gross	I
19	energy	B
20	(	B
21	GE	B
22	)	B
23	were	B
24	lower	B
25	(	B
26	P	I
27	<	I
28	0	B
29	.	I
30	05	I
31	)	B
32	for	B
33	dogs	B
34	fed	B
35	diets	B
36	containing	B
37	supplemental	I
38	fiber	I
39	compared	B
40	with	B
41	dogs	B
42	fed	B
43	the	I
44	control	I
45	diet	I
46	.	I

1	In	B
2	addition	B
3	,	B
4	the	B
5	consensus	B
6	amino	I
7	acid	B
8	motif	B
9	for	B
10	serine	B
11	threonine	B
12	receptor	B
13	kinases	B
14	was	B
15	also	B
16	present	B
17	.	B

1	Here	I
2	,	I
3	we	B
4	show	B
5	that	B
6	the	B
7	phorbol	B
8	ester	I
9	PMA	I
10	decreases	I
11	both	I
12	basal	B
13	and	B
14	dexamethasone	I
15	/	I
16	cAMP	B
17	-	I
18	induced	B
19	expression	B
20	of	B
21	a	B
22	luciferase	B
23	gene	B
24	under	I
25	the	I
26	control	I
27	of	I
28	the	B
29	G6Pase	B
30	promoter	B
31	in	B
32	transiently	B
33	transfected	B
34	H4IIE	B
35	hepatoma	B
36	cells	B
37	.	O

1	The	I
2	difference	B
3	between	B
4	the	B
5	patients	B
6	and	B
7	the	I
8	controls	I
9	was	I
10	statistically	I
11	significant	I
12	(	I
13	p	I
14	=	I
15	0	I
16	.	I
17	03	I
18	).	I

1	Altogether	B
2	,	B
3	we	B
4	confirm	B
5	that	B
6	all	B
7	genes	O
8	of	B
9	the	B
10	Rad52	I
11	recombinational	I
12	repair	I
13	pathway	I
14	are	B
15	required	B
16	for	B
17	the	B
18	survival	B
19	of	B
20	rad27	B
21	Delta	O
22	strains	O
23	at	O
24	both	O
25	permissive	O
26	(	B
27	23	I
28	degrees	I
29	C	B
30	)	B
31	and	B
32	semipermissive	B
33	(	B
34	30	I
35	degrees	I
36	C	B
37	)	B
38	temperatures	B
39	for	B
40	growth	B
41	.	O

1	Neuron	B
2	-	I
3	specific	I
4	Bcl	I
5	-	I
6	2	I
7	homology	B
8	3	I
9	domain	B
10	-	B
11	only	B
12	splice	B
13	variant	B
14	of	B
15	Bak	B
16	is	B
17	anti	B
18	-	B
19	apoptotic	B
20	in	O
21	neurons	B
22	,	B
23	but	B
24	pro	I
25	-	I
26	apoptotic	B
27	in	B
28	non	B
29	-	B
30	neuronal	B
31	cells	B
32	.	B

1	The	I
2	mechanism	I
3	of	B
4	the	B
5	induction	I
6	of	I
7	3beta	I
8	-	I
9	HSD	I
10	type	B
11	1	B
12	gene	B
13	expression	B
14	was	B
15	further	B
16	characterized	O
17	in	O
18	ZR	B
19	-	B
20	75	B
21	-	I
22	1	B
23	human	B
24	breast	B
25	cancer	B
26	cells	B
27	.	O

1	Contagious	B
2	bovine	B
3	pleuropneumonia	B
4	is	B
5	a	B
6	major	B
7	threat	B
8	for	B
9	cattle	B
10	in	B
11	Africa	I
12	.	I

1	Treatment	I
2	includes	B
3	both	B
4	medical	B
5	and	B
6	surgical	B
7	options	B
8	,	B
9	with	B
10	medical	B
11	therapy	I
12	further	B
13	subclassified	B
14	into	B
15	pharmacologic	B
16	and	B
17	pneumatic	B
18	dilation	B
19	.	B

1	Since	B
2	the	B
3	latter	B
4	is	B
5	very	B
6	small	B
7	for	B
8	physiological	B
9	flows	B
10	,	B
11	the	B
12	result	I
13	is	I
14	that	I
15	alpha	B
16	<	B
17	1	B
18	even	B
19	at	O
20	relatively	O
21	high	O
22	values	O
23	of	O
24	the	O
25	Reynolds	O
26	number	O
27	(	O
28	i	O
29	.	O
30	e	I
31	.,	I
32	for	I
33	non	B
34	-	I
35	negligible	B
36	inertia	B
37	)	B
38	and	B
39	we	B
40	validate	O
41	our	I
42	perturbation	B
43	theory	B
44	results	B
45	by	I
46	comparison	I
47	with	I
48	a	B
49	numerical	B
50	integration	B
51	of	B
52	the	B
53	full	B
54	model	B
55	.	B

1	This	B
2	plus	B
3	the	B
4	reduced	B
5	phosphorylation	B
6	of	B
7	p27	B
8	by	I
9	MAPK	I
10	enhanced	B
11	the	B
12	stability	B
13	of	B
14	p27	I
15	that	I
16	associated	B
17	with	B
18	nuclear	B
19	Cdk2	B
20	at	B
21	high	B
22	stoichiometry	B
23	and	B
24	inhibited	B
25	its	B
26	kinase	B
27	activity	B
28	.	B

1	Similar	I
2	data	B
3	were	B
4	also	B
5	obtained	B
6	when	B
7	either	B
8	dominant	B
9	negative	B
10	EGFR	I
11	-	I
12	CD533	B
13	or	I
14	dominant	I
15	negative	I
16	Ras	I
17	N17	B
18	were	B
19	used	B
20	to	I
21	block	I
22	MAPK	I
23	activation	I
24	.	I

1	The	I
2	assay	I
3	herein	I
4	described	I
5	allows	B
6	the	B
7	comparison	B
8	of	B
9	relative	B
10	FGFR	B
11	expression	B
12	levels	B
13	,	B
14	both	B
15	within	B
16	a	B
17	single	O
18	RNA	B
19	pool	I
20	and	I
21	among	I
22	multiple	I
23	RNA	I
24	pool	I
25	samples	I
26	.	I

1	This	B
2	was	B
3	most	B
4	pronounced	B
5	during	B
6	the	B
7	initial	B
8	phase	B
9	of	B
10	Erk	B
11	activation	B
12	.	O

1	DESIGN	B
2	:	I
3	Prospective	I
4	cohort	B
5	study	B
6	with	B
7	a	B
8	20	B
9	y	B
10	follow	B
11	-	B
12	up	B
13	period	B
14	,	B
15	the	B
16	First	B
17	National	I
18	Health	I
19	and	I
20	Examination	B
21	Survey	I
22	(	I
23	NHANES	I
24	1	B
25	)	B
26	Epidemiologic	B
27	Follow	I
28	-	I
29	up	I
30	Study	B
31	(	B
32	NHEFS	B
33	).	B

1	To	I
2	assess	B
3	the	I
4	maximum	I
5	oxygen	I
6	uptake	I
7	(	I
8	V	I
9	'	B
10	O2	B
11	max	B
12	)	B
13	of	B
14	Hong	B
15	Kong	B
16	Chinese	B
17	children	B
18	and	B
19	to	I
20	explore	I
21	its	I
22	association	I
23	with	I
24	respiratory	I
25	illnesses	I
26	,	B
27	we	B
28	conducted	B
29	the	B
30	Multistage	B
31	Fitness	B
32	Test	B
33	(	B
34	MFT	B
35	),	B
36	a	B
37	20	B
38	-	B
39	m	B
40	shuttle	B
41	run	B
42	test	I
43	,	I
44	in	B
45	1	B
46	,	B
47	427	B
48	schoolchildren	B
49	aged	B
50	between	B
51	8	B
52	-	B
53	12	B
54	years	B
55	.	I

1	After	B
2	all	B
3	doses	B
4	of	B
5	d	B
6	-	O
7	amphetamine	B
8	,	B
9	responding	O
10	occurred	O
11	largely	O
12	on	O
13	the	O
14	saline	O
15	key	O
16	under	O
17	both	I
18	schedules	B
19	.	I

1	A	B
2	novel	B
3	myeloid	B
4	-	B
5	restricted	B
6	zebrafish	B
7	CCAAT	B
8	/	B
9	enhancer	B
10	-	B
11	binding	B
12	protein	B
13	with	B
14	a	B
15	potent	B
16	transcriptional	B
17	activation	B
18	domain	B
19	.	O

1	METHODS	B
2	:	I
3	Humphrey	B
4	Field	B
5	Analyzer	B
6	model	B
7	630	B
8	(	B
9	HFA	B
10	I	B
11	,	B
12	program	B
13	30	I
14	-	I
15	2	I
16	with	I
17	a	B
18	rectangular	B
19	6	I
20	degrees	B
21	x	I
22	6	I
23	degrees	B
24	grid	B
25	)	B
26	was	B
27	used	B
28	as	B
29	the	I
30	conventional	B
31	perimetric	B
32	method	B
33	.	O

1	These	B
2	data	B
3	reveal	B
4	a	B
5	complex	B
6	network	B
7	of	B
8	interactions	B
9	between	B
10	GTPases	B
11	in	B
12	the	B
13	ARF	I
14	family	I
15	and	I
16	their	I
17	effectors	I
18	and	I
19	reveal	I
20	a	B
21	potential	B
22	for	B
23	cross	B
24	-	B
25	talk	I
26	not	I
27	demonstrated	I
28	previously	B
29	.	B

1	Net	B
2	lift	B
3	and	I
4	combined	I
5	drag	B
6	from	I
7	all	B
8	8	B
9	bearings	B
10	of	B
11	the	B
12	4	B
13	-	B
14	bladed	B
15	impeller	B
16	are	O
17	compared	B
18	with	O
19	predictions	B
20	based	B
21	on	B
22	2	B
23	-	B
24	D	I
25	theory	B
26	.	O

1	In	B
2	the	B
3	course	I
4	of	I
5	screening	B
6	for	B
7	transcription	B
8	factors	B
9	which	B
10	interact	B
11	with	B
12	the	B
13	human	B
14	myeloperoxidase	B
15	(	B
16	MPO	B
17	)	B
18	promoter	B
19	we	B
20	,	O
21	for	O
22	the	O
23	first	O
24	time	O
25	,	O
26	identified	O
27	and	O
28	cloned	B
29	the	O
30	cDNA	I
31	and	I
32	genomic	I
33	DNA	B
34	for	B
35	human	B
36	HBP1	B
37	(	B
38	HMG	B
39	-	B
40	Box	B
41	containing	B
42	protein	B
43	1	B
44	),	B
45	a	B
46	member	B
47	of	B
48	the	B
49	high	B
50	mobility	B
51	group	B
52	of	B
53	non	B
54	-	B
55	histone	B
56	chromosomal	B
57	proteins	B
58	.	B

1	Therefore	I
2	,	B
3	vitamin	B
4	D3	B
5	analogues	B
6	have	B
7	a	B
8	substantial	B
9	antipsoriatic	I
10	effect	I
11	.	I

1	Methylation	B
2	at	B
3	both	B
4	cytosine	B
5	residues	B
6	in	B
7	the	B
8	E2F	B
9	element	B
10	((	B
11	m	B
12	)	B
13	CG	B
14	(	B
15	m	B
16	)	B
17	CG	B
18	)	B
19	generated	B
20	a	O
21	new	O
22	methylcytosine	O
23	-	O
24	specific	O
25	DNA	O
26	-	O
27	protein	O
28	complex	B
29	.	I

1	Hepatitis	I
2	A	B
3	infected	B
4	food	B
5	handler	B
6	at	B
7	an	B
8	Edmonton	B
9	,	B
10	Alberta	B
11	retail	B
12	food	B
13	facility	B
14	:	I
15	public	I
16	health	B
17	protection	B
18	strategies	B
19	.	I

1	The	I
2	co	B
3	-	I
4	existence	I
5	of	B
6	TE	B
7	domains	B
8	within	B
9	modular	B
10	PKSs	B
11	along	B
12	with	B
13	physically	B
14	separated	B
15	,	B
16	monofunctional	O
17	TEs	O
18	(	O
19	TE	O
20	IIs	B
21	)	O
22	has	O
23	been	O
24	reported	O
25	for	O
26	a	O
27	number	O
28	of	O
29	modular	O
30	polyketide	O
31	and	I
32	non	I
33	-	I
34	ribosomal	B
35	peptide	B
36	synthases	B
37	(	O
38	NRPS	O
39	).	O

1	Two	B
2	independent	B
3	transgenic	B
4	lines	B
5	were	B
6	produced	B
7	,	B
8	and	B
9	both	B
10	showed	I
11	expression	I
12	of	B
13	the	B
14	Gus	B
15	gene	B
16	specifically	B
17	in	B
18	the	B
19	endosperm	B
20	during	B
21	mid	B
22	-	B
23	development	B
24	(	B
25	first	B
26	detected	B
27	10	O
28	-	O
29	12	B
30	d	O
31	after	O
32	anthesis	O
33	).	O

1	Treadmill	B
2	training	B
3	at	B
4	least	I
5	for	B
6	2	B
7	weeks	I
8	can	I
9	reduce	B
10	the	B
11	infarction	B
12	size	B
13	and	B
14	edema	I
15	caused	I
16	by	I
17	MCA	I
18	occlusion	I
19	(	B
20	P	I
21	<	I
22	0	B
23	.	I
24	01	B
25	).	B

1	Mechanism	B
2	in	B
3	the	I
4	sequential	B
5	control	I
6	of	B
7	cell	B
8	morphology	B
9	and	B
10	S	B
11	phase	B
12	entry	B
13	by	B
14	epidermal	B
15	growth	B
16	factor	B
17	involves	B
18	distinct	B
19	MEK	B
20	/	B
21	ERK	B
22	activations	B
23	.	I

1	We	B
2	randomly	B
3	assigned	B
4	1	B
5	,	B
6	219	B
7	subjects	B
8	to	B
9	receive	I
10	either	I
11	the	I
12	standard	I
13	three	B
14	-	B
15	times	B
16	-	I
17	weekly	I
18	(	B
19	TIW	B
20	)	B
21	interferon	B
22	alfa	B
23	-	B
24	2b	B
25	dose	B
26	(	B
27	3	I
28	MIU	I
29	)	I
30	or	I
31	the	I
32	once	I
33	-	I
34	weekly	I
35	(	I
36	QW	B
37	)	B
38	peginterferon	B
39	alfa	B
40	-	B
41	2b	B
42	(	B
43	0	B
44	.	I
45	5	I
46	,	I
47	1	B
48	.	I
49	0	I
50	,	B
51	or	B
52	1	I
53	.	I
54	5	I
55	microg	I
56	/	I
57	kg	B
58	).	B

1	These	B
2	data	B
3	suggest	B
4	that	B
5	proper	B
6	direct	B
7	binding	B
8	of	B
9	Nhp2p	B
10	to	B
11	H	I
12	/	I
13	ACA	I
14	snoRNAs	I
15	is	I
16	required	I
17	for	I
18	the	B
19	assembly	B
20	of	B
21	H	I
22	/	I
23	ACA	B
24	snoRNPs	B
25	and	B
26	hence	B
27	for	B
28	the	B
29	stability	B
30	of	B
31	some	B
32	of	B
33	their	B
34	components	B
35	.	B

1	The	I
2	decrements	I
3	in	I
4	cerebrovascular	B
5	resistance	B
6	induced	B
7	by	B
8	hexamethonium	B
9	,	B
10	in	B
11	mm	B
12	Hg	B
13	ml	I
14	(-	B
15	1	B
16	).	B
17	min	B
18	(-	B
19	1	B
20	),	O
21	were	B
22	:	O
23	under	I
24	control	I
25	.	I

1	Here	I
2	we	I
3	provide	I
4	the	I
5	first	B
6	evidence	I
7	for	I
8	the	I
9	involvement	I
10	of	I
11	GCN1	I
12	-	I
13	GCN2	I
14	interaction	B
15	in	B
16	activation	B
17	of	B
18	GCN2	B
19	per	B
20	se	B
21	.	B

1	As	B
2	a	B
3	reflection	B
4	of	B
5	uncertainties	B
6	in	B
7	the	B
8	estimates	B
9	for	B
10	individual	B
11	sources	B
12	,	O
13	the	O
14	90th	O
15	percentiles	O
16	of	B
17	PCDD	B
18	/	B
19	F	B
20	releases	B
21	for	B
22	1999	B
23	ranged	B
24	up	B
25	to	I
26	4	I
27	.	I
28	1	I
29	g	I
30	I	I
31	-	I
32	TEQ	B
33	/	B
34	y	I
35	.	I

1	To	I
2	test	I
3	the	I
4	hypothesis	I
5	that	I
6	these	I
7	elements	B
8	are	B
9	required	B
10	for	B
11	promoter	B
12	activity	B
13	,	B
14	we	B
15	compared	O
16	the	O
17	reporter	B
18	expression	B
19	activity	B
20	of	O
21	segments	B
22	containing	B
23	mutations	B
24	of	B
25	these	B
26	elements	B
27	with	B
28	activity	B
29	of	O
30	the	O
31	parent	O
32	Hlx	O
33	promoter	O
34	sequence	O
35	.	O

1	Using	I
2	RACE	I
3	techniques	I
4	we	B
5	have	I
6	cloned	B
7	and	B
8	sequenced	B
9	one	B
10	of	B
11	the	B
12	hamster	B
13	liver	I
14	3	I
15	-	I
16	hydroxy	I
17	-	I
18	hexobarbital	B
19	dehydrogenases	B
20	which	B
21	catalyze	B
22	not	B
23	only	B
24	cyclic	I
25	alcohols	I
26	but	B
27	also	B
28	17beta	B
29	-	I
30	hydroxy	B
31	-	B
32	steroids	B
33	and	I
34	3alpha	I
35	-	I
36	hydroxysteroids	I
37	.	I

1	Concerted	B
2	transcriptional	B
3	activation	B
4	of	B
5	the	B
6	low	B
7	density	B
8	lipoprotein	B
9	receptor	B
10	gene	B
11	by	I
12	insulin	I
13	and	I
14	luteinizing	I
15	hormone	B
16	in	B
17	cultured	B
18	porcine	B
19	granulosa	B
20	-	B
21	luteal	B
22	cells	B
23	:	I
24	possible	I
25	convergence	I
26	of	B
27	protein	B
28	kinase	B
29	a	B
30	,	B
31	phosphatidylinositol	B
32	3	B
33	-	I
34	kinase	I
35	,	B
36	and	B
37	mitogen	B
38	-	I
39	activated	I
40	protein	B
41	kinase	B
42	signaling	B
43	pathways	B
44	.	I

1	Human	B
2	T	B
3	-	B
4	cell	B
5	leukemia	B
6	virus	B
7	type	B
8	I	B
9	(	B
10	HTLV	I
11	-	I
12	I	I
13	)	I
14	Tax	B
15	is	B
16	a	B
17	potent	B
18	transcriptional	B
19	regulator	B
20	that	B
21	can	B
22	activate	B
23	or	B
24	repress	B
25	specific	B
26	cellular	B
27	genes	B
28	and	I
29	that	I
30	has	B
31	been	B
32	proposed	B
33	to	I
34	contribute	I
35	to	I
36	leukemogenesis	I
37	in	I
38	adult	B
39	T	B
40	-	B
41	cell	B
42	leukemia	B
43	.	I

1	Also	B
2	,	B
3	small	B
4	,	B
5	sense	B
6	and	I
7	antisense	I
8	approximately	I
9	22	I
10	nt	B
11	RNAs	B
12	,	B
13	derived	B
14	from	I
15	the	I
16	satRNA	I
17	,	B
18	were	B
19	associated	B
20	with	B
21	the	B
22	replicating	I
23	satellite	I
24	.	I

1	Deletional	B
2	analyses	B
3	of	B
4	VDR	B
5	indicated	B
6	that	B
7	GRIP1	B
8	and	B
9	RAC3	B
10	required	B
11	an	B
12	intact	B
13	VDR	B
14	activation	B
15	function	O
16	(	O
17	AF	O
18	-	B
19	2	B
20	)	B
21	domain	B
22	for	O
23	efficient	O
24	interaction	O
25	as	O
26	well	B
27	as	I
28	additional	I
29	but	B
30	distinct	B
31	regions	B
32	of	B
33	the	B
34	VDR	B
35	.	B

1	RESULTS	B
2	:	I
3	During	I
4	the	I
5	stabilization	B
6	period	B
7	,	B
8	PaCO2	B
9	(	B
10	mean	B
11	+/-	B
12	SD	I
13	)	B
14	was	B
15	33	B
16	+/-	B
17	5	B
18	mm	I
19	Hg	I
20	,	I
21	and	I
22	arrhythmias	I
23	were	I
24	not	I
25	detected	I
26	.	I

1	TT	B
2	cells	B
3	,	B
4	a	B
5	human	B
6	MTC	O
7	cell	O
8	line	O
9	expressing	O
10	MEN	O
11	2A	O
12	type	O
13	RET	O
14	,	B
15	display	O
16	transcriptionally	O
17	active	O
18	RelA	B
19	(	B
20	p65	I
21	)	I
22	in	I
23	the	I
24	nucleus	B
25	.	I

1	The	I
2	human	I
3	protein	B
4	sequence	I
5	exhibits	B
6	a	B
7	putative	B
8	DNA	B
9	-	B
10	binding	B
11	domain	B
12	similar	B
13	to	B
14	that	I
15	seen	I
16	in	B
17	rat	I
18	HBP1	B
19	and	I
20	shows	I
21	homology	I
22	with	I
23	the	B
24	activation	B
25	and	B
26	repressor	I
27	domains	I
28	previously	B
29	demonstrated	B
30	in	B
31	the	B
32	rat	I
33	protein	B
34	.	I

1	In	B
2	contrast	B
3	the	B
4	human	B
5	and	I
6	mouse	B
7	BCNT	I
8	proteins	B
9	contain	B
10	one	B
11	repeat	I
12	unit	B
13	and	B
14	lack	I
15	the	I
16	RTE	B
17	-	I
18	1	B
19	-	B
20	derived	B
21	portion	B
22	.	I

1	Direct	I
2	superoxide	B
3	scavenging	I
4	activity	B
5	of	B
6	nonsteroidal	B
7	anti	B
8	-	B
9	inflammatory	B
10	drugs	B
11	:	I
12	determination	I
13	by	I
14	electron	I
15	spin	I
16	resonance	I
17	using	B
18	the	I
19	spin	I
20	trap	I
21	method	B
22	.	B

1	A	B
2	single	B
3	nucleotide	B
4	polymorphism	B
5	(	B
6	SNP	B
7	)	B
8	in	B
9	exon	B
10	2	B
11	,	B
12	which	B
13	is	B
14	tightly	B
15	liked	I
16	to	I
17	another	I
18	SNP	I
19	(	I
20	GTG83	B
21	/	B
22	ATG83	B
23	),	B
24	creates	B
25	an	B
26	additional	B
27	alternative	O
28	in	B
29	-	I
30	frame	I
31	AUG	B
32	in	B
33	B	B
34	-	B
35	type	B
36	MTH1	B
37	mRNAs	B
38	yielding	B
39	the	B
40	fourth	B
41	MTH1	B
42	polypeptide	I
43	,	I
44	p26	I
45	that	I
46	possesses	I
47	an	I
48	additional	B
49	mitochondrial	B
50	targeting	B
51	signal	B
52	.	I

1	Six	I
2	of	B
3	the	B
4	gstC	I
5	'	B
6	mutants	B
7	,	B
8	primarily	B
9	in	B
10	the	B
11	C	B
12	-	B
13	terminal	B
14	half	B
15	of	O
16	C	O
17	',	O
18	exhibited	I
19	a	I
20	defect	I
21	in	B
22	the	I
23	ability	I
24	to	I
25	bind	I
26	L	I
27	protein	B
28	.	I

1	We	B
2	developed	I
3	a	B
4	system	B
5	for	B
6	domain	B
7	shuffling	B
8	to	I
9	establish	I
10	the	I
11	function	I
12	of	B
13	C1	B
14	domains	B
15	from	B
16	human	B
17	Raf	B
18	kinase	B
19	and	B
20	rat	B
21	PKC	B
22	eta	B
23	in	B
24	yeast	I
25	.	I

1	Expression	B
2	of	B
3	herpes	B
4	simplex	B
5	virus	B
6	type	B
7	2	B
8	US3	B
9	affects	B
10	the	B
11	Cdc42	I
12	/	B
13	Rac	B
14	pathway	B
15	and	B
16	attenuates	B
17	c	I
18	-	I
19	Jun	I
20	N	I
21	-	I
22	terminal	I
23	kinase	I
24	activation	B
25	.	I

1	Inhibition	B
2	of	B
3	constitutive	I
4	NF	B
5	-	I
6	kappaB	I
7	activity	B
8	results	B
9	in	B
10	cell	B
11	death	B
12	of	B
13	TT	B
14	cells	B
15	and	B
16	blocks	B
17	focus	B
18	formation	B
19	induced	I
20	by	I
21	oncogenic	I
22	forms	I
23	of	I
24	RET	I
25	in	I
26	NIH	I
27	3T3	B
28	cells	B
29	.	B

1	Corneal	B
2	scrapping	B
3	and	I
4	deep	B
5	stromal	B
6	biopsy	B
7	were	B
8	obtained	B
9	and	B
10	stained	B
11	for	B
12	microscopic	B
13	evaluation	B
14	with	B
15	periodic	B
16	acid	B
17	-	B
18	Schiff	B
19	,	B
20	Giemsa	B
21	,	B
22	and	B
23	Gomori	I
24	'	I
25	s	B
26	methenamine	B
27	silver	B
28	stains	B
29	.	B

1	ICAM	B
2	-	I
3	1	B
4	has	B
5	been	B
6	suggested	B
7	a	B
8	predictor	B
9	of	B
10	the	B
11	onset	B
12	of	B
13	GO	B
14	.	I

1	Once	B
2	ICP	B
3	reaches	B
4	critical	B
5	values	B
6	(>	B
7	30	B
8	mm	B
9	Hg	I
10	)	I
11	herniation	B
12	occurs	B
13	,	B
14	usually	B
15	within	B
16	2	B
17	to	B
18	5	I
19	days	I
20	.	I

1	The	I
2	present	I
3	data	B
4	also	B
5	demonstrate	B
6	that	B
7	ectopic	B
8	expression	B
9	of	B
10	blr1	B
11	increased	B
12	JNK	B
13	/	B
14	SAPK	B
15	activity	B
16	,	B
17	but	B
18	JNK	B
19	/	B
20	SAPK	B
21	activation	B
22	was	B
23	not	B
24	needed	B
25	for	B
26	accelerated	B
27	RA	B
28	-	B
29	induced	B
30	differentiation	B
31	and	B
32	growth	B
33	arrest	I
34	.	I

1	Here	I
2	,	I
3	we	B
4	identify	B
5	Rsc3	B
6	and	B
7	Rsc30	B
8	as	I
9	novel	I
10	components	I
11	of	B
12	the	B
13	essential	B
14	yeast	I
15	remodeler	I
16	RSC	B
17	complex	B
18	.	I

1	The	I
2	pharmacokinetic	I
3	profiles	B
4	of	B
5	digoxin	B
6	and	I
7	warfarin	I
8	were	B
9	not	B
10	altered	B
11	by	B
12	the	I
13	simultaneous	I
14	and	I
15	continued	I
16	administration	B
17	of	B
18	sevelamer	B
19	.	I

1	Forskolin	B
2	treatment	I
3	(	I
4	10	B
5	microM	I
6	)	I
7	of	B
8	the	B
9	transfected	B
10	cells	B
11	for	B
12	3	B
13	--	I
14	6	I
15	h	I
16	maximally	B
17	induced	B
18	luciferase	B
19	threefold	B
20	.	I

1	E2F1	B
2	-	I
3	mediated	I
4	transcriptional	B
5	inhibition	B
6	of	B
7	the	B
8	plasminogen	B
9	activator	B
10	inhibitor	B
11	type	B
12	1	B
13	gene	B
14	.	B

1	In	B
2	this	I
3	report	I
4	this	I
5	technique	I
6	was	I
7	applied	B
8	to	I
9	human	I
10	breast	I
11	carcinoma	B
12	MDA	B
13	-	B
14	MB231	B
15	cells	B
16	overexpressing	B
17	human	B
18	MPG	B
19	in	B
20	order	B
21	to	I
22	assess	I
23	whether	I
24	up	B
25	-	B
26	regulation	B
27	of	B
28	the	B
29	initial	B
30	step	B
31	in	B
32	BER	B
33	alters	B
34	the	B
35	activity	B
36	of	O
37	selected	O
38	other	B
39	BER	O
40	(	O
41	hOGG1	B
42	and	O
43	APE	I
44	/	B
45	ref	B
46	-	B
47	1	B
48	)	B
49	or	B
50	direct	B
51	reversal	O
52	(	B
53	MGMT	B
54	)	B
55	repair	O
56	activities	B
57	.	O

1	Chlamydia	B
2	and	I
3	cervical	B
4	cancer	B
5	:	I
6	a	I
7	real	I
8	association	I
9	?	I

1	In	B
2	children	B
3	unable	B
4	to	I
5	perform	I
6	forced	I
7	expiratory	I
8	maneuvers	B
9	(	B
10	n	B
11	=	B
12	25	I
13	),	I
14	FOT	B
15	,	B
16	contrary	B
17	to	I
18	the	I
19	interrupter	I
20	technique	I
21	,	I
22	clearly	B
23	identified	B
24	a	B
25	subgroup	B
26	of	B
27	young	B
28	children	B
29	with	B
30	high	B
31	resistance	O
32	values	O
33	at	O
34	baseline	O
35	,	O
36	which	O
37	returned	O
38	to	O
39	normal	I
40	after	I
41	bronchodilation	B
42	.	B

1	Together	B
2	,	B
3	these	B
4	results	B
5	identify	B
6	HPK1	B
7	as	I
8	a	I
9	new	B
10	component	B
11	of	B
12	TCR	B
13	signaling	B
14	.	I

1	Pro	B
2	-	I
3	inflammatory	B
4	cytokine	B
5	,	B
6	tumor	B
7	necrosis	B
8	factor	B
9	-	B
10	alpha	B
11	(	B
12	TNF	B
13	-	B
14	alpha	B
15	),	B
16	produced	B
17	from	I
18	adipose	B
19	tissues	B
20	in	B
21	obese	B
22	subjects	B
23	,	B
24	is	B
25	known	B
26	to	B
27	play	I
28	a	B
29	predominant	B
30	role	B
31	in	I
32	inducing	I
33	insulin	I
34	resistance	B
35	.	I

1	The	I
2	Schistosoma	I
3	mansoni	I
4	homologue	B
5	(	B
6	SmSmad2	I
7	)	I
8	was	B
9	overexpressed	B
10	in	B
11	bacteria	B
12	as	B
13	a	I
14	Sj26	I
15	-	I
16	GST	I
17	fusion	I
18	protein	I
19	and	I
20	used	I
21	to	I
22	raise	I
23	specific	I
24	antibodies	I
25	.	I

1	To	I
2	study	B
3	the	B
4	in	B
5	vivo	B
6	role	B
7	of	B
8	p16	B
9	.	I
10	7	B
11	,	B
12	a	B
13	phi29	B
14	mutant	I
15	containing	I
16	a	I
17	suppressible	I
18	mutation	I
19	in	I
20	gene	I
21	16	B
22	.	I
23	7	B
24	was	B
25	constructed	B
26	.	B

1	The	I
2	differences	B
3	in	B
4	the	B
5	CPIgG	B
6	,	B
7	CRP	B
8	,	B
9	and	B
10	fibrinogen	I
11	levels	I
12	in	I
13	patients	B
14	who	B
15	were	B
16	diagnosed	B
17	with	B
18	ACS	B
19	versus	B
20	those	B
21	who	I
22	were	I
23	not	B
24	(	B
25	non	B
26	-	I
27	ACS	I
28	)	B
29	were	B
30	evaluated	B
31	.	B

1	There	B
2	are	B
3	many	B
4	different	I
5	proposals	I
6	for	I
7	the	I
8	statistical	B
9	analysis	B
10	of	B
11	data	B
12	to	B
13	determine	I
14	early	I
15	onset	I
16	of	I
17	action	B
18	.	B

1	Coexpression	B
2	of	B
3	the	B
4	p120	B
5	(	B
6	ctn	B
7	)	B
8	protein	B
9	with	B
10	an	B
11	N	B
12	-	I
13	terminal	I
14	deletion	B
15	,	B
16	which	B
17	eliminates	B
18	some	B
19	potential	B
20	tyrosine	B
21	phosphorylation	B
22	sites	B
23	,	B
24	or	B
25	the	I
26	protein	I
27	with	B
28	a	B
29	single	B
30	amino	B
31	acid	B
32	substitution	I
33	(	I
34	tyrosine	B
35	at	B
36	217	B
37	to	I
38	phenylalanine	I
39	)	I
40	resulted	I
41	in	I
42	an	I
43	increase	I
44	in	I
45	the	I
46	aggregation	I
47	of	B
48	v	B
49	-	I
50	Src	I
51	-	I
52	transformed	I
53	EL	B
54	and	B
55	EalphaCL	I
56	cells	B
57	.	I

1	We	B
2	find	B
3	that	B
4	our	B
5	response	B
6	function	B
7	is	B
8	well	B
9	approximated	B
10	by	I
11	the	I
12	GSER	I
13	only	B
14	within	B
15	a	B
16	particular	B
17	frequency	B
18	range	B
19	determined	B
20	by	I
21	the	I
22	material	I
23	parameters	I
24	of	I
25	both	I
26	the	I
27	bead	B
28	and	B
29	the	I
30	network	B
31	.	I

1	The	I
2	novel	I
3	approach	B
4	to	I
5	insulin	I
6	administration	I
7	known	B
8	as	I
9	chronic	I
10	intermittent	I
11	intravenous	I
12	insulin	I
13	therapy	I
14	(	I
15	CIIIT	I
16	)	B
17	delivers	B
18	insulin	B
19	in	I
20	a	B
21	pulsatile	B
22	fashion	B
23	and	I
24	achieves	I
25	physiological	I
26	insulin	I
27	concentration	I
28	in	I
29	the	I
30	portal	I
31	vein	I
32	.	I

1	This	B
2	article	B
3	comparatively	B
4	evaluates	B
5	five	B
6	Generic	B
7	Systems	B
8	that	B
9	describe	B
10	the	B
11	basic	B
12	alternatives	B
13	to	I
14	composting	I
15	facility	I
16	design	I
17	and	I
18	control	I
19	.	I

1	With	B
2	a	B
3	GC	B
4	content	B
5	of	B
6	45	B
7	%	B
8	the	B
9	one	B
10	segment	B
11	would	B
12	correspond	B
13	to	I
14	"	I
15	isochore	I
16	H1	I
17	"	I
18	and	I
19	the	I
20	other	I
21	segment	B
22	(	B
23	39	B
24	%	B
25	GC	B
26	in	B
27	human	B
28	,	B
29	40	B
30	%	B
31	GC	B
32	in	B
33	mouse	B
34	)	B
35	to	B
36	"	I
37	isochore	I
38	L1	I
39	/	B
40	L2	B
41	".	I

1	A	B
2	review	B
3	of	B
4	the	B
5	literature	B
6	identified	B
7	8	B
8	comprehensive	B
9	clinical	B
10	studies	B
11	,	B
12	all	O
13	of	O
14	which	O
15	failed	O
16	to	I
17	document	I
18	any	B
19	relationship	B
20	between	B
21	NF1	B
22	and	I
23	intracranial	I
24	aneurysms	I
25	.	I

1	Serial	B
2	US	B
3	images	B
4	were	B
5	obtained	B
6	before	B
7	and	B
8	20	B
9	,	B
10	30	B
11	,	B
12	40	B
13	,	B
14	50	B
15	,	B
16	60	B
17	,	B
18	90	B
19	,	B
20	120	B
21	,	B
22	150	B
23	,	B
24	180	B
25	,	B
26	240	O
27	,	O
28	and	O
29	300	B
30	s	O
31	after	O
32	intravenous	B
33	injection	O
34	of	I
35	2	B
36	g	B
37	of	B
38	contrast	B
39	agent	B
40	using	B
41	conventional	B
42	and	B
43	harmonic	B
44	PD	B
45	US	B
46	.	I

1	Eight	I
2	CAD	B
3	patients	B
4	who	B
5	were	B
6	matched	B
7	to	I
8	the	I
9	treated	I
10	patients	B
11	for	B
12	age	B
13	(+/-	B
14	3	I
15	years	I
16	),	I
17	baseline	B
18	low	B
19	density	B
20	lipoprotein	B
21	(+/-	I
22	5	I
23	mg	I
24	/	B
25	dL	B
26	),	B
27	and	I
28	triglycerides	I
29	(+/-	I
30	50	I
31	mg	B
32	/	B
33	dL	B
34	)	B
35	but	B
36	who	I
37	had	I
38	never	I
39	been	B
40	treated	B
41	with	B
42	lipid	B
43	-	B
44	lowering	B
45	drugs	B
46	were	B
47	selected	B
48	as	I
49	controls	I
50	.	I

1	Here	I
2	we	I
3	present	B
4	evidence	I
5	that	I
6	the	I
7	distal	I
8	half	B
9	(	B
10	Stem	B
11	2	B
12	)	B
13	of	B
14	the	B
15	conserved	B
16	base	B
17	-	B
18	paired	I
19	stem	I
20	structure	B
21	found	I
22	in	I
23	all	B
24	hY	B
25	RNAs	B
26	also	B
27	plays	B
28	a	B
29	critical	B
30	role	B
31	in	B
32	the	B
33	export	B
34	process	I
35	.	I

1	The	I
2	contrasting	I
3	effects	B
4	of	B
5	dopaminergic	B
6	stimulation	I
7	on	B
8	the	B
9	motor	I
10	performance	I
11	and	I
12	on	I
13	some	B
14	aspects	B
15	of	B
16	cognitive	B
17	processing	B
18	suggest	I
19	the	I
20	existence	I
21	of	B
22	complex	B
23	interactions	B
24	within	B
25	pre	B
26	-	B
27	and	I
28	postsynaptic	I
29	brain	I
30	dopamine	B
31	receptors	B
32	,	B
33	and	B
34	an	B
35	intervention	B
36	of	B
37	segregated	B
38	basal	B
39	ganglia	B
40	-	O
41	prefrontal	B
42	cortex	B
43	loops	B
44	in	B
45	motor	I
46	and	I
47	cognitive	I
48	behaviour	I
49	.	I

1	The	I
2	size	I
3	of	B
4	the	B
5	infarct	B
6	was	B
7	determined	B
8	using	B
9	the	B
10	creatine	B
11	kinase	B
12	integral	B
13	method	B
14	.	B

1	These	B
2	corrections	B
3	do	B
4	not	B
5	involve	B
6	sequences	I
7	predicted	B
8	to	I
9	function	I
10	as	I
11	transcription	I
12	factor	I
13	binding	B
14	sites	B
15	.	I

1	A	B
2	comprehensive	B
3	neuropsychological	B
4	battery	B
5	was	B
6	administered	B
7	to	B
8	48	I
9	veterans	I
10	with	I
11	Gulf	I
12	War	B
13	Illness	B
14	(	B
15	GWI	B
16	)	B
17	characterized	B
18	by	B
19	severe	B
20	fatigue	B
21	(	B
22	GV	I
23	-	I
24	F	B
25	)	B
26	and	B
27	39	B
28	healthy	I
29	veterans	I
30	(	I
31	GV	I
32	-	I
33	H	I
34	).	I

1	Quantitative	B
2	PCR	B
3	studies	B
4	indicated	B
5	that	B
6	synthesis	B
7	and	B
8	transport	B
9	of	B
10	vector	B
11	DNA	B
12	into	B
13	the	B
14	nucleus	B
15	were	B
16	similar	B
17	for	B
18	macrophages	B
19	infected	B
20	with	B
21	the	B
22	clone	I
23	239	I
24	and	I
25	316	I
26	pseudotypes	I
27	,	B
28	suggesting	B
29	that	B
30	the	B
31	restriction	B
32	for	B
33	SIVmac239	B
34	infection	I
35	is	I
36	after	I
37	reverse	B
38	transcription	B
39	and	B
40	nuclear	I
41	import	I
42	of	B
43	viral	B
44	DNA	B
45	.	B

1	EXAFS	B
2	measurements	B
3	around	B
4	the	B
5	Ge	B
6	-	B
7	K	B
8	edge	B
9	have	I
10	been	B
11	carried	B
12	out	B
13	for	B
14	liquid	B
15	Ge	B
16	-	I
17	Si	I
18	alloys	B
19	for	B
20	the	B
21	first	B
22	time	B
23	to	B
24	investigate	I
25	the	I
26	local	B
27	structure	B
28	around	B
29	a	B
30	Ge	B
31	atom	B
32	.	B

1	Hp	B
2	positive	B
3	relatives	B
4	of	B
5	gastric	B
6	cancer	B
7	had	B
8	a	B
9	markedly	B
10	higher	O
11	prevalence	B
12	of	B
13	atrophy	O
14	than	O
15	those	O
16	with	O
17	Hp	O
18	negativity	O
19	without	O
20	cancer	O
21	relatives	O
22	(	O
23	29	O
24	vs	I
25	.	I

1	Thus	B
2	,	B
3	replication	B
4	fork	B
5	movement	B
6	near	B
7	HML	B
8	pauses	B
9	at	B
10	a	B
11	silent	B
12	origin	B
13	which	B
14	is	B
15	competent	B
16	for	B
17	replication	B
18	initiation	B
19	but	I
20	kept	I
21	silent	B
22	through	I
23	Orc2p	I
24	,	B
25	a	B
26	component	B
27	of	B
28	the	B
29	replication	B
30	initiator	B
31	.	B

1	Cardiac	B
2	markers	B
3	troponin	B
4	T	B
5	,	B
6	CK	B
7	-	B
8	MB	I
9	mass	I
10	and	I
11	myoglobin	I
12	were	I
13	helpful	I
14	in	I
15	the	I
16	differential	I
17	diagnosis	I
18	of	B
19	chest	B
20	pain	B
21	,	B
22	even	O
23	when	O
24	the	O
25	ECG	O
26	was	O
27	unremarkable	O
28	or	O
29	nonspecific	I
30	.	I

1	RESULTS	B
2	:	I
3	A	I
4	novel	I
5	gene	I
6	was	B
7	cloned	B
8	.	B

1	Both	B
2	pancreatic	B
3	and	B
4	intestinal	I
5	cell	I
6	lines	B
7	were	B
8	found	I
9	to	I
10	express	I
11	a	I
12	number	B
13	of	B
14	POU	B
15	(	B
16	OCT	B
17	binding	B
18	)	B
19	homeodomain	B
20	proteins	B
21	examined	O
22	by	O
23	electrophoretic	I
24	mobility	I
25	shift	I
26	assay	I
27	.	I

1	In	B
2	conclusion	B
3	,	B
4	USPIO	B
5	-	B
6	enhanced	B
7	MRI	B
8	data	B
9	were	B
10	capable	B
11	to	I
12	characterize	I
13	tumor	I
14	microvessel	I
15	properties	I
16	in	I
17	this	I
18	breast	I
19	cancer	I
20	model	B
21	:	I
22	microvascular	I
23	permeability	I
24	(	I
25	determined	I
26	using	I
27	USPIO	B
28	)	B
29	correlated	B
30	significantly	B
31	with	B
32	tumor	B
33	grade	B
34	.	I

1	Radiolabeled	B
2	biantennary	B
3	N	B
4	-	I
5	glycans	I
6	synthesized	I
7	by	I
8	Pro	I
9	(-)	B
10	5Lec20	I
11	were	B
12	proportionately	B
13	less	B
14	ricin	B
15	-	I
16	bound	I
17	than	B
18	similar	B
19	species	B
20	from	B
21	parental	B
22	CHO	B
23	cells	B
24	,	B
25	and	B
26	Lec20	I
27	cell	I
28	extracts	B
29	had	B
30	a	B
31	markedly	B
32	reduced	B
33	ability	O
34	to	B
35	transfer	I
36	Gal	I
37	to	I
38	GlcNAc	I
39	-	I
40	terminating	I
41	acceptors	B
42	.	B

1	CONCLUSION	B
2	:	I
3	The	I
4	training	I
5	of	B
6	novices	B
7	using	B
8	MIST	B
9	-	I
10	VR	I
11	yields	B
12	quantifiable	I
13	changes	I
14	in	I
15	skill	B
16	that	B
17	are	B
18	transferable	B
19	to	I
20	a	I
21	simple	I
22	real	I
23	task	I
24	and	I
25	are	I
26	similar	I
27	to	I
28	the	I
29	results	I
30	achieved	I
31	with	I
32	conventional	B
33	training	B
34	.	B

1	To	I
2	investigate	B
3	the	B
4	convergent	B
5	role	B
6	of	B
7	the	B
8	insulin	I
9	/	B
10	IGF	I
11	-	I
12	I	I
13	effector	I
14	pathway	B
15	mediating	B
16	bihormonal	B
17	stimulation	B
18	of	B
19	LDL	I
20	receptor	I
21	promoter	B
22	expression	B
23	,	B
24	transfected	B
25	granulosa	B
26	-	B
27	luteal	B
28	cells	B
29	were	B
30	pretreated	B
31	for	B
32	30	I
33	min	I
34	with	I
35	two	B
36	specific	B
37	inhibitors	B
38	of	O
39	phophatidylinositol	O
40	3	O
41	-	O
42	kinase	O
43	,	O
44	wortmannin	O
45	(	O
46	100	O
47	nM	O
48	)	O
49	and	O
50	LY	O
51	294002	O
52	(	O
53	10	O
54	microM	I
55	),	I
56	or	I
57	of	I
58	mitogen	I
59	-	I
60	activated	O
61	protein	O

1	Instead	B
2	,	B
3	affective	B
4	flattening	B
5	was	B
6	associated	B
7	with	B
8	both	B
9	dopamine	B
10	receptor	B
11	sensitivity	B
12	and	B
13	psychomotor	I
14	slowing	I
15	.	I

1	Other	B
2	therapies	B
3	are	B
4	also	B
5	available	I
6	,	B
7	including	B
8	hypertonic	B
9	saline	B
10	solution	B
11	,	B
12	THAM	B
13	(	B
14	Tris	B
15	-	I
16	hydroxy	B
17	-	B
18	methyl	B
19	-	I
20	aminomethane	B
21	)	B
22	buffer	B
23	,	B
24	and	B
25	high	B
26	-	O
27	dose	B
28	barbiturates	B
29	.	B

1	CONCLUSION	B
2	:	I
3	There	I
4	are	I
5	no	B
6	differences	B
7	in	B
8	the	B
9	measurement	I
10	data	B
11	derived	B
12	from	I
13	this	I
14	method	I
15	and	I
16	actual	I
17	measurement	I
18	data	I
19	from	I
20	an	I
21	object	B
22	created	B
23	by	I
24	the	I
25	computer	I
26	-	I
27	aided	I
28	dental	B
29	design	B
30	program	B
31	.	I

1	NF	B
2	-	I
3	kappaB	I
4	pathway	B
5	activation	B
6	occurs	B
7	during	B
8	transformation	B
9	induced	B
10	by	B
11	a	B
12	number	B
13	of	B
14	classical	B
15	oncogenes	B
16	,	B
17	including	B
18	Bcr	B
19	/	B
20	Abl	B
21	,	O
22	Ras	O
23	and	O
24	Rac	B
25	,	B
26	and	B
27	is	B
28	necessary	B
29	for	B
30	full	B
31	transforming	B
32	potential	O
33	.	O

1	Our	B
2	results	B
3	indicate	B
4	that	B
5	Gab1	B
6	is	B
7	involved	I
8	in	I
9	the	I
10	control	I
11	of	I
12	egr	B
13	-	B
14	1	B
15	expression	B
16	regulated	I
17	by	I
18	insulin	I
19	.	I

1	The	I
2	human	I
3	cytomegalovirus	I
4	(	B
5	HCMV	I
6	)	B
7	major	B
8	immediate	B
9	-	B
10	early	I
11	protein	I
12	IE2	I
13	is	I
14	a	B
15	nuclear	B
16	phosphoprotein	B
17	that	B
18	is	B
19	believed	B
20	to	I
21	be	I
22	a	I
23	key	I
24	regulator	B
25	in	B
26	both	B
27	lytic	I
28	and	I
29	latent	I
30	infections	I
31	.	I

1	Unexpectedly	B
2	,	B
3	Arg1	B
4	-	B
5	expressing	B
6	COS1	B
7	cells	B
8	showed	B
9	no	B
10	significant	B
11	proteinase	I
12	activity	I
13	to	I
14	various	I
15	synthesized	I
16	substrates	I
17	under	I
18	neutral	I
19	or	I
20	acidic	I
21	conditions	B
22	in	B
23	this	I
24	study	B
25	.	B

1	METHODS	B
2	:	I
3	126	B
4	patients	B
5	with	B
6	histologically	B
7	confirmed	B
8	MFH	B
9	were	B
10	analyzed	B
11	.	B

1	Regression	B
2	analyses	B
3	showed	B
4	that	B
5	SOREMP	B
6	dream	B
7	occurrences	B
8	were	B
9	significantly	O
10	related	B
11	to	B
12	the	I
13	amount	I
14	of	B
15	REM	B
16	sleep	B
17	,	B
18	while	B
19	NREMP	O
20	dream	O
21	occurrences	O
22	were	O
23	related	O
24	to	O
25	arousals	I
26	from	I
27	NREM	I
28	sleep	B
29	.	I

1	[	I
2	Diabetologia	I
3	(	I
4	2001	I
5	)	I
6	44	B
7	[	I
8	Suppl	B
9	3	I
10	]:	B
11	B37	B
12	-	B
13	B44	I
14	]	I

1	RESULTS	B
2	:	I
3	In	I
4	vivo	I
5	,	B
6	there	B
7	was	B
8	a	B
9	wide	B
10	distribution	B
11	with	B
12	the	B
13	coefficient	B
14	of	B
15	variation	B
16	(	I
17	SD	I
18	/	B
19	mean	B
20	x	I
21	100	I
22	%)	I
23	for	B
24	different	I
25	valve	I
26	sizes	B
27	ranging	B
28	from	I
29	21	I
30	%	I
31	to	I
32	39	I
33	%	I
34	in	B
35	the	B
36	St	B
37	Jude	B
38	Medical	B
39	valve	B
40	and	B
41	from	I
42	25	I
43	%	I
44	to	I
45	33	I
46	%	I
47	in	I
48	the	I
49	Omnicarbon	I
50	valve	I
51	.	I

1	A	B
2	microsporidian	B
3	,	B
4	Nosema	B
5	algerae	B
6	Vavra	B
7	and	B
8	undeen	B
9	,	B
10	was	O
11	found	O
12	parasitizing	O
13	larvae	I
14	and	I
15	adults	I
16	of	B
17	a	B
18	laboratory	B
19	colony	I
20	of	B
21	Culex	B
22	pipiens	B
23	L	B
24	.	B
25	originated	B
26	from	I
27	Gharbia	I
28	Governorate	I
29	.	I

1	Nearly	B
2	all	B
3	isolates	I
4	of	B
5	S	B
6	.	I
7	intermedius	B
8	and	B
9	most	I
10	isolates	I
11	of	I
12	S	I
13	.	I
14	constellatus	I
15	,	B
16	but	B
17	only	B
18	19	B
19	%	B
20	of	B
21	those	B
22	of	B
23	S	B
24	.	I
25	anginosus	B
26	,	B
27	were	B
28	associated	B
29	with	B
30	abscess	B
31	.	I

1	One	B
2	of	B
3	the	B
4	conserved	B
5	RNA	I
6	subdomains	B
7	,	B
8	designated	B
9	P3	B
10	,	B
11	has	B
12	previously	B
13	been	B
14	shown	B
15	to	B
16	be	I
17	required	I
18	for	I
19	nucleolar	B
20	localization	B
21	.	B

1	A	B
2	total	B
3	of	B
4	25	B
5	patients	B
6	with	B
7	malignant	I
8	brain	I
9	tumours	I
10	were	I
11	investigated	B
12	.	I

1	Interventions	B
2	aimed	B
3	at	B
4	these	B
5	specific	B
6	mediators	B
7	and	B
8	processes	B
9	may	B
10	be	B
11	successful	B
12	in	B
13	reducing	B
14	the	B
15	very	B
16	significant	B
17	human	B
18	and	I
19	economic	B
20	costs	I
21	of	B
22	vascular	B
23	access	B
24	dysfunction	B
25	.	B

1	We	B
2	used	B
3	stored	B
4	plasma	B
5	samples	B
6	from	B
7	409	B
8	patients	B
9	in	B
10	the	B
11	National	I
12	Institute	I
13	of	B
14	Neurological	B
15	Diseases	B
16	and	I
17	Stroke	I
18	(	B
19	NINDS	B
20	)	B
21	tissue	B
22	plasminogen	B
23	activator	B
24	(	B
25	t	B
26	-	I
27	PA	B
28	)	B
29	Stroke	B
30	Trial	B
31	to	B
32	examine	I
33	the	I
34	relationship	I
35	between	I
36	an	B
37	apolipoprotein	I
38	(	I
39	Apo	B
40	)	B
41	E2	B
42	or	B
43	an	B
44	Apo	B
45	E4	B
46	phenotype	B
47	and	B
48	a	B
49	favorable	B
50	outcome	O
51	3	I
52	months	B
53	after	B
54	stroke	B
55	,	B
56	the	B
57	risk	B
58	of	B
59	intracerebral	B
60	hemorrhage	O
61	,	B
62	and	O
63	the	I
64	response	I
65	to	I
66	intravenous	I
67	t	I
68	-	I
69	PA	B
70	therapy	I
71	.	I

1	These	B
2	results	B
3	were	B
4	robust	B
5	to	I
6	changes	I
7	in	I
8	the	I
9	baseline	B
10	assumptions	I
11	of	I
12	the	I
13	model	B
14	.	I

1	Cis	B
2	-	B
3	acting	B
4	CCAAT	B
5	elements	B
6	are	B
7	frequently	B
8	found	B
9	in	B
10	eukaryotic	B
11	promoter	B
12	regions	B
13	.	B

1	The	I
2	binary	B
3	and	I
4	tertiary	I
5	combinations	B
6	of	B
7	plant	B
8	-	B
9	derived	B
10	molluscicides	I
11	Azadirachta	B
12	indica	B
13	and	I
14	Cedrus	I
15	deodara	B
16	oil	B
17	with	B
18	synergists	I
19	MGK	I
20	-	I
21	264	I
22	,	B
23	piperonyl	B
24	butoxide	B
25	(	B
26	PB	B
27	)	B
28	and	B
29	fruit	B
30	powder	B
31	of	B
32	Embelia	B
33	ribes	B
34	were	B
35	used	B
36	against	I
37	the	I
38	Lymnaea	I
39	acuminata	I
40	.	I

1	This	B
2	article	B
3	reports	B
4	the	B
5	design	B
6	and	I
7	development	B
8	of	B
9	an	B
10	ECG	B
11	simulator	I
12	intended	I
13	for	I
14	use	I
15	in	I
16	the	I
17	testing	I
18	,	B
19	calibration	B
20	and	B
21	maintenance	I
22	of	I
23	electrocardiographic	B
24	equipment	B
25	.	B

1	Exchanging	B
2	the	B
3	human	B
4	propeptide	B
5	in	B
6	this	I
7	chimera	I
8	with	I
9	either	B
10	the	B
11	murine	B
12	MIC	I
13	-	I
14	1	I
15	or	I
16	TGF	I
17	-	I
18	beta1	I
19	propeptide	B
20	resulted	B
21	in	B
22	secretion	B
23	of	B
24	the	B
25	unprocessed	B
26	,	B
27	monomeric	B
28	chimera	B
29	,	B
30	suggesting	B
31	a	B
32	specific	B
33	interaction	B
34	between	B
35	the	B
36	human	B
37	MIC	I
38	-	I
39	1	I
40	propeptide	B
41	and	B
42	mature	B
43	peptide	B
44	.	B

1	RESULTS	B
2	:	I
3	The	I
4	analyzed	I
5	fragment	I
6	has	I
7	significant	I
8	activity	B
9	in	B
10	EpCAM	B
11	positive	B
12	cells	B
13	,	B
14	and	B
15	it	B
16	is	B
17	regulated	I
18	negatively	I
19	by	I
20	tumor	I
21	necrosis	B
22	factor	B
23	alpha	B
24	(	B
25	TNFalpha	I
26	).	I

1	The	I
2	mutant	I
3	receptors	I
4	,	B
5	as	I
6	well	I
7	as	I
8	sBMPR	I
9	-	I
10	IA	I
11	,	I
12	were	B
13	expressed	B
14	as	I
15	fusion	I
16	proteins	I
17	with	I
18	thioredoxin	I
19	in	B
20	Escherichia	B
21	coli	I
22	,	B
23	and	B
24	purified	I
25	using	B
26	reverse	B
27	phase	B
28	high	B
29	performance	B
30	liquid	B
31	chromatography	B
32	(	B
33	RP	B
34	-	I
35	HPLC	I
36	)	B
37	after	B
38	digestion	B
39	with	B
40	enterokinase	B
41	.	I

1	The	I
2	dual	I
3	specificity	I
4	kinases	I
5	mitogen	B
6	-	I
7	activated	B
8	protein	B
9	kinase	B
10	(	B
11	MAPK	B
12	)	B
13	kinase	B
14	(	B
15	MKK	B
16	)	B
17	7	B
18	and	B
19	MKK4	B
20	are	B
21	the	B
22	only	B
23	molecules	B
24	known	B
25	to	B
26	directly	I
27	activate	B
28	the	B
29	stress	B
30	kinases	B
31	stress	B
32	-	O
33	activated	O
34	protein	O
35	kinases	O
36	(	B
37	SAPKs	B
38	)/	B
39	c	I
40	-	I
41	Jun	I
42	N	I
43	-	I
44	terminal	I
45	kinases	I
46	(	B
47	JNKs	B
48	)	B
49	in	B
50	response	B
51	to	I
52	environmental	I
53	or	I
54	mitogenic	I
55	stimuli	I
56	.	I

1	This	B
2	unique	I
3	work	B
4	needs	B
5	to	I
6	be	I
7	edited	I
8	critically	B
9	and	B
10	afterwards	B
11	translated	I
12	into	I
13	Urdu	I
14	and	I
15	other	I
16	languages	B
17	for	B
18	the	B
19	benefit	B
20	of	B
21	the	B
22	present	B
23	day	B
24	students	B
25	and	B
26	scholars	B
27	.	I

1	RANTES	I
2	(	I
3	regulated	I
4	upon	I
5	activation	B
6	,	B
7	normally	B
8	T	B
9	-	B
10	cell	B
11	expressed	B
12	and	B
13	presumably	I
14	secreted	I
15	)	B
16	is	B
17	a	B
18	CC	B
19	chemokine	B
20	which	B
21	recruits	B
22	and	I
23	activates	I
24	monocytes	I
25	,	I
26	lymphocytes	B
27	,	B
28	and	B
29	eosinophils	B
30	,	B
31	all	B
32	cell	B
33	types	B
34	present	B
35	in	B
36	the	B
37	lung	B
38	inflammatory	B
39	infiltrate	B
40	induced	B
41	by	O
42	RSV	I
43	infection	I
44	.	I

1	Gabapentin	B
2	for	B
3	opiod	B
4	-	I
5	related	B
6	myoclonus	B
7	in	B
8	cancer	B
9	patients	B
10	.	B

1	Recently	B
2	,	B
3	it	B
4	was	B
5	shown	O
6	that	O
7	purified	O
8	RAG1	O
9	/	O
10	2	O
11	proteins	B
12	can	O
13	cleave	O
14	DNA	O
15	hairpins	O
16	in	B
17	vitro	I
18	,	B
19	but	B
20	the	B
21	same	B
22	activity	B
23	was	O
24	also	O
25	described	O
26	for	O
27	a	O
28	protein	O
29	complex	O
30	of	O
31	the	O
32	DNA	O
33	repair	O
34	proteins	B
35	Nbs1	O
36	/	B
37	Mre11	O
38	/	O
39	Rad50	B
40	.	O

1	APC	B
2	-	B
3	resistance	B
4	was	B
5	determined	B
6	with	B
7	a	B
8	functional	B
9	method	B
10	with	O
11	high	B
12	sensitivity	O
13	and	O
14	specificity	B
15	for	B
16	the	B
17	factor	B
18	V	B
19	Leiden	B
20	mutation	B
21	.	I

1	A	B
2	picture	B
3	is	B
4	emerging	B
5	showing	B
6	a	B
7	gradient	O
8	of	O
9	function	O
10	among	O
11	p53	O
12	,	O
13	p73	O
14	,	O
15	p63	O
16	ranging	O
17	from	I
18	tumor	I
19	suppression	B
20	to	I
21	development	I
22	.	I

1	High	B
2	plasma	B
3	AVP	B
4	levels	B
5	observed	I
6	in	I
7	the	I
8	two	I
9	cases	B
10	suggest	I
11	that	B
12	SSRIs	I
13	stimulate	B
14	AVP	B
15	secretion	B
16	,	B
17	thereby	B
18	causing	B
19	SIADH	O
20	.	I

1	Mutation	I
2	of	B
3	the	B
4	octamer	I
5	element	I
6	also	B
7	significantly	B
8	reduced	B
9	the	B
10	ability	B
11	of	B
12	HDAC1	I
13	to	I
14	confer	I
15	repression	I
16	of	I
17	inducible	I
18	HLA	I
19	-	I
20	DRA	I
21	promoter	I
22	activation	B
23	.	I

1	Requirements	B
2	for	B
3	the	B
4	nuclear	B
5	-	B
6	cytoplasmic	I
7	translocation	I
8	of	I
9	infected	I
10	-	I
11	cell	B
12	protein	B
13	0	B
14	of	B
15	herpes	B
16	simplex	B
17	virus	B
18	1	B
19	.	B

1	The	I
2	system	I
3	,	B
4	designed	B
5	to	I
6	exploit	I
7	the	I
8	relatively	I
9	constant	I
10	small	I
11	intestine	I
12	transit	I
13	time	B
14	,	B
15	consists	B
16	of	B
17	a	B
18	drug	B
19	-	B
20	containing	B
21	core	B
22	coated	B
23	with	I
24	a	B
25	polymeric	B
26	matrix	B
27	formed	B
28	by	I
29	a	I
30	channeling	I
31	agent	I
32	(	I
33	NaCl	B
34	,	B
35	mannitol	B
36	,	B
37	and	B
38	Emdex	B
39	)	B
40	and	B
41	an	B
42	inert	B
43	polymer	B
44	(	I
45	Eudragit	I
46	RS100	I
47	).	I

1	The	I
2	activity	B
3	of	B
4	Rac1	B
5	leads	I
6	to	I
7	STAT3	I
8	translocation	I
9	to	I
10	the	I
11	nucleus	I
12	coincident	I
13	with	I
14	STAT3	I
15	-	I
16	dependent	I
17	gene	I
18	expression	I
19	.	I

1	Treatment	I
2	of	I
3	ischemic	I
4	heart	B
5	disease	B
6	in	B
7	the	B
8	elderly	B

1	To	I
2	avoid	B
3	misinterpretations	B
4	,	B
5	special	B
6	reference	B
7	values	B
8	should	B
9	be	O
10	applied	O
11	for	B
12	preadolescents	B
13	,	B
14	at	B
15	least	I
16	with	I
17	regard	I
18	to	I
19	FVC	I
20	and	I
21	FEV1	B
22	.	B

1	STUDY	I
2	OBJECTIVE	I
3	:	I
4	This	B
5	study	B
6	assessed	B
7	several	B
8	methodological	I
9	aspects	I
10	related	I
11	to	I
12	the	I
13	quality	B
14	of	B
15	published	B
16	controlled	B
17	clinical	B
18	trials	B
19	(	B
20	CCTs	B
21	)	I
22	in	B
23	relation	B
24	to	I
25	the	I
26	participation	I
27	of	I
28	an	B
29	epidemiologist	B
30	/	B
31	biostatistician	B
32	(	B
33	E	B
34	/	B
35	B	B
36	).	B

1	To	I
2	the	I
3	best	B
4	of	B
5	our	B
6	knowledge	B
7	,	B
8	SNTCS	B
9	is	B
10	highly	B
11	malignant	B
12	.	I

1	Northern	B
2	blot	B
3	analysis	B
4	with	B
5	one	B
6	of	B
7	the	B
8	PARNAs	B
9	revealed	B
10	a	B
11	highly	B
12	abundant	B
13	signal	I
14	of	I
15	approximately	I
16	2	I
17	.	I
18	0	I
19	kilobases	B
20	(	B
21	kb	I
22	)	I
23	present	B
24	in	B
25	all	B
26	cell	B
27	lines	B
28	tested	B
29	.	I

1	The	I
2	effect	I
3	of	B
4	crude	B
5	oil	B
6	spillage	B
7	on	B
8	growth	B
9	,	B
10	productivity	O
11	and	B
12	nutrient	I
13	uptake	I
14	of	I
15	maize	I
16	(	B
17	Zea	B
18	mays	B
19	L	B
20	.)	B
21	was	B
22	assessed	B
23	in	B
24	a	B
25	pot	B
26	experiment	B
27	using	B
28	an	B
29	Evwreni	B
30	manifold	B
31	sample	I
32	of	I
33	a	B
34	petroleum	B
35	development	B
36	company	B
37	,	B
38	which	O
39	had	O
40	a	B
41	specific	O
42	gravity	O
43	of	O
44	0	B
45	.	O
46	8778	B
47	.	I

1	10	B
2	.	I
3	0	B
4	+/-	B
5	2	B
6	.	I
7	0	I
8	pmol	I
9	/	B
10	24	B
11	h	B
12	,	B
13	P	B
14	<	B
15	0	B
16	.	I
17	01	B
18	)	B
19	and	B
20	remained	I
21	elevated	B
22	.	I

1	Pitx2	B
2	rescues	B
3	the	B
4	GABAergic	B
5	differentiation	B
6	defect	B
7	and	I
8	partially	I
9	rescues	I
10	the	I
11	axon	B
12	guidance	B
13	and	B
14	behavioral	I
15	phenotypes	I
16	of	I
17	unc	B
18	-	I
19	30	I
20	mutants	I
21	,	B
22	indicating	B
23	a	B
24	high	B
25	degree	B
26	of	B
27	functional	B
28	conservation	I
29	between	B
30	these	B
31	evolutionarily	B
32	related	B
33	genes	B
34	.	I

1	Phosphatidylinositol	B
2	3	I
3	-	I
4	kinase	I
5	potentiates	I
6	,	B
7	but	B
8	does	B
9	not	B
10	trigger	I
11	,	I
12	T	B
13	cell	B
14	proliferation	B
15	mediated	B
16	by	I
17	the	I
18	IL	I
19	-	I
20	2	I
21	receptor	B
22	.	I

1	In	B
2	addition	B
3	,	B
4	stonin	B
5	2	B
6	binds	B
7	to	I
8	the	I
9	C2B	I
10	domains	I
11	of	B
12	synaptotagmins	B
13	I	I
14	and	I
15	II	I
16	.	I

1	Sequence	B
2	comparison	B
3	and	B
4	binding	B
5	studies	B
6	of	B
7	the	B
8	18	I
9	-	I
10	bp	I
11	MOK2	I
12	-	I
13	binding	I
14	sites	I
15	present	B
16	in	B
17	intron	B
18	2	B
19	of	B
20	human	B
21	,	B
22	bovine	B
23	,	B
24	and	B
25	mouse	B
26	IRBP	B
27	genes	B
28	show	I
29	that	B
30	the	B
31	3	I
32	'-	I
33	half	B
34	sequence	B
35	is	B
36	the	B
37	essential	B
38	core	B
39	element	B
40	for	B
41	MOK2	I
42	binding	I
43	.	I

1	Measurements	B
2	were	B
3	obtained	B
4	:	I
5	(	I
6	i	B
7	)	B
8	just	B
9	after	B
10	the	B
11	traumatic	B
12	exposure	B
13	(	B
14	D0	B
15	);	B
16	(	B
17	ii	B
18	)	B
19	3	B
20	days	I
21	after	I
22	this	I
23	first	I
24	measurement	I
25	(	I
26	D3	B
27	);	B
28	and	B
29	(	I
30	iii	B
31	)	B
32	30	I
33	days	I
34	after	I
35	(	I
36	D30	I
37	).	I

1	Long	B
2	-	B
3	term	B
4	results	I
5	with	I
6	MACOP	I
7	-	I
8	B	B
9	and	I
10	radiation	I
11	therapy	I
12	for	I
13	aggressive	I
14	lymphomas	I
15	]	I
16	BACKGROUND	I
17	:	I
18	Long	I
19	-	I
20	term	I
21	results	I
22	are	I
23	needed	I
24	to	I
25	evaluate	I
26	chemotherapy	I
27	regimens	B
28	and	B
29	prognostic	I
30	factors	I
31	in	B
32	non	B
33	-	I
34	Hodgkin	I
35	'	I
36	s	B
37	lymphomas	B
38	(	B
39	NHL	B
40	).	B

1	From	B
2	the	B
3	above	B
4	results	B
5	,	B
6	we	B
7	might	B
8	infer	B
9	that	B
10	the	B
11	seizure	I
12	type	B
13	of	B
14	TLE	B
15	and	B
16	a	B
17	high	B
18	frequency	B
19	of	B
20	seizure	B
21	are	I
22	two	B
23	major	B
24	independent	B
25	precipitate	B
26	factors	B
27	for	B
28	abnormal	B
29	latencies	I
30	of	B
31	P300	B
32	in	B
33	the	B
34	epileptic	B
35	patients	B
36	.	B

1	Rapamycin	B
2	(	B
3	FRAP	B
4	/	B
5	mTOR	B
6	inhibitor	B
7	)	B
8	blocked	B
9	4E	I
10	-	I
11	BP1	I
12	phosphorylation	I
13	causing	I
14	a	B
15	predominance	B
16	of	B
17	the	B
18	alpha	B
19	(	B
20	hypophosphorylated	B
21	)	B
22	band	B
23	.	B

1	We	B
2	investigate	B
3	the	B
4	reaction	I
5	kinetics	B
6	of	B
7	small	B
8	spherical	B
9	particles	B
10	with	B
11	inertia	B
12	,	B
13	obeying	B
14	coalescence	B
15	type	B
16	of	B
17	reaction	B
18	,	B
19	B	B
20	+	B
21	B	B
22	-->	B
23	B	B
24	,	B
25	and	B
26	being	B
27	advected	B
28	by	B
29	hydrodynamical	B
30	flows	B
31	with	B
32	time	B
33	-	B
34	periodic	B
35	forcing	B
36	.	O

1	Corticosteroid	I
2	-	I
3	mediated	I
4	transcriptional	B
5	inhibition	B
6	was	B
7	greater	B
8	for	B
9	MR	B
10	/	B
11	GR	B
12	in	B
13	combination	B
14	than	B
15	for	O
16	MR	B
17	or	B
18	GR	I
19	alone	B
20	.	B

1	These	B
2	data	B
3	define	B
4	a	B
5	conserved	B
6	pathway	B
7	wherein	B
8	sequential	B
9	histone	B
10	modifications	B
11	establish	I
12	a	I
13	"	B
14	histone	B
15	code	B
16	"	B
17	essential	B
18	for	B
19	the	B
20	epigenetic	B
21	inheritance	B
22	of	B
23	heterochromatin	B
24	assembly	B
25	.	I

1	The	I
2	bovine	I
3	PGHS	B
4	-	I
5	2	B
6	cDNA	I
7	was	I
8	cloned	B
9	by	B
10	a	B
11	combination	B
12	of	B
13	reverse	B
14	transcription	B
15	-	B
16	polymerase	B
17	chain	B
18	reaction	I
19	and	I
20	cDNA	I
21	library	I
22	screening	I
23	.	I

1	Telomerase	B
2	is	B
3	a	B
4	ribonucleoprotein	B
5	complex	B
6	that	B
7	synthesizes	B
8	telomeric	O
9	DNA	O
10	onto	O
11	chromosomes	O
12	using	B
13	its	B
14	RNA	O
15	component	B
16	as	I
17	template	I
18	.	I

1	The	I
2	iterative	I
3	method	B
4	proposed	B
5	by	I
6	Bengtsson	B
7	[	I
8	Appl	B
9	.	I

1	Several	B
2	distinct	B
3	apoptotic	B
4	stimuli	B
5	induce	B
6	the	B
7	expression	B
8	and	B
9	caspase	B
10	-	I
11	dependent	I
12	cleavage	B
13	of	B
14	hTAF	B
15	(	B
16	II	B
17	)	B
18	80	B
19	delta	B
20	.	B
21	hTAF	I
22	(	I
23	II	B
24	)	B
25	80	B
26	delta	B
27	,	B
28	unlike	B
29	hTAF	B
30	(	B
31	II	B
32	)	B
33	80	B
34	,	B
35	forms	O
36	a	B
37	TFIID	I
38	-	I
39	like	I
40	complex	I
41	lacking	B
42	hTAF	B
43	(	B
44	II	B
45	)	B
46	31	B
47	.	B

1	With	B
2	NEU	B
3	overexpression	I
4	,	B
5	nodal	B
6	control	B
7	decreased	I
8	from	I
9	72	I
10	%	I
11	to	I
12	34	I
13	%	I
14	(	I
15	p	I
16	=	I
17	.	I
18	008	I
19	).	B

1	The	I
2	mouse	I
3	platelet	B
4	-	B
5	derived	B
6	growth	B
7	factor	B
8	(	B
9	PDGF	B
10	)	B
11	beta	B
12	-	O
13	receptor	O
14	promoter	O
15	contains	O
16	a	O
17	CCAAT	O
18	motif	O
19	,	O
20	and	O
21	NF	O
22	-	O
23	Y	O
24	plays	O
25	an	O
26	essential	O
27	role	O
28	in	O
29	its	O
30	transcription	O
31	.	O

1	Biol	I
2	.	I

1	The	I
2	loop	B
3	domain	B
4	of	B
5	heat	B
6	shock	B
7	transcription	B
8	factor	B
9	1	B
10	dictates	B
11	DNA	B
12	-	B
13	binding	B
14	specificity	B
15	and	I
16	responses	I
17	to	I
18	heat	I
19	stress	B
20	.	B

1	This	B
2	activation	B
3	was	B
4	then	B
5	blocked	B
6	by	I
7	CGS	I
8	12066A	I
9	.	I

1	Among	B
2	the	B
3	transcription	B
4	factors	B
5	known	B
6	to	B
7	interact	B
8	with	B
9	Groucho	B
10	-	B
11	related	B
12	protein	B
13	,	B
14	only	B
15	RUNX1	B
16	was	B
17	appreciably	O
18	downregulated	B
19	by	I
20	E2A	B
21	-	I
22	HLF	B
23	.	B

1	A	B
2	new	B
3	intron	B
4	of	B
5	476	B
6	base	B
7	pairs	B
8	was	B
9	found	O
10	in	B
11	the	B
12	middle	B
13	of	B
14	the	B
15	5	I
16	'-	I
17	untranslated	B
18	leader	B
19	sequence	B
20	and	I
21	was	B
22	shown	B
23	to	B
24	robustly	I
25	enhance	B
26	the	B
27	promoter	B
28	activity	B
29	.	B

1	Our	B
2	findings	B
3	further	B
4	our	B
5	understanding	B
6	of	B
7	how	B
8	ZBP	B
9	-	B
10	89	B
11	modulates	I
12	cell	B
13	proliferation	B
14	and	B
15	reveals	B
16	a	B
17	novel	B
18	mechanism	B
19	by	I
20	which	B
21	the	B
22	p53	B
23	protein	B
24	is	B
25	stabilized	I
26	.	I

1	In	B
2	the	B
3	free	I
4	-	I
5	swimming	B
6	rotatory	B
7	test	I
8	mice	I
9	spend	B
10	most	I
11	of	B
12	the	B
13	time	B
14	swimming	B
15	close	B
16	to	I
17	the	I
18	wall	I
19	of	B
20	the	B
21	container	B
22	attempting	B
23	to	I
24	escape	I
25	from	I
26	an	I
27	aversive	B
28	test	I
29	situation	I
30	.	I

1	As	B
2	well	B
3	,	B
4	mixtures	B
5	of	B
6	(	B
7	LA	I
8	)(	I
9	12	B
10	)	B
11	with	B
12	the	B
13	longer	I
14	chain	I
15	PEs	I
16	exhibit	I
17	unusual	I
18	biomodal	I
19	enthalpy	I
20	variations	I
21	,	B
22	suggesting	B
23	peptide	B
24	immiscibility	B
25	in	B
26	thicker	B
27	gel	B
28	state	O
29	bilayers	B
30	.	B

1	At	B
2	the	B
3	time	B
4	of	B
5	the	B
6	blind	B
7	therapeutic	B
8	doses	B
9	,	B
10	Tg	B
11	-	B
12	off	B
13	values	B
14	ranged	B
15	from	O
16	8	B
17	to	I
18	608	I
19	microg	I
20	/	I
21	l	I
22	.	I

1	Nephrotoxicity	B
2	after	B
3	orthotopic	B
4	liver	B
5	transplantation	I
6	in	I
7	cyclosporin	I
8	A	B
9	and	I
10	FK	I
11	506	I
12	-	I
13	treated	I
14	patients	B
15	.	B

1	In	B
2	contrast	B
3	to	I
4	MPc3	I
5	,	B
6	data	B
7	indicate	B
8	that	B
9	the	B
10	Pc	B
11	protein	B
12	M33	B
13	does	B
14	not	B
15	interact	B
16	with	B
17	AF9	B
18	.	I

1	Hydrocoele	B
2	is	B
3	common	B
4	in	B
5	men	B
6	in	B
7	Wuchereria	B
8	bancrofti	B
9	-	B
10	endemic	B
11	areas	B
12	,	B
13	the	B
14	treatment	B
15	for	B
16	which	B
17	is	B
18	currently	B
19	surgical	B
20	intervention	B
21	.	I

1	Of	B
2	the	I
3	patients	B
4	in	B
5	each	I
6	regimen	I
7	who	I
8	reached	I
9	study	B
10	end	B
11	points	B
12	,	B
13	17	B
14	of	B
15	29	B
16	(	I
17	59	I
18	%)	I
19	were	B
20	in	B
21	regimen	I
22	A	I
23	,	B
24	11	B
25	of	B
26	20	B
27	(	B
28	55	B
29	%)	B
30	were	B
31	in	B
32	regimen	I
33	B	I
34	,	B
35	and	B
36	28	I
37	of	I
38	43	I
39	(	I
40	65	I
41	%)	B
42	were	B
43	in	B
44	regimen	I
45	C	I
46	met	I
47	the	I
48	treatment	I
49	success	I
50	criterion	I
51	.	I

1	One	B
2	maternal	I
3	death	I
4	,	B
5	reduced	B
6	body	B
7	weight	B
8	,	B
9	and	B
10	reduced	B
11	weight	I
12	gain	I
13	were	B
14	noted	B
15	at	B
16	the	B
17	high	B
18	dose	B
19	;	B
20	confirmed	B
21	pregnancy	O
22	rates	O
23	were	B
24	84	B
25	to	I
26	100	I
27	%	I
28	for	B
29	each	I
30	group	I
31	.	I

1	Karger	B
2	AG	B
3	,	B
4	Basel	B

1	In	B
2	regards	B
3	to	I
4	the	I
5	latter	I
6	activity	B
7	,	B
8	it	B
9	has	B
10	been	B
11	shown	B
12	that	O
13	S3	O
14	contains	O
15	vigorous	O
16	N	B
17	-	I
18	glycosylase	B
19	activity	O
20	for	O
21	the	O
22	removal	O
23	of	O
24	8	O
25	-	O
26	oxoguanine	O
27	residues	O
28	in	O
29	DNA	O
30	that	O
31	leaves	O
32	baseless	B
33	sites	O
34	in	O
35	their	B
36	places	B
37	.	O

1	We	B
2	describe	B
3	a	B
4	total	B
5	of	B
6	39	B
7	DEAH	B
8	helicases	B
9	in	I
10	these	I
11	four	B
12	species	B
13	.	I

1	A	B
2	prospective	B
3	trial	B
4	was	B
5	undertaken	B
6	to	B
7	determine	I
8	(	I
9	1	I
10	)	B
11	clinical	B
12	characteristics	B
13	of	B
14	patients	B
15	with	B
16	chest	B
17	pain	B
18	;	B
19	(	B
20	2	B
21	)	B
22	value	B
23	of	O
24	cardiac	O
25	markers	O
26	troponin	O
27	T	O
28	,	O
29	myoglobin	O
30	and	I
31	CK	I
32	-	I
33	MB	I
34	mass	I
35	in	B
36	differentiating	B
37	cardiac	B
38	and	B
39	noncardiac	B
40	chest	B
41	pain	B
42	;	O
43	(	O
44	3	O
45	)	B
46	the	B
47	proportion	O
48	of	B
49	patients	B
50	with	B
51	ACS	B
52	in	B
53	whom	I
54	these	I
55	markers	I
56	provided	I
57	helpful	I
58	additional	I
59	information	B
60	on	B
61	admission	B
62	and	I
63	afterwards	I
64	.	I

1	Inactivity	B
2	of	B
3	the	B
4	human	B
5	cytomegalovirus	B
6	(	B
7	HCMV	B
8	)	B
9	major	B
10	immediate	B
11	-	B
12	early	I
13	regulatory	I
14	region	B
15	(	B
16	MIERR	B
17	),	B
18	which	B
19	is	B
20	composed	B
21	of	B
22	promoter	B
23	,	B
24	enhancer	B
25	,	B
26	unique	B
27	region	B
28	,	B
29	and	B
30	modulator	B
31	,	B
32	is	B
33	linked	B
34	to	I
35	lack	I
36	of	I
37	HCMV	I
38	replication	B
39	in	B
40	latently	B
41	infected	B
42	cells	B
43	and	B
44	in	B
45	other	B
46	nonpermissive	B
47	cell	B
48	types	B
49	,	B
50	including	B
51	human	B
52	embryonal	B
53	NTera2	B
54	carcinoma	B
55	(	B
56	NT2	B
57	)	I
58	cells	B
59	.	B

1	The	I
2	observed	I
3	triplexes	B
4	depend	I
5	on	B
6	the	B
7	length	B
8	of	B
9	the	B
10	repeat	I
11	.	I

1	Statistical	B
2	Analysis	B
3	included	B
4	ANOVA	I
5	,	I
6	the	I
7	Pearson	B
8	Product	B
9	Moment	B
10	Correlation	B
11	Coefficient	B
12	,	B
13	Principal	B
14	Components	B
15	Analysis	B
16	and	B
17	Discriminant	I
18	Function	I
19	Analysis	B
20	and	B
21	the	I
22	calculation	B
23	of	B
24	Cronbach	B
25	'	B
26	s	B
27	alpha	B
28	(	B
29	alpha	B
30	)	B
31	RESULTS	B
32	:	I
33	Both	I
34	Sensitivity	B
35	and	I
36	specificity	I
37	exceed	I
38	90	I
39	.	I
40	00	I
41	at	I
42	23	I
43	/	I
44	24	B
45	,	B
46	Chronbach	B
47	'	B
48	s	B
49	alpha	B
50	for	B
51	the	B
52	total	B
53	scale	B
54	was	B
55	equal	O
56	to	O
57	0	I
58	.	I
59	95	I
60	.	I

1	BACKGROUND	I
2	:	I
3	Previous	I
4	studies	I
5	have	I
6	indicated	I
7	that	I
8	the	I
9	60	B
10	-,	B
11	30	I
12	-,	I
13	28	I
14	-	I
15	and	I
16	12	I
17	-	I
18	item	I
19	versions	I
20	of	B
21	the	B
22	General	B
23	Health	B
24	Questionnaire	I
25	(	I
26	GHQ	I
27	)	B
28	are	B
29	liable	B
30	to	I
31	retest	I
32	effects	I
33	,	B
34	especially	B
35	when	B
36	administered	B
37	multiple	B
38	times	B
39	with	B
40	short	B
41	intervals	B
42	.	I

1	Cross	I
2	-	I
3	linking	I
4	FcalphaR	I
5	on	I
6	wt	I
7	-	I
8	ITAM	I
9	or	I
10	IIA	I
11	-	I
12	ITAM	I
13	cells	I
14	triggered	I
15	equivalent	I
16	PI	I
17	3	I
18	-	I
19	kinase	I
20	-	I
21	dependent	I
22	activation	B
23	of	B
24	PKBalpha	B
25	.	B

1	An	B
2	F222W	B
3	:	I
4	W21F	I
5	rGST	B
6	A1	B
7	-	B
8	1	B
9	double	B
10	mutant	I
11	provides	B
12	a	B
13	direct	B
14	fluorescence	O
15	probe	O
16	of	O
17	changes	O
18	in	O
19	the	O
20	environment	B
21	of	O
22	the	O
23	C	B
24	-	O
25	terminal	O
26	residue	I
27	.	I

1	Binding	B
2	of	B
3	serum	B
4	response	B
5	factor	B
6	to	I
7	CArG	I
8	box	I
9	sequences	B
10	is	B
11	necessary	B
12	but	B
13	not	B
14	sufficient	I
15	to	I
16	restrict	I
17	gene	I
18	expression	I
19	to	I
20	arterial	I
21	smooth	I
22	muscle	I
23	cells	I
24	.	I

1	They	B
2	consist	B
3	of	B
4	at	B
5	least	I
6	two	B
7	separable	B
8	components	B
9	,	B
10	one	B
11	heat	B
12	stable	B
13	and	B
14	the	I
15	other	I
16	heat	B
17	labile	B
18	.	I

1	No	B
2	preferential	B
3	VH	B
4	/	B
5	VL	B
6	-	B
7	chains	B
8	correlated	B
9	with	B
10	any	B
11	of	O
12	the	O
13	12	B
14	different	O
15	antigen	I
16	reactivities	B
17	,	B
18	even	B
19	for	B
20	mAbs	B
21	with	I
22	nearly	I
23	identical	I
24	cross	B
25	-	I
26	reactivities	I
27	.	I

1	These	B
2	results	B
3	were	B
4	compared	B
5	with	B
6	the	B
7	estimates	B
8	of	B
9	penetration	B
10	from	I
11	steady	I
12	-	I
13	state	I
14	calculations	I
15	,	B
16	square	B
17	root	B
18	of	B
19	time	B
20	calculations	B
21	,	B
22	and	B
23	a	B
24	biologically	B
25	based	B
26	mathematical	B
27	model	B
28	.	B

1	Based	B
2	on	B
3	this	I
4	analysis	B
5	,	B
6	we	B
7	propose	B
8	that	B
9	the	B
10	interactions	B
11	of	B
12	Sos	B
13	with	B
14	the	B
15	switch	B
16	1	B
17	and	B
18	switch	B
19	2	B
20	regions	B
21	of	B
22	Ras	B
23	have	B
24	distinct	I
25	functional	I
26	consequences	B
27	:	I
28	the	I
29	interaction	I
30	with	B
31	switch	B
32	2	B
33	mediates	B
34	the	B
35	anchoring	B
36	of	B
37	Ras	B
38	to	B
39	Sos	I
40	,	B
41	whereas	I
42	the	I
43	interaction	I
44	with	B
45	switch	B
46	1	B
47	leads	I
48	to	I
49	disruption	I
50	of	I
51	the	I
52	nucleotide	B
53	-	B
54	binding	B
55	site	B
56	and	I
57	GDP	B
58	dissociation	B
59	.	B

1	Thus	B
2	,	B
3	the	B
4	interaction	B
5	of	B
6	Tat	B
7	with	B
8	the	B
9	components	B
10	of	B
11	this	I
12	rel	I
13	/	B
14	AP1	B
15	cooperative	B
16	complex	B
17	seems	B
18	to	I
19	induce	I
20	quantitative	I
21	and	I
22	qualitative	I
23	alterations	B
24	of	B
25	this	I
26	complex	I
27	as	I
28	activation	I
29	progresses	B
30	,	B
31	resulting	B
32	in	I
33	a	B
34	decrease	I
35	of	I
36	IL	I
37	-	I
38	2	I
39	gene	I
40	transcription	I
41	.	I

1	SIT	B
2	(	B
3	SHP2	I
4	-	I
5	interacting	I
6	transmembrane	I
7	adaptor	I
8	protein	I
9	)	B
10	is	B
11	a	B
12	recently	B
13	identified	B
14	transmembrane	I
15	adaptor	I
16	protein	I
17	,	B
18	which	B
19	is	B
20	expressed	B
21	in	I
22	lymphocytes	I
23	.	I

1	In	B
2	this	I
3	manuscript	B
4	we	B
5	demonstrate	B
6	that	B
7	two	O
8	tandem	O
9	Ets	O
10	sites	O
11	in	O
12	the	O
13	mouse	O
14	GL	O
15	alpha	O
16	promoter	O
17	bind	O
18	the	O
19	transcription	O
20	factors	O
21	Elf	O
22	-	O
23	1	O
24	and	O
25	PU	B
26	.	O
27	1	B
28	,	B
29	and	O
30	that	B
31	the	B
32	3	I
33	'	B
34	site	I
35	is	I
36	essential	B
37	for	B
38	expression	B
39	of	B
40	a	B
41	luciferase	B
42	reporter	B
43	gene	B
44	driven	B
45	by	I
46	the	I
47	GL	B
48	alpha	B
49	promoter	B
50	.	B

1	ICA	B
2	in	B
3	the	B
4	reference	B
5	solution	B
6	was	B
7	characterised	B
8	by	O
9	LC	O
10	and	O
11	time	B
12	-	O
13	of	B
14	-	O
15	flight	B
16	(	B
17	TOF	I
18	)	I
19	MS	I
20	and	I
21	quantified	I
22	by	I
23	LC	I
24	chemiluminescent	B
25	nitrogen	B
26	detection	B
27	(	B
28	LC	B
29	-	O
30	CLND	B
31	).	B

1	These	B
2	disorders	B
3	include	I
4	low	B
5	-	I
6	back	B
7	pain	B
8	,	B
9	saddle	B
10	anesthesia	O
11	,	O
12	bilateral	O
13	sciatica	O
14	,	O
15	then	O
16	motor	O
17	weakness	B
18	of	B
19	the	B
20	lower	B
21	extremities	B
22	or	B
23	chronic	I
24	paraplegia	I
25	and	I
26	,	B
27	bladder	B
28	dysfunction	I
29	.	I

1	C	B
2	.	I
3	elegans	B
4	embryogenesis	I
5	begins	I
6	with	I
7	a	B
8	stereotyped	B
9	sequence	I
10	of	B
11	asymmetric	B
12	cell	B
13	divisions	B
14	that	B
15	are	B
16	largely	B
17	responsible	B
18	for	B
19	establishing	B
20	the	B
21	nematode	B
22	body	B
23	plan	B
24	.	B

1	Additionally	B
2	,	B
3	a	B
4	CaCO3	B
5	-	O
6	CO2	B
7	/	O
8	N2	O
9	buffered	B
10	solution	B
11	was	O
12	necessary	O
13	to	O
14	maintain	B
15	a	B
16	pH	B
17	of	B
18	8	B
19	.	B

1	Mss4	B
2	also	B
3	acts	B
4	as	B
5	a	B
6	relatively	B
7	inefficient	B
8	guanine	B
9	nucleotide	B
10	exchange	B
11	factor	O
12	(	O
13	GEF	O
14	).	B

1	Effects	I
2	of	B
3	3	I
4	'	B
5	terminus	B
6	modifications	B
7	on	B
8	mRNA	B
9	functional	B
10	decay	B
11	during	B
12	in	B
13	vitro	B
14	protein	B
15	synthesis	B
16	.	I

1	Disciplinary	B
2	action	B
3	for	B
4	DNA	B
5	violation	B
6	.	B

1	This	B
2	is	B
3	necessary	B
4	if	B
5	psychiatric	B
6	diagnoses	B
7	are	B
8	ultimately	B
9	going	I
10	to	I
11	be	I
12	refined	I
13	and	I
14	validated	I
15	against	I
16	biological	I
17	criteria	I
18	.	I

1	We	B
2	also	B
3	demonstrate	B
4	that	B
5	the	B
6	spo20	B
7	(+)	B
8	gene	O
9	product	B
10	is	B
11	structurally	I
12	homologous	I
13	to	I
14	Saccharomyces	I
15	cerevisiae	I
16	Sec14	B
17	,	B
18	the	B
19	major	B
20	phosphatidylinositol	B
21	transfer	B
22	protein	B
23	of	B
24	budding	B
25	yeast	B
26	.	I

1	In	B
2	addition	B
3	,	B
4	another	B
5	derivative	B
6	of	B
7	pCMVJS21	B
8	(	B
9	pCMVJS21DeltaGP	B
10	)	B
11	in	B
12	which	B
13	the	B
14	gag	B
15	,	B
16	pol	B
17	(	B
18	and	I
19	orf	I
20	-	I
21	x	I
22	)	I
23	coding	B
24	sequences	B
25	were	B
26	deleted	B
27	also	B
28	gave	B
29	transformed	B
30	foci	B
31	.	I

1	It	B
2	is	B
3	shown	B
4	that	B
5	,	B
6	for	B
7	any	B
8	periodic	O
9	input	O
10	,	O
11	the	O
12	map	B
13	representing	B
14	the	O
15	relation	O
16	between	O
17	input	B
18	phases	I
19	at	I
20	consecutive	I
21	discharge	B
22	times	B
23	can	B
24	be	B
25	restricted	B
26	to	B
27	a	I
28	piecewise	I
29	continuous	I
30	,	B
31	orientation	B
32	preserving	B
33	circle	B
34	map	B
35	.	I

1	Decreased	I
2	serum	B
3	ceruloplasmin	B
4	and	I
5	copper	I
6	levels	B
7	in	B
8	cervical	B
9	dystonia	B
10	.	I

1	Northern	B
2	blot	B
3	analysis	B
4	of	B
5	RNAs	B
6	from	B
7	a	B
8	number	B
9	of	B
10	mouse	B
11	tissues	B
12	reveals	B
13	that	B
14	Atp6i	B
15	is	B
16	expressed	B
17	predominantly	B
18	in	B
19	osteoclasts	B
20	,	B
21	and	B
22	this	I
23	predominant	I
24	expression	I
25	was	B
26	confirmed	B
27	by	B
28	reverse	B
29	-	B
30	transcription	B
31	polymerase	B
32	chain	B
33	reaction	I
34	(	I
35	RT	I
36	-	I
37	PCR	B
38	)	B
39	assay	B
40	and	B
41	immunohistochemical	B
42	analysis	B
43	.	I

1	Behavioural	B
2	tests	B
3	with	B
4	192	B
5	specimen	B
6	of	B
7	the	B
8	roman	B
9	garden	B
10	snail	B
11	Helix	B
12	pomatia	B
13	L	B
14	.	O
15	were	B
16	performed	B
17	in	O
18	order	B
19	to	I
20	clarify	I
21	whether	I
22	the	I
23	thermopreferendum	B
24	of	B
25	this	I
26	pulmonate	I
27	is	I
28	influenced	B
29	not	B
30	only	B
31	by	I
32	the	I
33	temperature	B
34	of	B
35	the	B
36	substratum	B
37	but	B
38	also	B
39	by	I
40	air	I
41	temperature	B
42	.	I

1	As	B
2	well	B
3	,	B
4	IFN	B
5	-	B
6	gamma	B
7	-	I
8	induced	I
9	expression	B
10	of	B
11	IRF	I
12	-	I
13	1	I
14	and	I
15	its	I
16	binding	B
17	to	I
18	the	I
19	IRF	I
20	element	I
21	is	I
22	inhibited	B
23	.	I

1	Baseline	B
2	BMD	I
3	values	B
4	were	B
5	significantly	B
6	lower	B
7	in	B
8	the	B
9	oligo	B
10	-	I
11	amenorrheic	B
12	group	B
13	than	B
14	in	B
15	the	B
16	two	B
17	others	B
18	at	B
19	the	B
20	level	B
21	of	B
22	lumbar	I
23	spine	I
24	(	B
25	anteroposterior	B
26	view	I
27	:	I
28	0	I
29	.	I
30	941	I
31	+/-	B
32	0	B
33	.	I
34	039	I
35	in	I
36	oligo	B
37	-	I
38	amenorrheic	I
39	vs	B
40	1	B
41	.	B
42	077	B
43	+/-	B
44	0	B
45	.	I
46	029	I
47	or	I
48	1	I
49	.	I
50	051	I
51	+/-	I
52	0	I
53	.	I
54	017	I
55	g	I
56	x	I
57	cm	I
58	(-	I
59	2	B
60	),	B
61	P	I
62	<	I
63	0	B
64	.	I
65	005	I
66	,	B
67	in	B
68	the	B
69	eumenorrheic	I
70	and	I
71	contraceptive	I
72	user	I
73	groups	I
74	,	I
75	respectively	I
76	)	I
77	but	B
78	not	I
79	in	I
80	weight	I
81	-	I
82	bearing	I
83	bone	B
84	such	B
85	as	B
86	proximal	I
87	and	I
88	midshaft	I
89	femur	I
90	.	I

1	The	I
2	glucose	I
3	/	B
4	insulin	I
5	stimulation	I
6	was	I
7	inhibited	B
8	by	I
9	the	B
10	addition	I
11	of	B
12	polyunsaturated	B
13	fatty	B
14	acids	B
15	.	B

1	We	B
2	report	B
3	the	B
4	results	B
5	of	B
6	a	B
7	detailed	B
8	policy	B
9	analysis	B
10	comparing	B
11	2	B
12	CJD	B
13	-	I
14	related	I
15	decisions	B
16	:	I
17	a	I
18	1995	B
19	recall	B
20	of	B
21	blood	B
22	from	B
23	a	B
24	donor	B
25	with	B
26	classic	I
27	CJD	B
28	and	I
29	the	I
30	1999	I
31	decision	B
32	to	B
33	defer	I
34	donations	I
35	from	I
36	individuals	B
37	with	B
38	a	B
39	6	B
40	-	B
41	month	B
42	travel	B
43	history	B
44	to	B
45	the	I
46	UK	I
47	between	I
48	1980	B
49	and	B
50	1996	B
51	due	B
52	to	B
53	concerns	I
54	related	I
55	to	I
56	variant	I
57	CJD	I
58	.	I

1	The	I
2	5	I
3	'	I
4	flanking	B
5	sequence	B
6	of	B
7	the	B
8	3B	B
9	gene	B
10	is	B
11	extremely	I
12	A	B
13	+	B
14	T	B
15	rich	B
16	but	B
17	contains	B
18	five	I
19	G	I
20	/	I
21	C	B
22	rich	B
23	stretches	B
24	,	B
25	each	B
26	approximately	I
27	7bp	I
28	long	B
29	,	B
30	which	B
31	have	B
32	strong	B
33	sequence	I
34	similarity	B
35	to	B
36	the	I
37	G	I
38	boxes	I
39	found	I
40	upstream	I
41	of	B
42	other	B
43	developmentally	B
44	regulated	I
45	Dictyostelium	I
46	genes	I
47	.	I

1	PACAP	I
2	mRNA	B
3	was	B
4	widely	B
5	expressed	B
6	in	B
7	most	B
8	human	B
9	tissues	B
10	;	B
11	in	B
12	transfected	B
13	cells	B
14	,	B
15	PACAP	O
16	was	B
17	diffusely	I
18	expressed	I
19	in	I
20	the	I
21	cytoplasm	I
22	.	I

1	The	I
2	proportion	I
3	of	I
4	the	I
5	biopsies	I
6	found	I
7	to	I
8	be	I
9	seropositive	I
10	for	I
11	HBs	I
12	antigen	I
13	was	B
14	27	B
15	.	B
16	9	I
17	%,	B
18	and	I
19	these	I
20	showed	I
21	either	I
22	MGN	B
23	or	B
24	MPGN	B
25	pattern	B
26	.	B

1	In	B
2	the	B
3	present	B
4	study	B
5	,	B
6	we	B
7	have	O
8	determined	B
9	the	I
10	ICBP90	I
11	gene	I
12	structure	B
13	by	I
14	screening	I
15	of	B
16	a	B
17	human	B
18	placenta	B
19	genomic	B
20	library	B
21	and	B
22	PCR	B
23	analysis	B
24	.	B

1	In	B
2	the	B
3	stable	B
4	transfectants	B
5	(	B
6	BM3	I
7	cells	B
8	)	B
9	expressing	B
10	a	B
11	mutant	B
12	bacterial	B
13	P450	B
14	AA	B
15	epoxygenase	B
16	,	B
17	F87V	B
18	BM3	O
19	,	B
20	which	B
21	was	B
22	genetically	O
23	engineered	B
24	to	I
25	metabolize	I
26	arachidonic	I
27	acid	B
28	only	B
29	to	I
30	14	I
31	,	I
32	15	B
33	-	B
34	EET	B
35	,	B
36	AA	B
37	did	B
38	not	B
39	induce	B
40	apoptosis	B
41	and	B
42	protected	B
43	against	B
44	agonist	B
45	-	B
46	induced	B
47	apoptosis	B
48	.	O

1	The	I
2	revitalization	I
3	of	B
4	surgery	B
5	for	B
6	Parkinson	B
7	'	B
8	s	B
9	disease	B
10	(	B
11	PD	B
12	)	B
13	has	O
14	fueled	O
15	discussion	O
16	about	O
17	the	B
18	best	B
19	methodology	O
20	to	O
21	define	I
22	the	I
23	target	I
24	.	I

1	Foreigners	I
2	return	I
3	.	I

1	She	B
2	drank	B
3	alcohol	B
4	once	B
5	or	I
6	twice	I
7	a	I
8	week	I
9	and	I
10	regularly	I
11	took	B
12	an	B
13	analgesic	B
14	preparation	B
15	,	B
16	containing	B
17	aspirin	B
18	and	I
19	acetaminophen	I
20	,	B
21	for	B
22	alleviation	B
23	of	B
24	headaches	B
25	.	B

1	The	I
2	authors	I
3	did	I
4	not	I
5	detect	B
6	any	B
7	significant	B
8	correlations	B
9	between	B
10	parameters	I
11	of	I
12	the	I
13	lipids	I
14	of	I
15	bone	B
16	marrow	B
17	and	B
18	leptin	I
19	levels	B
20	in	B
21	serum	B
22	and	B
23	bone	B
24	marrow	B
25	.	B

1	When	B
2	the	B
3	blood	B
4	clot	B
5	is	B
6	formed	B
7	in	B
8	the	B
9	vitreous	B
10	cavity	I
11	,	I
12	intravitreal	B
13	injection	I
14	of	I
15	t	I
16	-	I
17	PA	B
18	can	B
19	convert	B
20	plasminogen	B
21	to	I
22	plasmin	I
23	and	I
24	remove	I
25	the	B
26	clot	I
27	.	I

1	When	B
2	this	I
3	CCAAT	B
4	box	B
5	was	B
6	inserted	B
7	into	B
8	a	B
9	heterologous	O
10	promoter	O
11	construct	O
12	,	O
13	OA	O
14	induction	O
15	was	B
16	dependent	O
17	on	O
18	an	B
19	intact	O
20	CCAAT	O
21	box	O
22	.	O

1	Encouraged	I
2	by	I
3	a	I
4	Dutch	B
5	study	B
6	using	B
7	etidronate	B
8	/	B
9	fluoride	B
10	in	B
11	corticoid	B
12	-	B
13	induced	B
14	osteoporosis	B
15	,	B
16	we	B
17	performed	O
18	a	O
19	pilot	O
20	study	O
21	in	O
22	33	O
23	men	O
24	with	O
25	severe	O
26	established	O
27	primary	O
28	osteoporosis	O
29	giving	O
30	cyclically	O
31	etidronate	O
32	for	O
33	14	O
34	days	O
35	followed	O
36	by	O
37	fluoride	O
38	plus	O
39	calcium	O
40	/	O
41	vitamin	O
42	D	O
43	for	O
44	76	O
45	days	O
46	.	O

1	Far	B
2	Western	B
3	blot	B
4	analysis	B
5	suggested	B
6	that	B
7	the	B
8	tandem	B
9	SH2	B
10	domains	B
11	of	B
12	SHP2	O
13	bind	B
14	to	I
15	Gab1	I
16	in	I
17	a	I
18	specific	B
19	orientation	B
20	,	B
21	in	B
22	which	B
23	the	B
24	N	B
25	-	I
26	SH2	I
27	domain	B
28	binds	B
29	to	B
30	phosphotyrosine	I
31	(	I
32	Tyr	I
33	(	I
34	P	I
35	))-	I
36	627	I
37	and	I
38	the	I
39	C	B
40	-	B
41	SH2	B
42	domain	B
43	binds	B
44	to	B
45	Tyr	I
46	(	I
47	P	I
48	)-	I
49	659	I
50	.	I

1	Electrophoretic	B
2	mobility	I
3	shift	B
4	assays	I
5	and	I
6	coimmunoprecipitation	I
7	studies	I
8	suggest	I
9	that	I
10	homo	I
11	-	I
12	and	I
13	heterodimerization	I
14	occurs	B
15	between	B
16	cKrox	B
17	family	B
18	members	B
19	.	B

1	Expression	B
2	of	B
3	human	B
4	RACK1	B
5	efficiently	B
6	relieves	B
7	E1A	O
8	-	B
9	mediated	B
10	growth	B
11	inhibition	B
12	in	O
13	HF7c	B
14	and	B
15	protects	B
16	human	B
17	tumor	B
18	cells	B
19	from	O
20	E1A	B
21	-	I
22	induced	B
23	apoptosis	B
24	.	O

1	By	B
2	using	B
3	space	B
4	-	I
5	discrete	I
6	/	B
7	continuous	B
8	metapopulation	B
9	dynamic	B
10	models	B
11	and	I
12	computer	I
13	simulations	I
14	,	B
15	we	B
16	show	B
17	that	B
18	there	B
19	can	B
20	be	B
21	two	B
22	principally	B
23	different	O
24	regimes	I
25	of	B
26	metapopulation	B
27	dynamics	I
28	.	I

1	Arterial	B
2	blood	B
3	gas	B
4	tensions	B
5	were	O
6	similar	O
7	across	O
8	all	B
9	ventilation	O
10	modes	O
11	.	O

1	Four	B
2	casein	B
3	kinase	B
4	I	B
5	isoforms	B
6	are	B
7	differentially	I
8	partitioned	B
9	between	B
10	nucleus	B
11	and	B
12	cytoplasm	B
13	.	I

1	CONCLUSION	B
2	:	I
3	Extrusion	I
4	cooking	B
5	is	B
6	effective	B
7	for	B
8	the	B
9	inactivation	B
10	of	B
11	DON	B
12	but	B
13	is	B
14	of	B
15	limited	B
16	value	B
17	for	B
18	AFB1	B
19	,	B
20	even	B
21	if	B
22	metabisulphite	B
23	is	B
24	added	B
25	.	O

1	Also	B
2	,	B
3	the	B
4	EWS	B
5	protein	B
6	stimulates	B
7	transcription	B
8	mediated	B
9	by	I
10	the	I
11	COOH	I
12	-	I
13	terminal	I
14	transactivation	B
15	domain	B
16	of	B
17	the	B
18	cofactor	B
19	CREB	B
20	-	B
21	binding	B
22	protein	B
23	(	B
24	CBP	B
25	).	B

1	HSF	I
2	binds	I
3	DNA	B
4	as	I
5	a	B
6	trimer	B
7	,	B
8	and	B
9	additional	B
10	trimers	B
11	can	B
12	bind	B
13	DNA	B
14	co	B
15	-	B
16	operatively	I
17	.	I

1	Two	B
2	cases	B
3	with	B
4	marked	B
5	chronic	B
6	arm	B
7	lymphoedema	B
8	reported	B
9	major	B
10	and	B
11	persistent	I
12	improvements	I
13	in	I
14	arm	I
15	volume	I
16	for	B
17	at	B
18	least	I
19	12	I
20	months	B
21	after	B
22	treatment	B
23	with	I
24	HBO2	B
25	.	I

1	Growth	B
2	hormone	B
3	and	B
4	insulin	I
5	-	I
6	like	I
7	growth	B
8	factor	B
9	I	B
10	receptors	B
11	in	B
12	the	B
13	temporomandibular	B
14	joint	B
15	of	B
16	the	B
17	rat	B
18	.	I

1	Folate	B
2	metabolism	B
3	in	B
4	the	B
5	human	B
6	malaria	B
7	parasite	B
8	Plasmodium	B
9	falciparum	B
10	is	B
11	an	B
12	essential	B
13	activity	B
14	for	B
15	cell	B
16	growth	O
17	and	O
18	replication	O
19	,	O
20	and	O
21	the	B
22	target	I
23	of	B
24	an	B
25	important	I
26	class	I
27	of	B
28	therapeutic	B
29	agents	B
30	in	B
31	widespread	B
32	use	I
33	.	I

1	These	B
2	results	B
3	indicate	B
4	that	B
5	BACM	B
6	has	B
7	antiplaque	B
8	and	B
9	stronger	B
10	antidegradation	I
11	effects	B
12	than	B
13	GLCM	B
14	.	O

1	A	B
2	mutation	B
3	in	B
4	the	I
5	C	B
6	domain	B
7	of	B
8	Rb	B
9	,	B
10	L901Q	B
11	,	B
12	has	B
13	been	B
14	identified	B
15	that	B
16	completely	B
17	abolishes	B
18	cdk4	I
19	/	I
20	D1	B
21	phosphorylation	B
22	of	B
23	the	B
24	isolated	B
25	C	B
26	domain	B
27	.	B

1	Homo	I
2	-	I
3	oligomerisation	I
4	and	I
5	nuclear	I
6	localisation	B
7	of	B
8	mouse	B
9	histone	B
10	deacetylase	B
11	1	B
12	.	I

1	Energy	B
2	expenditure	B
3	was	B
4	obtained	B
5	using	B
6	a	B
7	primed	B
8	,	B
9	3	O
10	-	B
11	hour	I
12	infusion	I
13	of	B
14	NaH	B
15	(	B
16	13	B
17	)	B
18	CO	B
19	(	I
20	3	I
21	'),	I
22	breath	I
23	(	B
24	13	I
25	)	I
26	CO	I
27	(	I
28	2	I
29	)	B
30	enrichment	I
31	determination	I
32	by	I
33	isotope	B
34	ratio	B
35	mass	I
36	spectroscopy	B
37	,	B
38	and	B
39	the	I
40	application	B
41	of	B
42	a	B
43	standard	B
44	regression	B
45	equation	B
46	.	I

1	Fasting	I
2	gastrin	I
3	levels	B
4	(	B
5	normal	B
6	range	B
7	:	I
8	25	I
9	-	I
10	110	I
11	mU	B
12	/	B
13	L	B
14	)	B
15	varied	B
16	from	O
17	48	I
18	.	I
19	78	I
20	mU	I
21	/	B
22	L	B
23	-	B
24	168	B
25	.	I
26	20	I
27	(	I
28	mean	I
29	:	I
30	85	I
31	.	I
32	23	I
33	mU	I
34	/	B
35	L	B
36	).	B

1	Identification	B
2	of	B
3	pulmonary	B
4	vein	B
5	stenosis	B
6	after	B
7	radiofrequency	B
8	ablation	B
9	for	B
10	atrial	B
11	fibrillation	I
12	using	B
13	MRI	I
14	.	I

1	The	I
2	continuing	I
3	development	B
4	of	B
5	ligands	B
6	that	B
7	function	B
8	as	B
9	selective	B
10	estrogens	I
11	or	I
12	antiestrogens	I
13	for	I
14	ERalpha	I
15	or	I
16	ERbeta	I
17	should	B
18	allow	B
19	optimized	B
20	tissue	B
21	selectivity	B
22	of	B
23	these	B
24	agents	B
25	for	B
26	menopausal	I
27	hormone	I
28	replacement	I
29	therapy	I
30	and	I
31	the	I
32	treatment	I
33	and	I
34	prevention	I
35	of	I
36	breast	I
37	cancer	I
38	.	I

1	Baseline	B
2	variables	B
3	associated	B
4	with	B
5	CD	B
6	included	B
7	a	B
8	less	B
9	frequent	I
10	use	I
11	of	I
12	prestroke	I
13	aspirin	I
14	and	I
15	a	I
16	higher	I
17	incidence	I
18	of	I
19	early	I
20	CT	I
21	changes	I
22	of	B
23	edema	B
24	or	I
25	mass	I
26	effect	I
27	or	I
28	dense	I
29	middle	I
30	cerebral	I
31	artery	I
32	sign	I
33	.	I

1	A	B
2	peculiar	B
3	people	B
4	:	I
5	"	B
6	the	B
7	physiological	B
8	aspects	B
9	of	B
10	Mormonism	B
11	1850	B
12	-	B
13	1975	B
14	."	B

1	SH2D1A	B
2	protein	B
3	levels	B
4	are	B
5	up	B
6	-	B
7	regulated	I
8	by	I
9	CD40	I
10	cross	B
11	-	I
12	linking	I
13	and	I
14	down	I
15	-	I
16	regulated	I
17	by	I
18	B	I
19	cell	B
20	receptor	B
21	ligation	B
22	.	I

1	The	I
2	Genescan	B
3	program	B
4	predicted	B
5	an	B
6	open	B
7	reading	B
8	frame	B
9	of	B
10	a	B
11	novel	B
12	,	B
13	intron	B
14	-	B
15	less	B
16	gene	I
17	adjacent	I
18	to	I
19	the	I
20	B236	I
21	spot	B
22	that	B
23	encodes	B
24	a	B
25	putative	B
26	493	I
27	-	I
28	amino	I
29	acid	B
30	protein	B
31	containing	B
32	the	I
33	SNAG	I
34	repressor	I
35	motif	I
36	in	B
37	the	B
38	NH2	B
39	-	I
40	terminal	I
41	region	B
42	and	B
43	five	B
44	C2H2	B
45	-	I
46	type	B
47	zinc	B
48	finger	B
49	motifs	B
50	in	B
51	the	I
52	COOH	I
53	-	I
54	terminal	I
55	half	B
56	.	B

1	Under	B
2	our	B
3	conditions	B
4	,	B
5	the	B
6	combination	B
7	O3	B
8	/	B
9	UV	B
10	did	B
11	not	O
12	improve	B
13	the	B
14	degradation	I
15	rate	I
16	obtained	I
17	by	I
18	ozonation	I
19	.	I

1	The	I
2	metabolic	I
3	events	B
4	occurring	B
5	at	B
6	or	I
7	near	I
8	that	I
9	structure	B
10	and	I
11	involving	I
12	cyclin	B
13	D3	B
14	cause	B
15	the	B
16	translocation	I
17	of	I
18	ICP0	B
19	to	I
20	the	I
21	cytoplasm	I
22	.	I

1	In	B
2	the	B
3	single	B
4	case	B
5	the	B
6	restoration	B
7	of	B
8	a	B
9	structured	B
10	daily	B
11	routine	B
12	represents	B
13	the	B
14	presupposition	B
15	for	B
16	a	B
17	cognitive	B
18	therapy	I
19	.	I

1	Immunofluorescence	B
2	studies	B
3	in	B
4	C2C12	I
5	myotubes	I
6	show	B
7	that	B
8	Smad2	B
9	and	B
10	MEF2A	B
11	co	B
12	-	B
13	localise	B
14	in	B
15	the	B
16	nucleus	B
17	of	B
18	multinuclear	B
19	myotubes	B
20	during	B
21	differentiation	B
22	.	B

1	In	B
2	35	B
3	of	B
4	those	B
5	patients	B
6	DD	B
7	was	B
8	measured	O
9	also	O
10	with	O
11	microlatex	B
12	tests	B
13	--	B
14	Tinaquant	B
15	and	B
16	BC	I
17	d	B
18	-	B
19	dimer	B
20	.	I

1	Simulating	B
2	the	B
3	impact	B
4	during	B
5	human	B
6	jumping	B
7	by	B
8	means	B
9	of	B
10	a	B
11	4	B
12	-	B
13	degrees	B
14	-	B
15	of	B
16	-	B
17	freedom	B
18	model	B
19	with	O
20	time	B
21	-	O
22	dependent	B
23	properties	I
24	.	I

1	A	B
2	novel	B
3	approach	B
4	was	B
5	developed	B
6	for	B
7	identifying	B
8	transcription	B
9	factor	B
10	activities	B
11	associated	O
12	with	O
13	NGF	O
14	-	O
15	activated	O
16	,	O
17	but	O
18	not	B
19	EGF	B
20	-	O
21	activated	B
22	,	B
23	signaling	O
24	,	B
25	using	B
26	random	B
27	oligonucleotide	O
28	clones	O
29	from	O
30	a	O
31	DNA	O
32	recognition	O
33	library	B
34	to	I
35	isolate	I
36	specific	I
37	DNA	B
38	binding	B
39	proteins	B
40	from	B
41	PC12	I
42	nuclear	B
43	extracts	B
44	.	B

1	Atheroma	B
2	appears	B
3	as	B
4	a	B
5	very	B
6	low	B
7	signal	B
8	intensity	I
9	area	I
10	on	I
11	2	B
12	-	I
13	dimensional	I
14	time	I
15	-	I
16	of	I
17	-	I
18	flight	I
19	(	B
20	TOF	I
21	)	I
22	magnetic	B
23	resonance	B
24	(	B
25	MR	B
26	)	B
27	images	B
28	,	B
29	and	B
30	its	B
31	components	B
32	have	B
33	various	B
34	signal	I
35	intensities	I
36	on	B
37	spin	I
38	-	I
39	echo	I
40	(	I
41	SE	I
42	)	B
43	images	B
44	.	B

1	Finally	I
2	a	B
3	10	B
4	-	I
5	nucleotide	B
6	region	B
7	flanking	B
8	the	B
9	exon	B
10	4	B
11	protein	B
12	-	B
13	binding	B
14	site	B
15	is	B
16	homologous	B
17	to	I
18	instability	I
19	elements	B
20	within	B
21	five	B
22	other	B
23	transcripts	B
24	,	B
25	suggesting	B
26	that	B
27	a	B
28	common	O
29	coding	O
30	region	O
31	determinant	O
32	may	O
33	exist	B
34	.	O

1	Chronic	B
2	nutritional	B
3	diseases	B
4	of	B
5	infectious	B
6	origin	B
7	:	B
8	an	B
9	assessment	B
10	of	B
11	a	B
12	nascent	B
13	field	I
14	.	I

1	The	I
2	cut	B
3	-	I
4	off	B
5	percentage	I
6	positivity	I
7	value	B
8	was	B
9	established	B
10	using	B
11	500	B
12	brucellosis	B
13	-	B
14	positive	I
15	and	I
16	500	B
17	brucellosis	B
18	-	I
19	negative	I
20	serum	B
21	samples	B
22	,	B
23	confirmed	B
24	with	O
25	reference	B
26	to	B
27	the	I
28	sample	I
29	data	I
30	using	B
31	the	I
32	indirect	B
33	ELISA	B
34	kit	I
35	.	I

1	PROCEDURE	B
2	:	I
3	Cannulas	I
4	were	B
5	surgically	B
6	positioned	B
7	in	B
8	the	B
9	abomasal	B
10	body	I
11	and	I
12	pyloric	I
13	antrum	B
14	of	B
15	each	I
16	calf	I
17	.	I

1	The	I
2	utilities	I
3	measured	I
4	in	I
5	our	I
6	study	B
7	can	B
8	be	B
9	applied	B
10	directly	B
11	to	B
12	quality	B
13	-	I
14	of	B
15	-	B
16	life	B
17	determinations	B
18	in	B
19	clinical	B
20	trials	B
21	of	O
22	adjuvant	O
23	IFN	B
24	alpha	B
25	-	B
26	2b	B
27	to	I
28	measure	I
29	the	I
30	net	B
31	benefit	B
32	of	B
33	therapy	B
34	.	I

1	Cells	B
2	lacking	B
3	p116	B
4	exhibit	B
5	a	B
6	striking	B
7	defect	B
8	in	B
9	the	B
10	formation	I
11	of	I
12	these	I
13	macropinocytic	B
14	structures	I
15	,	B
16	a	B
17	concomitant	B
18	reduction	I
19	in	I
20	the	I
21	rate	I
22	of	I
23	fluid	B
24	phase	B
25	pinocytosis	B
26	,	B
27	a	B
28	significant	B
29	decrease	B
30	in	I
31	the	I
32	efficiency	B
33	of	B
34	chemotactic	B
35	aggregation	B
36	,	B
37	and	B
38	a	B
39	decrease	I
40	in	I
41	cellular	I
42	F	B
43	-	B
44	actin	B
45	content	I
46	.	I

1	Ectopic	I
2	expression	B
3	of	B
4	the	B
5	dominant	I
6	mutant	I
7	Lg3	I
8	allele	I
9	is	I
10	believed	I
11	to	I
12	cause	I
13	the	I
14	phenotype	I
15	.	I

1	Specimen	B
2	mass	B
3	reduction	I
4	increased	I
5	with	I
6	irradiance	B
7	from	I
8	19	I
9	to	I
10	72	I
11	%	I
12	of	I
13	the	B
14	initial	B
15	mass	B
16	for	B
17	9	B
18	--	B
19	31	B
20	W	B
21	/	B
22	cm	B
23	(	B
24	2	B
25	),	B
26	respectively	I
27	.	I

1	Analysis	B
2	of	B
3	the	B
4	genome	I
5	sequence	I
6	revealed	I
7	26	B
8	,	B
9	588	B
10	protein	B
11	-	B
12	encoding	B
13	transcripts	B
14	for	B
15	which	B
16	there	B
17	was	O
18	strong	O
19	corroborating	B
20	evidence	B
21	and	I
22	an	I
23	additional	B
24	approximately	B
25	12	B
26	,	B
27	000	O
28	computationally	B
29	derived	B
30	genes	I
31	with	I
32	mouse	I
33	matches	B
34	or	B
35	other	I
36	weak	B
37	supporting	B
38	evidence	I
39	.	I

1	The	I
2	other	I
3	inhibitor	B
4	was	B
5	a	B
6	single	B
7	TAR	B
8	decoy	B
9	,	B
10	driven	B
11	by	I
12	the	I
13	U6	B
14	small	B
15	nuclear	B
16	RNA	B
17	promoter	B
18	(	B
19	U6	B
20	-	B
21	P	I
22	).	I

1	By	B
2	comparison	B
3	,	B
4	in	B
5	nontumorigenic	B
6	Ad5	B
7	cells	B
8	,	B
9	class	B
10	I	B
11	expression	B
12	is	B
13	high	B
14	due	B
15	to	B
16	negligible	I
17	binding	B
18	of	B
19	COUP	B
20	-	B
21	TF	B
22	and	B
23	strong	B
24	binding	B
25	of	B
26	NF	B
27	-	B
28	kappaB	I
29	.	I

1	Moreover	B
2	,	B
3	a	B
4	complex	B
5	containing	B
6	PTP	I
7	phi	I
8	,	B
9	paxillin	B
10	,	B
11	and	B
12	a	B
13	paxillin	I
14	-	I
15	associated	I
16	tyrosine	B
17	kinase	B
18	,	B
19	Pyk2	B
20	,	B
21	can	B
22	be	B
23	immunoprecipitated	B
24	from	I
25	macrophage	I
26	lysates	I
27	,	B
28	and	B
29	the	I
30	catalytic	B
31	domain	B
32	of	B
33	PTP	B
34	phi	B
35	selectively	B
36	binds	B
37	paxillin	I
38	and	I
39	Pyk2	I
40	in	I
41	vitro	I
42	.	I

1	Our	B
2	previous	B
3	studies	B
4	have	I
5	shown	B
6	that	B
7	SHP	B
8	-	O
9	1	B
10	,	B
11	a	O
12	SH2	O
13	domain	O
14	-	O
15	containing	B
16	protein	B
17	-	I
18	tyrosine	B
19	phosphatase	B
20	,	B
21	is	B
22	expressed	B
23	not	B
24	only	B
25	in	B
26	cells	B
27	of	O
28	hematopoietic	B
29	lineages	B
30	,	B
31	but	B
32	also	B
33	in	B
34	many	B
35	non	B
36	-	B
37	hematopoietic	B
38	cells	B
39	under	B
40	the	I
41	control	I
42	of	I
43	an	B
44	alternative	B
45	tissue	I
46	-	I
47	specific	I
48	promoter	B
49	,	B
50	P1	B
51	.	B

1	Whereas	B
2	Smad2	B
3	was	B
4	rapidly	B
5	phosphorylated	B
6	by	I
7	TGF	I
8	-	I
9	beta	B
10	and	B
11	involved	I
12	in	I
13	the	I
14	initial	B
15	activation	B
16	of	B
17	Agc	B
18	expression	B
19	in	B
20	confluent	B
21	cells	B
22	,	B
23	Smad2	B
24	activation	B
25	was	B
26	not	O
27	required	O
28	for	O
29	maintaining	O
30	the	I
31	high	B
32	level	O
33	of	O
34	Agc	O
35	expression	B
36	.	I

1	The	I
2	astronaut	B
3	crew	I
4	operates	B
5	the	B
6	payload	B
7	and	I
8	documents	B
9	its	B
10	operation	B
11	.	I

1	This	B
2	molecule	B
3	,	B
4	wH22xeGFP	B
5	,	O
6	consists	O
7	of	B
8	the	O
9	entire	B
10	humanized	B
11	anti	B
12	-	I
13	FcgammaRI	I
14	mAb	B
15	H22	B
16	with	B
17	eGFP	B
18	genetically	I
19	fused	I
20	to	I
21	the	I
22	C	I
23	-	I
24	terminal	I
25	end	I
26	of	B
27	each	I
28	CH3	I
29	domain	B
30	.	B
31	wH22xeGFP	B
32	binds	B
33	within	B
34	the	B
35	ligand	B
36	-	B
37	binding	B
38	region	B
39	by	O
40	its	B
41	Fc	O
42	end	O
43	,	O
44	as	O
45	well	B
46	as	I
47	outside	I
48	the	I
49	ligand	B
50	-	B
51	binding	B
52	region	B
53	by	B
54	its	B
55	Fab	B
56	ends	B
57	,	B
58	thereby	B
59	cross	B
60	-	B
61	linking	I
62	FcgammaRI	I
63	.	I

1	On	I
2	the	I
3	other	I
4	hand	B
5	,	B
6	hepatic	B
7	arterial	B
8	infusion	B
9	therapy	B
10	prolongs	I
11	the	I
12	survival	I
13	of	B
14	H3	B
15	patients	B
16	only	B
17	.	B

1	Hepatitis	I
2	B	I
3	and	I
4	C	B
5	seroprevalence	B
6	rates	I
7	among	B
8	high	B
9	-	B
10	risk	B
11	adolescents	B
12	are	O
13	lower	B
14	in	B
15	El	B
16	Paso	O
17	than	O
18	in	O
19	other	O
20	similar	O
21	US	O
22	populations	O
23	,	O
24	presenting	O
25	an	O
26	ideal	O
27	climate	O
28	for	O
29	prevention	O
30	programs	B
31	.	O

1	We	B
2	found	I
3	that	B
4	the	B
5	SOCS	I
6	box	B
7	interacted	B
8	with	I
9	Cullin	I
10	-	I
11	2	I
12	and	I
13	promoted	I
14	ubiquitination	I
15	of	I
16	TEL	I
17	-	I
18	JAK2	I
19	.	I

1	A	B
2	patient	B
3	is	B
4	described	I
5	with	I
6	skin	B
7	lesions	B
8	resembling	B
9	Kaposi	B
10	'	B
11	s	O
12	sarcoma	O
13	(	O
14	KS	O
15	).	O

1	Special	B
2	issues	B
3	devoted	B
4	to	B
5	the	I
6	biosynthesis	I
7	of	I
8	woody	B
9	plant	B
10	biopolymers	B
11	and	B
12	related	B
13	substances	I
14	.	I

1	These	B
2	data	B
3	suggest	B
4	that	B
5	ADAM	B
6	-	B
7	TS12	B
8	may	B
9	play	B
10	roles	B
11	in	B
12	pulmonary	B
13	cells	B
14	during	O
15	fetal	O
16	development	B
17	or	O
18	in	B
19	tumor	I
20	processes	B
21	through	I
22	its	I
23	proteolytic	I
24	activity	B
25	or	I
26	as	I
27	a	I
28	molecule	B
29	potentially	B
30	involved	B
31	in	I
32	regulation	B
33	of	B
34	cell	B
35	adhesion	B
36	.	B

1	Progressive	B
2	study	B
3	and	B
4	robustness	B
5	test	I
6	of	I
7	QSAR	I
8	model	I
9	based	B
10	on	B
11	quantum	B
12	chemical	B
13	parameters	B
14	for	I
15	predicting	B
16	BCF	B
17	of	B
18	selected	B
19	polychlorinated	B
20	organic	B
21	compounds	B
22	(	B
23	PCOCs	B
24	).	B

1	Additional	I
2	deletion	B
3	mutations	B
4	revealed	B
5	a	B
6	new	B
7	,	B
8	67	B
9	-	I
10	amino	I
11	-	I
12	acid	B
13	functional	B
14	domain	B
15	within	B
16	the	B
17	proline	B
18	-	B
19	rich	B
20	region	B
21	of	B
22	SLP	B
23	-	I
24	76	I
25	,	B
26	which	B
27	we	B
28	have	B
29	termed	B
30	the	B
31	P	I
32	-	I
33	1	I
34	domain	B
35	.	B

1	Patients	B
2	with	B
3	type	B
4	III	B
5	SOD	B
6	may	B
7	have	I
8	visceral	I
9	hyperalgesia	B
10	;	B
11	a	B
12	trial	B
13	of	B
14	antidepressants	B
15	or	B
16	a	I
17	therapeutic	B
18	trial	B
19	with	B
20	botulinum	I
21	toxin	I
22	injection	I
23	into	I
24	the	I
25	ampulla	I
26	should	B
27	be	B
28	considered	B
29	prior	B
30	to	I
31	more	I
32	invasive	I
33	endoscopic	I
34	therapy	I
35	.	I

1	We	B
2	have	I
3	now	B
4	tested	B
5	all	B
6	known	B
7	mammalian	B
8	Groucho	B
9	family	B
10	members	O
11	for	B
12	their	B
13	ability	B
14	to	I
15	interact	I
16	specifically	I
17	with	B
18	individual	B
19	Tcf	B
20	/	B
21	Lef	B
22	family	I
23	members	B
24	.	I

1	Body	B
2	weight	I
3	reduction	I
4	increases	I
5	insulin	I
6	sensitivity	I
7	and	I
8	improves	I
9	both	I
10	blood	B
11	glucose	B
12	and	B
13	blood	B
14	pressure	B
15	control	B
16	.	I

1	Sequence	B
2	analysis	B
3	indicates	B
4	that	B
5	RBP21	B
6	shares	B
7	homology	B
8	with	B
9	other	B
10	retinoblastoma	B
11	-	I
12	binding	B
13	proteins	B
14	in	B
15	the	B
16	pRb	B
17	-	B
18	binding	B
19	motif	B
20	LxCxE	O
21	at	O
22	the	O
23	C	O
24	-	O
25	terminal	O
26	region	O
27	.	O

1	Tolerance	B
2	in	B
3	renal	B
4	transplantation	B
5	after	B
6	allogeneic	B
7	bone	B
8	marrow	B
9	transplantation	B
10	-	B
11	6	B
12	-	I
13	year	I
14	follow	B
15	-	B
16	up	B
17	.	I

1	By	B
2	analyzing	B
3	5	I
4	'-	B
5	deletion	B
6	insulin	I
7	promoter	B
8	-	I
9	reporter	I
10	constructs	B
11	in	B
12	transient	B
13	transfections	B
14	of	B
15	clonal	B
16	INS	B
17	-	B
18	1	B
19	beta	B
20	-	O
21	cells	O
22	,	O
23	we	O
24	located	O
25	activating	O
26	Hh	O
27	-	O
28	responsive	O
29	regions	O
30	within	O
31	the	O
32	rat	O
33	insulin	O
34	I	I
35	promoter	B
36	that	O
37	include	O
38	the	B
39	glucose	B
40	-	B
41	response	I
42	elements	B
43	Far	B
44	(	B
45	E2	B
46	)	O
47	and	O
48	Flat	B
49	(	O
50	A2	B
51	/	B
52	A3	O
53	).	O

1	However	B
2	,	B
3	when	B
4	directed	B
5	to	B
6	the	I
7	nucleosome	I
8	by	I
9	fusion	I
10	to	I
11	core	I
12	histone	I
13	H2A	I
14	or	I
15	H2B	I
16	,	B
17	the	B
18	non	B
19	-	I
20	histone	I
21	tail	I
22	forms	I
23	an	I
24	MCB	B
25	that	B
26	appears	B
27	identical	B
28	to	I
29	that	I
30	of	I
31	the	I
32	endogenous	I
33	protein	I
34	.	I

1	Data	B
2	were	B
3	obtained	B
4	from	B
5	2	B
6	undergraduate	B
7	student	B
8	samples	B
9	,	B
10	a	O
11	self	O
12	-	B
13	report	B
14	group	B
15	(	B
16	n	B
17	=	I
18	132	I
19	)	I
20	who	I
21	provided	I
22	NEO	I
23	-	I
24	PI	I
25	-	I
26	R	I
27	self	I
28	-	I
29	ratings	I
30	on	B
31	2	B
32	occasions	I
33	separated	I
34	by	I
35	a	I
36	7	B
37	-	B
38	to	I
39	14	I
40	-	I
41	day	I
42	interval	I
43	and	I
44	an	I
45	informant	B
46	group	I
47	(	I
48	n	B
49	=	I
50	109	I
51	)	B
52	who	B
53	provided	B
54	ratings	B
55	of	B
56	well	B
57	-	I
58	known	B
59	friends	B
60	or	I
61	relatives	B
62	on	B
63	2	B
64	occasions	I
65	separated	I
66	by	I
67	a	I
68	6	B
69	month	B
70	interval	B
71	.	B

1	Pulmonary	B
2	embolectomy	B
3	and	B
4	lung	B
5	transplantation	B
6	are	B
7	the	B
8	main	B
9	indications	B
10	for	B
11	the	B
12	use	B
13	of	I
14	heart	B
15	-	I
16	lung	B
17	-	B
18	machine	I
19	.	I

1	Comparison	B
2	of	B
3	German	B
4	language	B
5	versions	B
6	of	B
7	the	B
8	QWB	B
9	-	B
10	SA	I
11	and	I
12	SF	B
13	-	I
14	36	B
15	evaluating	B
16	outcomes	B
17	for	B
18	patients	B
19	with	B
20	prostate	B
21	disease	B
22	.	B

1	The	I
2	median	I
3	preoperative	I
4	best	B
5	-	I
6	corrected	B
7	visual	I
8	acuity	B
9	of	B
10	0	B
11	.	B
12	08	B
13	(	B
14	range	B
15	hand	B
16	motions	B
17	/	B
18	0	B
19	.	B
20	003	I
21	to	I
22	0	I
23	.	I
24	4	I
25	),	I
26	improved	B
27	by	I
28	5	I
29	lines	I
30	to	I
31	a	I
32	median	I
33	final	I
34	postoperative	I
35	best	B
36	-	B
37	corrected	B
38	visual	I
39	acuity	B
40	of	B
41	0	B
42	.	B
43	25	I
44	(	I
45	range	I
46	0	B
47	.	B
48	025	I
49	-	I
50	0	B
51	.	I
52	5	I
53	)	I
54	(	I
55	P	I
56	=	I
57	0	I
58	.	I
59	001	I
60	).	I

1	Angina	B
2	(	B
3	Q	B
4	)	B
5	persistence	B
6	showed	B
7	marked	B
8	associations	B
9	with	B
10	previous	B
11	myocardial	B
12	infarction	B
13	,	B
14	diagnosed	B
15	angina	B
16	,	B
17	electrocardiogram	B
18	ischemia	B
19	,	O
20	and	O
21	subsequent	B
22	major	O
23	ischemic	O
24	heart	O
25	disease	O
26	events	O
27	from	O
28	Q5	B
29	onward	B
30	.	O

1	Site	I
2	-	I
3	directed	I
4	mutagenesis	I
5	of	I
6	CAR	I
7	revealed	I
8	that	B
9	CAR	B
10	residues	B
11	Leu73	I
12	and	I
13	Lys121	I
14	and	I
15	/	I
16	or	I
17	Lys123	I
18	are	I
19	critical	I
20	contact	I
21	residues	I
22	,	B
23	with	B
24	Tyr80	B
25	and	I
26	Tyr83	I
27	being	I
28	peripherally	I
29	involved	I
30	in	I
31	the	I
32	binding	B
33	interaction	B
34	with	B
35	the	B
36	Ad5	B
37	,	B
38	Ad9	B
39	,	B
40	Ad12	B
41	,	B
42	and	B
43	Ad41L	B
44	fiber	B
45	knobs	B
46	.	B

1	Transforming	B
2	growth	B
3	factor	B
4	-	B
5	beta	B
6	(	O
7	TGF	B
8	-	O
9	beta	B
10	)	O
11	induced	O
12	growth	O
13	arrest	O
14	of	O
15	cells	O
16	involves	O
17	regulation	O
18	of	O
19	the	O
20	activities	O
21	of	O
22	both	O
23	D	O
24	-	O
25	and	O
26	E	O
27	-	O
28	type	O
29	cyclin	O
30	kinase	O
31	complexes	O
32	thought	O
33	to	I
34	be	I
35	mediated	I
36	primarily	I
37	by	I
38	the	I
39	regulation	I
40	of	B
41	p15	B
42	(	B
43	Ink4b	I
44	)	I
45	and	I
46	p27	I
47	(	I
48	Kip1	I
49	)	I
50	cyclin	B
51	kinase	B
52	inhibitors	B
53	.	B

1	These	B
2	data	B
3	indicate	B
4	that	B
5	the	B
6	SmSmad2	I
7	responds	I
8	to	I
9	the	I
10	TGF	I
11	-	I
12	beta	B
13	signals	B
14	by	B
15	interaction	B
16	with	B
17	receptor	B
18	I	B
19	,	B
20	which	B
21	phosphorylates	B
22	it	B
23	,	B
24	whereupon	B
25	it	B
26	translocates	B
27	into	O
28	the	O
29	nucleus	O
30	presumably	O
31	to	I
32	regulate	I
33	target	I
34	gene	I
35	transcription	I
36	and	I
37	consequently	B
38	elicit	I
39	a	B
40	specific	B
41	TGF	B
42	-	B
43	beta	B
44	effect	B
45	.	B

1	We	B
2	propose	B
3	that	B
4	TFOs	B
5	represent	B
6	a	B
7	therapeutic	B
8	potential	B
9	to	I
10	specifically	I
11	diminish	I
12	the	I
13	expression	B
14	of	B
15	c	I
16	-	I
17	sis	I
18	/	B
19	PDGF	B
20	-	B
21	B	B
22	proto	B
23	-	B
24	oncogene	B
25	in	B
26	various	B
27	pathologic	B
28	settings	B
29	where	B
30	constitutive	B
31	expression	I
32	of	B
33	this	I
34	gene	I
35	has	I
36	been	B
37	observed	B
38	.	I

1	The	I
2	increased	I
3	clearance	I
4	observed	I
5	in	I
6	young	I
7	infants	I
8	is	I
9	in	I
10	contrast	I
11	to	I
12	other	I
13	opioids	I
14	.	I

1	Peripheral	B
2	metabolism	B
3	of	B
4	androgens	B
5	takes	B
6	place	B
7	in	B
8	various	B
9	areas	B
10	within	B
11	the	O
12	pilosebaceous	O
13	unit	O
14	,	O
15	as	O
16	indicated	B
17	by	I
18	local	I
19	differences	B
20	in	O
21	the	O
22	activities	O
23	of	O
24	aromatase	O
25	,	O
26	5alpha	O
27	-	O
28	reductase	I
29	as	I
30	well	I
31	as	I
32	of	I
33	the	I
34	presence	B
35	of	B
36	the	B
37	androgen	I
38	receptors	I
39	.	I

1	This	B
2	unique	I
3	location	I
4	of	I
5	cavernous	B
6	malformation	B
7	is	B
8	associated	B
9	with	B
10	a	B
11	risk	B
12	of	B
13	permanent	B
14	loss	B
15	of	B
16	the	B
17	vision	B
18	.	O

1	The	I
2	JHRLSS	I
3	has	I
4	been	B
5	used	B
6	in	B
7	prior	B
8	studies	B
9	to	I
10	assess	I
11	RLS	I
12	severity	I
13	,	I
14	but	B
15	has	B
16	not	B
17	previously	B
18	been	B
19	validated	B
20	in	B
21	relation	B
22	to	I
23	direct	I
24	measures	I
25	of	I
26	the	I
27	morbidity	B
28	associated	B
29	with	B
30	RLS	I
31	.	I

1	Consistent	B
2	effects	B
3	on	B
4	pVHL	B
5	function	B
6	were	B
7	observed	B
8	for	B
9	all	B
10	mutations	B
11	within	B
12	each	O
13	subclass	I
14	.	I

1	Interestingly	B
2	,	B
3	the	B
4	CYP71D20	I
5	-	I
6	encoded	B
7	enzyme	B
8	activity	B
9	was	B
10	capable	B
11	of	O
12	converting	O
13	both	O
14	5	O
15	-	I
16	epi	B
17	-	I
18	aristolochene	B
19	and	B
20	1	B
21	-	I
22	deoxycapsidiol	B
23	to	I
24	capsidiol	I
25	in	I
26	vitro	I
27	,	B
28	consistent	B
29	with	B
30	the	B
31	notion	B
32	that	B
33	this	I
34	P450	I
35	enzyme	B
36	catalyzes	B
37	both	B
38	hydroxylations	B
39	of	B
40	its	O
41	hydrocarbon	O
42	substrate	O
43	.	O

1	A	B
2	new	B
3	species	B
4	of	B
5	Euspondylus	B
6	is	B
7	described	B
8	based	B
9	on	B
10	a	B
11	female	B
12	(	B
13	taken	B
14	within	B
15	a	B
16	bromeliad	O
17	)	O
18	from	O
19	Cerro	O
20	El	O
21	Humo	O
22	,	O
23	Sucre	O
24	,	O
25	northeastern	O
26	Venezuela	O
27	.	O

1	The	I
2	most	I
3	important	I
4	finding	I
5	,	B
6	however	B
7	,	B
8	was	B
9	that	B
10	IMT	O
11	values	O
12	were	O
13	related	O
14	with	O
15	24	O
16	h	O
17	SBP	O
18	or	O
19	PP	I
20	standard	I
21	deviation	B
22	(	B
23	P	I
24	<	I
25	0	B
26	.	I
27	001	I
28	),	I
29	a	B
30	measure	B
31	of	B
32	overall	B
33	SBP	B
34	or	B
35	PP	I
36	variability	I
37	.	I

1	In	B
2	addition	B
3	,	B
4	severe	B
5	vision	B
6	loss	B
7	can	B
8	be	B
9	seen	B
10	with	B
11	interferon	I
12	alfa	B
13	-	I
14	2b	B
15	-	I
16	associated	B
17	retinopathy	I
18	.	I

1	FLP	I
2	and	I
3	Cre	I
4	recombinase	I
5	function	I
6	in	I
7	Xenopus	B
8	embryos	B
9	.	B

1	Keratoconjunctivitis	I
2	sicca	I
3	appears	I
4	to	I
5	be	I
6	a	I
7	common	B
8	ocular	B
9	complication	I
10	and	I
11	all	I
12	children	B
13	with	B
14	JRA	B
15	should	B
16	be	B
17	screened	B
18	for	B
19	it	B
20	with	B
21	a	B
22	comprehensive	O
23	battery	O
24	of	O
25	tests	B
26	.	O

1	Moreover	B
2	,	B
3	PTax	B
4	expressed	B
5	higher	B
6	background	B
7	activities	B
8	than	O
9	PTF	O
10	,	O
11	indicating	O
12	that	O
13	the	O
14	sequence	O
15	of	O
16	the	O
17	synthetic	O
18	regulatory	B
19	region	B
20	can	O
21	influence	O
22	background	O
23	levels	B
24	.	O

1	After	B
2	allowing	B
3	time	B
4	for	B
5	absorption	B
6	,	B
7	participants	B
8	completed	B
9	a	B
10	bridge	B
11	simulator	O
12	task	I
13	.	I

1	The	I
2	cleavage	B
3	site	I
4	between	B
5	VPg	B
6	and	I
7	RNA	I
8	dependent	I
9	RNA	I
10	polymerase	I
11	was	B
12	predicted	B
13	to	I
14	be	I
15	E445	I
16	-	I
17	T446	I
18	based	B
19	on	B
20	the	B
21	amino	B
22	acid	B
23	sequence	B
24	analysis	B
25	of	B
26	the	B
27	polyprotein	B
28	from	B
29	different	I
30	sobemoviruses	I
31	.	I

1	Conformational	B
2	changes	B
3	of	B
4	the	B
5	ferric	I
6	uptake	I
7	regulation	I
8	protein	I
9	upon	B
10	metal	B
11	activation	B
12	and	B
13	DNA	B
14	binding	B
15	;	B
16	first	B
17	evidence	B
18	of	B
19	structural	B
20	homologies	B
21	with	B
22	the	B
23	diphtheria	B
24	toxin	I
25	repressor	I
26	.	I

1	At	B
2	visit	B
3	5	B
4	,	B
5	the	B
6	isokinetic	B
7	test	I
8	showed	I
9	impaired	I
10	muscle	I
11	function	I
12	recovery	I
13	from	I
14	23	I
15	%	I
16	to	I
17	32	I
18	%,	I
19	while	B
20	the	B
21	manual	B
22	test	I
23	showed	I
24	almost	I
25	full	I
26	recovery	I
27	.	I

1	Constitutive	B
2	phosphorylation	I
3	and	I
4	nuclear	I
5	localization	B
6	of	B
7	Smad3	B
8	are	B
9	correlated	B
10	with	B
11	increased	B
12	collagen	B
13	gene	B
14	transcription	B
15	in	B
16	activated	B
17	hepatic	B
18	stellate	B
19	cells	B
20	.	B

1	Cholesteryl	B
2	ester	I
3	transfer	I
4	protein	B
5	and	I
6	atherosclerosis	B
7	in	B
8	Japanese	B
9	subjects	B
10	:	I
11	a	I
12	study	B
13	based	B
14	on	B
15	coronary	B
16	angiography	I
17	.	I

1	And	B
2	,	B
3	most	B
4	importantly	B
5	,	B
6	reconstitution	B
7	of	B
8	a	B
9	consensus	B
10	CRE	B
11	,	B
12	within	B
13	the	B
14	21	B
15	-	B
16	bp	I
17	enhancers	I
18	increases	I
19	binding	B
20	of	B
21	CREB	B
22	/	B
23	ATF	O
24	proteins	B
25	but	B
26	abrogates	B
27	basal	B
28	repression	O
29	of	O
30	LTR	O
31	-	O
32	directed	O
33	transcription	O
34	in	O
35	vitro	B
36	.	I

1	Stable	B
2	transfection	B
3	of	B
4	human	B
5	CHOP	B
6	cDNA	I
7	into	I
8	mammary	I
9	carcinoma	B
10	cells	B
11	demonstrated	O
12	that	O
13	CHOP	O
14	functioned	O
15	not	O
16	as	B
17	a	I
18	mediator	I
19	of	I
20	hGH	B
21	-	B
22	stimulated	B
23	mitogenesis	O
24	but	B
25	rather	B
26	enhanced	B
27	the	B
28	protection	I
29	from	I
30	apoptosis	B
31	afforded	B
32	by	I
33	hGH	B
34	in	B
35	a	B
36	p38	B
37	MAPK	B
38	-	B
39	dependent	B
40	manner	B
41	.	I

1	The	I
2	combination	I
3	of	B
4	ifosfamide	B
5	,	B
6	epirubicin	B
7	and	B
8	etoposide	B
9	(	B
10	IEV	I
11	)	B
12	is	B
13	an	B
14	effective	B
15	salvage	B
16	regimen	I
17	for	I
18	lymphoproliferative	B
19	disease	B
20	.	B

1	Interestingly	B
2	,	B
3	the	B
4	activity	B
5	of	B
6	IkappaB	B
7	kinase	B
8	(	B
9	IKK	B
10	-	I
11	beta	B
12	),	B
13	which	B
14	plays	B
15	an	B
16	essential	B
17	role	B
18	in	B
19	NF	B
20	-	I
21	kappaB	I
22	activation	B
23	through	I
24	IkappaB	I
25	phosphorylation	I
26	,	B
27	was	B
28	largely	B
29	enhanced	B
30	in	B
31	paclitaxel	B
32	-	I
33	treated	B
34	cells	B
35	,	B
36	detected	B
37	as	B
38	IkappaBalpha	B
39	phosphorylation	I
40	.	I

1	The	I
2	recessive	I
3	hos1	I
4	mutation	I
5	causes	I
6	enhanced	B
7	induction	I
8	of	I
9	the	I
10	CBF	I
11	transcription	I
12	factors	I
13	by	I
14	low	I
15	temperature	B
16	as	B
17	well	I
18	as	I
19	of	I
20	their	I
21	downstream	B
22	cold	B
23	-	B
24	responsive	B
25	genes	I
26	.	I

1	Apart	B
2	from	I
3	antimicrobial	I
4	properties	I
5	,	I
6	recent	B
7	data	B
8	indicate	B
9	that	B
10	PMN	B
11	also	B
12	exert	B
13	anti	B
14	-	B
15	inflammatory	B
16	effects	B
17	by	B
18	stimulation	I
19	and	I
20	release	B
21	of	B
22	cytokine	B
23	antagonists	B
24	such	B
25	as	I
26	interleukin	I
27	-	I
28	1	I
29	receptor	B
30	antagonist	B
31	(	B
32	IL	I
33	-	I
34	1ra	I
35	).	I

1	Early	B
2	indicators	B
3	of	B
4	the	B
5	effect	B
6	of	B
7	a	B
8	breast	B
9	cancer	B
10	screening	B
11	program	B
12	for	B
13	low	B
14	-	B
15	income	I
16	women	B
17	.	I

1	An	B
2	association	I
3	was	B
4	demonstrated	B
5	between	B
6	the	B
7	expression	B
8	of	B
9	aberrantly	B
10	and	B
11	/	B
12	or	I
13	alternatively	I
14	spliced	I
15	mdm2	B
16	mRNAs	B
17	and	I
18	a	I
19	lack	I
20	of	B
21	progesterone	B
22	receptor	B
23	.	I

1	BACKGROUND	I
2	:	I
3	Dermoscopy	I
4	is	I
5	a	I
6	noninvasive	B
7	technique	I
8	that	I
9	increases	B
10	the	B
11	diagnostic	B
12	accuracy	B
13	of	B
14	pigmented	B
15	skin	B
16	lesions	O
17	,	B
18	particularly	O
19	improving	B
20	the	B
21	diagnosis	B
22	of	B
23	patients	B
24	with	B
25	cutaneous	B
26	melanoma	I
27	in	I
28	situ	I
29	(	I
30	CMIS	B
31	)	B
32	and	B
33	early	I
34	invasive	I
35	melanoma	I
36	.	I

1	Increased	I
2	erythropoietin	I
3	synthesis	I
4	in	I
5	patients	B
6	with	B
7	COLD	B
8	or	B
9	left	I
10	heart	I
11	failure	B
12	is	B
13	related	B
14	to	I
15	alterations	I
16	in	I
17	renal	I
18	haemodynamics	B
19	.	I

1	The	I
2	(	I
3	two	I
4	-	I
5	motif	B
6	)	B
7	domain	B
8	fold	B
9	contains	B
10	a	B
11	pair	B
12	of	B
13	calcium	B
14	binding	B
15	sites	B
16	very	B
17	similar	B
18	to	B
19	those	I
20	found	I
21	in	I
22	a	B
23	two	B
24	-	B
25	domain	B
26	prokaryotic	B
27	betagamma	B
28	-	O
29	crystallin	B
30	fold	B
31	family	B
32	member	B
33	,	B
34	Protein	B
35	S	B
36	.	B

1	Twenty	I
2	-	I
3	five	I
4	patients	B
5	also	B
6	received	B
7	PET	I
8	examinations	I
9	during	I
10	the	B
11	staging	B
12	procedures	B
13	.	B

1	In	B
2	the	B
3	last	B
4	case	B
5	,	B
6	both	B
7	hydroxychloroquine	B
8	,	O
9	carbamazepine	O
10	and	O
11	fluvoxamine	B
12	had	O
13	a	O
14	common	O
15	imputability	O
16	which	O
17	was	O
18	plausible	O
19	.	O

1	In	B
2	all	B
3	of	B
4	these	B
5	cases	B
6	,	B
7	expression	B
8	of	B
9	the	B
10	implicated	B
11	genes	I
12	was	B
13	absent	I
14	.	I

1	A	B
2	subset	B
3	of	B
4	patients	B
5	(	B
6	n	B
7	=	B
8	30	I
9	)	I
10	underwent	B
11	multichannel	B
12	pressure	B
13	flow	B
14	studies	B
15	,	B
16	which	B
17	demonstrated	B
18	that	B
19	transrectal	B
20	HIFU	B
21	reduces	I
22	bladder	I
23	outflow	I
24	obstruction	B
25	.	I

1	Biochemical	I
2	experiments	B
3	have	I
4	shown	B
5	that	B
6	CopG	B
7	co	B
8	-	I
9	operatively	I
10	associates	I
11	to	I
12	its	I
13	target	I
14	DNA	B
15	at	B
16	low	B
17	protein	B
18	:	I
19	DNA	I
20	ratios	I
21	,	B
22	completely	B
23	protecting	B
24	four	B
25	helical	B
26	turns	B
27	on	O
28	the	O
29	same	B
30	face	B
31	of	I
32	the	I
33	double	I
34	helix	B
35	in	B
36	both	B
37	directions	I
38	from	I
39	the	I
40	inverted	I
41	repeat	I
42	that	I
43	constitutes	B
44	the	B
45	CopG	I
46	primary	I
47	target	I
48	.	I

1	The	I
2	mechanism	I
3	of	B
4	ligand	B
5	-	B
6	activated	B
7	estrogen	B
8	receptor	B
9	alpha	B
10	(	B
11	ERalpha	B
12	)-	B
13	dependent	B
14	activation	B
15	of	B
16	gene	B
17	expression	B
18	through	I
19	the	I
20	SRE	I
21	was	B
22	determined	B
23	by	I
24	mutational	I
25	analysis	B
26	of	B
27	the	B
28	promoter	B
29	,	B
30	analysis	B
31	of	O
32	mitogen	O
33	-	O
34	activated	B
35	protein	O
36	kinase	O
37	(	B
38	MAPK	B
39	)	B
40	pathway	O
41	activation	B
42	by	O
43	E2	B
44	,	O
45	and	O
46	transforming	O
47	growth	O
48	factor	O
49	alpha	O
50	(	O
51	TGF	O
52	-	O
53	alpha	O
54	)	O
55	as	O
56	a	O
57	positive	O
58	control	O
59	.	I

1	This	B
2	study	B
3	investigated	B
4	whether	B
5	boron	B
6	would	B
7	enhance	B
8	the	B
9	ability	B
10	of	B
11	17beta	B
12	-	B
13	estradiol	B
14	(	B
15	E2	B
16	)	O
17	or	O
18	parathyroid	B
19	hormone	B
20	(	B
21	PTH	B
22	)	B
23	to	I
24	improve	I
25	bone	I
26	quality	B
27	in	B
28	ovariectomized	B
29	OVX	B
30	rats	B
31	.	I

1	2001	I
2	.	I

1	The	I
2	Gap69C	B
3	is	B
4	a	B
5	single	B
6	-	B
7	copy	B
8	gene	I
9	producing	I
10	a	B
11	major	B
12	2	B
13	.	I
14	1	I
15	-	I
16	kb	I
17	mRNA	B
18	throughout	B
19	development	B
20	,	B
21	but	B
22	its	B
23	amount	O
24	is	B
25	decreased	I
26	in	I
27	larvae	I
28	.	I

1	In	B
2	the	B
3	long	B
4	term	B
5	,	B
6	questions	B
7	still	B
8	remain	B
9	about	B
10	whether	B
11	pre	B
12	-	I
13	dialysis	B
14	rHu	B
15	EPO	B
16	either	B
17	speeds	B
18	up	B
19	or	B
20	delays	I
21	the	I
22	onset	B
23	of	B
24	dialysis	B
25	.	B

1	The	I
2	validity	I
3	of	I
4	the	I
5	FPS	I
6	-	I
7	R	I
8	was	B
9	further	B
10	supported	B
11	by	B
12	strong	B
13	positive	B
14	correlations	B
15	with	B
16	the	B
17	VAS	B
18	(	B
19	r	B
20	=	B
21	0	B
22	.	I
23	92	I
24	,	I
25	N	B
26	=	I
27	45	I
28	)	I
29	and	I
30	the	I
31	CAS	I
32	(	I
33	r	B
34	=	I
35	0	I
36	.	I
37	84	I
38	,	B
39	N	B
40	=	I
41	45	I
42	)	I
43	in	B
44	this	I
45	clinical	I
46	sample	I
47	.	I

1	The	I
2	BFA	I
3	System	I
4	reads	I
5	a	B
6	text	B
7	file	B
8	with	B
9	flows	B
10	,	B
11	measured	B
12	with	B
13	fluorescent	B
14	microsphere	B
15	technique	B
16	,	B
17	and	B
18	constructs	B
19	the	B
20	lung	B
21	anatomy	B
22	with	B
23	volumetric	B
24	pixels	I
25	showing	B
26	the	B
27	flows	B
28	with	B
29	a	B
30	color	B
31	schema	B
32	.	B

1	Therefore	I
2	,	B
3	to	I
4	understand	I
5	how	I
6	ErbB1	I
7	/	I
8	ErbB2	B
9	signaling	B
10	contributes	I
11	to	I
12	this	I
13	process	I
14	,	I
15	we	B
16	used	B
17	the	B
18	ErbB	B
19	kinase	I
20	inhibitor	B
21	AG1478in	B
22	ErbB2	B
23	-	I
24	dependent	I
25	BT	B
26	-	I
27	474	B
28	and	B
29	SKBR	I
30	-	I
31	3	I
32	human	I
33	breast	I
34	cancer	I
35	cells	B
36	.	B

1	Deletion	B
2	analyses	B
3	implicate	B
4	the	B
5	N	B
6	-	B
7	terminal	I
8	110	B
9	amino	I
10	acids	I
11	of	B
12	Grb14	B
13	and	I
14	ankyrin	I
15	repeats	I
16	10	B
17	-	I
18	19	I
19	of	B
20	tankyrase	B
21	2	B
22	in	B
23	mediating	B
24	this	I
25	interaction	I
26	.	I

1	Hormonal	I
2	regulation	B
3	of	B
4	multiple	B
5	promoters	B
6	of	B
7	the	B
8	rat	B
9	mitochondrial	B
10	glycerol	B
11	-	B
12	3	I
13	-	I
14	phosphate	I
15	dehydrogenase	I
16	gene	I
17	:	I
18	identification	I
19	of	I
20	a	B
21	complex	B
22	hormone	B
23	-	B
24	response	I
25	element	B
26	in	B
27	the	B
28	ubiquitous	B
29	promoter	B
30	B	B
31	.	I

1	SAMPLE	I
2	POPULATION	I
3	:	I
4	MCB	I
5	from	I
6	7	I
7	racing	I
8	Greyhounds	B
9	euthanatized	B
10	for	B
11	reasons	B
12	unrelated	B
13	to	I
14	MCB	I
15	abnormalities	B
16	.	I

1	Structural	B
2	studies	B
3	have	I
4	shown	B
5	that	B
6	class	B
7	I	B
8	major	B
9	histocompatibility	B
10	complex	B
11	(	B
12	MHC	B
13	)-	B
14	restricted	B
15	peptide	B
16	-	B
17	specific	B
18	T	B
19	cell	O
20	receptor	O
21	(	O
22	TCR	O
23	)-	B
24	alpha	O
25	/	B
26	betas	B
27	make	B
28	multiple	I
29	contacts	B
30	with	B
31	the	B
32	alpha1	B
33	and	B
34	alpha2	I
35	helices	B
36	of	B
37	the	B
38	MHC	B
39	,	B
40	but	B
41	it	B
42	is	B
43	unclear	B
44	which	B
45	or	I
46	how	I
47	many	B
48	of	B
49	these	B
50	interactions	B
51	contribute	B
52	to	I
53	functional	I
54	binding	I
55	.	I

1	Fans	B
2	in	B
3	tunnels	B
4	and	I
5	open	B
6	windows	B
7	at	B
8	aboveground	I
9	locations	I
10	appeared	B
11	to	I
12	greatly	I
13	reduce	I
14	the	I
15	likelihood	B
16	of	B
17	high	B
18	PH3	B
19	concentrations	B
20	in	B
21	enclosed	B
22	areas	B
23	.	I

1	In	B
2	DNA	B
3	strand	B
4	exchange	B
5	reactions	B
6	using	B
7	oligonucleotides	B
8	,	B
9	we	B
10	found	B
11	that	B
12	Rec2	B
13	exhibited	B
14	a	I
15	pairing	B
16	bias	B
17	that	B
18	is	B
19	opposite	B
20	that	B
21	of	B
22	RecA	B
23	.	I

1	A	B
2	major	B
3	mechanism	B
4	by	B
5	which	B
6	estrogens	B
7	prevent	B
8	osteoporosis	I
9	seems	I
10	to	I
11	be	I
12	repression	I
13	of	I
14	transcription	B
15	of	B
16	NF	B
17	-	B
18	kappa	I
19	B	I
20	target	I
21	genes	I
22	,	I
23	such	B
24	as	I
25	the	I
26	osteoclast	I
27	-	I
28	activating	I
29	cytokines	B
30	interleukin	B
31	-	I
32	6	I
33	and	I
34	interleukin	I
35	-	I
36	1	I
37	.	I

1	Linear	B
2	eight	B
3	-	B
4	or	I
5	nine	I
6	-	I
7	residue	I
8	D	I
9	-	I
10	peptides	I
11	derived	I
12	from	I
13	the	I
14	pocket	I
15	-	I
16	binding	B
17	domain	B
18	of	B
19	the	B
20	cyclic	B
21	molecules	B
22	also	B
23	bind	B
24	specifically	B
25	.	B

1	As	B
2	expected	I
3	,	B
4	homologous	B
5	loxP	B
6	sequences	B
7	efficiently	B
8	underwent	B
9	Cre	B
10	-	B
11	mediated	I
12	recombination	I
13	.	I

1	Multistage	B
2	models	I
3	and	I
4	the	I
5	A	B
6	-	I
7	bomb	B
8	survivor	I
9	data	B
10	:	I
11	implications	I
12	for	I
13	carcinogenic	B
14	mechanisms	B
15	?	B

1	The	I
2	results	I
3	indicate	I
4	that	B
5	a	B
6	more	B
7	differentiated	B
8	diagnosis	B
9	of	B
10	the	B
11	molar	B
12	relationship	B
13	will	I
14	allow	B
15	for	B
16	a	B
17	more	B
18	causally	B
19	directed	B
20	correction	B
21	of	B
22	Class	B
23	II	B
24	molar	B
25	relationship	B
26	.	I

1	It	B
2	is	B
3	surprising	B
4	that	B
5	dnaE173	B
6	,	B
7	a	B
8	potent	B
9	mutator	B
10	mutation	B
11	specific	I
12	for	B
13	sequence	I
14	substitution	I
15	as	I
16	well	I
17	as	I
18	single	I
19	-	I
20	base	I
21	frameshift	B
22	,	B
23	did	B
24	not	B
25	enhance	B
26	the	B
27	frequency	B
28	of	B
29	the	B
30	hot	B
31	-	B
32	spot	B
33	frameshift	B
34	mutation	B
35	.	I

1	Hypercalcemia	B
2	associated	B
3	with	B
4	elevated	B
5	serum	B
6	PTH	B
7	concentration	B
8	indicating	B
9	primary	B
10	hyperparathyroidism	B
11	was	B
12	found	O
13	in	B
14	7	B
15	BC	O
16	patients	B
17	(	B
18	7	B
19	%)	O
20	and	O
21	in	I
22	none	I
23	of	B
24	healthy	I
25	women	B
26	or	I
27	patients	B
28	with	B
29	thyroid	B
30	cancer	B
31	.	I

1	[	I
2	figure	I
3	:	I
4	see	I
5	text	I
6	]	I
7	The	I
8	Stille	I
9	coupling	I
10	reaction	I
11	has	I
12	been	B
13	performed	B
14	in	B
15	1	B
16	-	B
17	butyl	B
18	-	B
19	3	I
20	-	I
21	methylimidazolium	I
22	tetrafluoroborate	I
23	(	I
24	BMIM	I
25	BF4	I
26	),	I
27	a	B
28	room	B
29	-	B
30	temperature	B
31	ionic	B
32	liquid	B
33	(	I
34	RTIL	B
35	).	B

1	Examination	B
2	of	B
3	various	B
4	promoter	B
5	deletion	B
6	mutants	B
7	indicated	B
8	that	B
9	SF	B
10	-	B
11	1	B
12	acts	B
13	through	I
14	the	I
15	proximal	I
16	promoter	B
17	region	B
18	and	B
19	upstream	B
20	promoter	B
21	sequences	B
22	.	I

1	ORF1	I
2	(	I
3	1029	I
4	bp	I
5	;	I
6	EMBL	I
7	databank	B
8	,	B
9	Accession	B
10	No	B
11	.	I

1	Vector	I
2	stocks	I
3	containing	I
4	envelope	B
5	proteins	B
6	from	I
7	three	I
8	different	I
9	SIVmac	I
10	clones	I
11	,	B
12	namely	B
13	,	B
14	SIVmac239	B
15	(	B
16	T	B
17	-	B
18	lymphocyte	B
19	tropic	B
20	[	I
21	T	B
22	-	B
23	tropic	I
24	]),	I
25	SIVmac316	I
26	(	B
27	macrophage	B
28	tropic	I
29	[	I
30	M	I
31	-	I
32	tropic	I
33	]),	I
34	and	I
35	SIVmac1A11	I
36	(	I
37	dualtropic	I
38	),	I
39	were	I
40	tested	B
41	.	I

1	ISS	B
2	and	I
3	the	B
4	acute	B
5	physiology	B
6	and	I
7	chronic	I
8	health	I
9	evaluation	I
10	(	B
11	APACHE	B
12	II	B
13	)	B
14	calculated	B
15	on	B
16	admission	B
17	.	I

1	Ga	B
2	-	B
3	67	I
4	and	I
5	Tl	I
6	-	I
7	201	B
8	scintigraphy	B
9	in	B
10	extramedullary	B
11	plasmacytoma	B
12	:	I
13	a	I
14	case	B
15	report	B
16	.	B

1	Finally	I
2	,	B
3	there	B
4	are	B
5	a	B
6	growing	B
7	number	B
8	of	B
9	arguments	B
10	favouring	B
11	the	B
12	use	B
13	of	I
14	ACE	I
15	inhibitors	B
16	very	B
17	early	I
18	in	I
19	patients	I
20	with	B
21	diabetes	B
22	mellitus	B
23	.	B

1	This	B
2	paper	B
3	describes	B
4	the	B
5	results	B
6	of	B
7	an	B
8	initial	B
9	study	B
10	on	O
11	the	B
12	application	B
13	of	B
14	linear	O
15	solvation	O
16	energy	O
17	relationships	O
18	(	O
19	LSERs	O
20	)	O
21	to	O
22	the	I
23	prediction	I
24	of	B
25	internal	B
26	standard	B
27	compounds	B
28	in	B
29	reversed	I
30	-	I
31	phase	I
32	liquid	I
33	chromatographic	I
34	(	I
35	RPLC	I
36	)	B
37	method	B
38	development	B
39	.	B

1	A	B
2	38	I
3	-	I
4	year	I
5	-	I
6	old	I
7	woman	I
8	with	I
9	ulcerative	I
10	colitis	I
11	subsequently	I
12	developed	I
13	sarcoidosis	I
14	.	I

1	Blood	B
2	from	I
3	dams	I
4	was	I
5	collected	I
6	prior	I
7	to	I
8	inoculation	I
9	and	I
10	at	I
11	time	B
12	of	B
13	necropsy	B
14	for	B
15	measurement	I
16	of	I
17	IgM	I
18	and	I
19	IgG	I
20	antibodies	B
21	to	I
22	M	I
23	.	I
24	pulmonis	I
25	.	I

1	She	B
2	has	B
3	since	B
4	developed	I
5	a	I
6	positive	I
7	anti	B
8	-	I
9	cardiolipin	B
10	antibody	I
11	but	I
12	does	I
13	not	I
14	meet	I
15	diagnostic	I
16	criteria	I
17	for	I
18	systemic	I
19	lupus	I
20	erythematosis	I
21	.	I
22	CONCLUSION	I
23	:	I
24	The	I
25	presence	I
26	of	I
27	known	B
28	autoimmune	B
29	disease	B
30	in	B
31	a	B
32	woman	B
33	with	B
34	POF	B
35	should	B
36	not	B
37	dissuade	B
38	the	B
39	clinician	B
40	from	I
41	evaluating	I
42	for	B
43	a	B
44	potential	B
45	genetic	B
46	cause	B
47	.	B

1	The	I
2	mutation	I
3	experiments	B
4	showed	I
5	that	B
6	the	B
7	most	I
8	critical	B
9	sequence	I
10	for	B
11	the	B
12	repression	B
13	of	B
14	PTH	B
15	was	B
16	5	I
17	'-	B
18	GGGGGAGGGGAG	I
19	-	I
20	3	I
21	'	I
22	(+	B
23	1	B
24	to	I
25	+	I
26	12	B
27	)	B
28	of	B
29	PTHSR	B
30	.	B

1	Thus	B
2	,	B
3	while	B
4	the	B
5	folds	B
6	of	B
7	all	B
8	Myb	O
9	domains	O
10	resemble	O
11	each	O
12	other	I
13	closely	I
14	,	B
15	the	B
16	function	B
17	of	B
18	each	B
19	Myb	B
20	domain	B
21	depends	O
22	on	O
23	the	O
24	amino	B
25	acid	B
26	residues	B
27	that	B
28	are	B
29	located	B
30	on	B
31	the	B
32	surface	I
33	of	B
34	each	I
35	protein	I
36	.	I

1	A	B
2	cDNA	I
3	clone	I
4	encoding	I
5	C2H2	I
6	-	I
7	type	B
8	zinc	B
9	finger	B
10	protein	B
11	,	B
12	SCOF	B
13	-	B
14	1	B
15	,	B
16	was	B
17	isolated	B
18	from	O
19	soybean	B
20	.	I

1	The	I
2	purpose	B
3	of	B
4	this	I
5	study	B
6	was	B
7	to	B
8	evaluate	I
9	simplified	I
10	methods	B
11	for	B
12	estimation	B
13	of	B
14	Technetium	B
15	Tc	B
16	99m	B
17	(	B
18	99mTc	B
19	)-	B
20	pentetate	B
21	and	I
22	orthoiodohippurate	I
23	I	I
24	131	B
25	(	B
26	131I	B
27	-	B
28	OIH	B
29	)	B
30	plasma	B
31	clearance	B
32	in	B
33	dogs	B
34	and	I
35	cats	I
36	with	I
37	1	B
38	and	I
39	2	I
40	blood	B
41	samples	B
42	.	B

1	Sevelamer	I
2	hydrochloride	I
3	(	I
4	Renagel	I
5	)	I
6	is	I
7	a	B
8	nonabsorbed	B
9	phosphate	B
10	-	B
11	binding	B
12	polymer	B
13	marketed	B
14	for	B
15	the	B
16	treatment	I
17	of	I
18	hyperphosphatemia	B
19	in	B
20	adult	B
21	patients	B
22	receiving	B
23	hemodialysis	I
24	.	I

1	Using	I
2	a	B
3	novel	B
4	method	B
5	combining	B
6	chromatin	B
7	immunoprecipitation	B
8	and	B
9	genomic	B
10	array	B
11	hybridization	B
12	,	B
13	we	B
14	have	O
15	identified	B
16	a	B
17	460	B
18	-	I
19	kb	I
20	CENP	I
21	-	I
22	A	I
23	-	I
24	binding	B
25	DNA	B
26	domain	B
27	of	B
28	a	B
29	neocentromere	B
30	derived	B
31	from	I
32	the	I
33	20p12	I
34	region	B
35	of	B
36	an	B
37	invdup	B
38	(	B
39	20p	B
40	)	B
41	human	B
42	marker	B
43	chromosome	B
44	.	I

1	Cases	B
2	of	B
3	lung	B
4	cancer	B
5	with	B
6	intramedullary	B
7	metastasis	B
8	are	B
9	rare	B
10	,	B
11	especially	B
12	those	B
13	diagnosed	B
14	before	B
15	death	B
16	.	B

1	Direct	I
2	current	I
3	polarography	I
4	and	I
5	differential	I
6	pulse	I
7	polarographic	B
8	methods	B
9	have	O
10	been	B
11	developed	O
12	for	B
13	the	B
14	qualitative	B
15	as	I
16	well	I
17	as	I
18	quantitative	I
19	analysis	B
20	of	B
21	vitamin	B
22	B1	B
23	,	B
24	B2	B
25	and	B
26	B6	I
27	.	I

1	Fluorimetric	B
2	determination	B
3	of	B
4	methylmercury	I
5	as	I
6	an	I
7	ion	I
8	-	I
9	association	I
10	complex	I
11	with	I
12	rhodamine	I
13	B	B
14	in	B
15	the	I
16	presence	B
17	of	B
18	iodide	B
19	.	I

1	The	I
2	corresponding	I
3	genotype	B
4	was	B
5	determined	B
6	with	B
7	a	B
8	restriction	B
9	enzyme	B
10	-	I
11	based	B
12	assay	B
13	.	I

1	Patients	B
2	were	B
3	divided	B
4	into	B
5	two	B
6	group	B
7	;	B
8	Control	B
9	group	B
10	A	B
11	in	B
12	which	B
13	a	B
14	hot	B
15	-	B
16	water	B
17	circulating	B
18	system	B
19	was	B
20	used	B
21	and	B
22	group	I
23	B	B
24	in	B
25	which	B
26	a	B
27	transtracheal	B
28	heating	B
29	and	B
30	humidification	I
31	system	I
32	by	I
33	ANAMED	I
34	HUMITUBE	I
35	was	B
36	used	B
37	,	B
38	during	B
39	gastric	B
40	cancer	B
41	operation	B
42	.	I

1	Mental	B
2	rotation	B
3	of	B
4	paired	I
5	figures	I
6	engendered	I
7	activation	I
8	in	I
9	the	I
10	left	I
11	superior	I
12	parietal	I
13	lobule	I
14	and	I
15	the	I
16	right	I
17	frontal	B
18	medial	B
19	gyrus	B
20	.	B

1	Here	I
2	we	I
3	demonstrate	B
4	that	B
5	the	B
6	Ras	B
7	-	B
8	activated	B
9	Raf	B
10	-	B
11	MEK	B
12	-	O
13	extracellular	B
14	signal	O
15	-	I
16	regulated	I
17	kinase	I
18	(	I
19	ERK	B
20	)	B
21	signaling	B
22	pathway	B
23	can	B
24	specifically	B
25	control	B
26	the	B
27	expression	B
28	of	B
29	individual	B
30	integrin	B
31	subunits	B
32	in	B
33	a	B
34	variety	B
35	of	B
36	human	B
37	and	B
38	mouse	B
39	cell	B
40	lines	B
41	.	B

1	These	B
2	TxRE	B
3	contain	B
4	cyclic	I
5	AMP	I
6	-	I
7	responsive	I
8	elements	B
9	(	B
10	CRE	B
11	),	B
12	but	B
13	,	B
14	remarkably	B
15	,	B
16	the	B
17	"	B
18	TGACGTCA	B
19	"	B
20	consensus	B
21	is	B
22	never	B
23	strictly	B
24	conserved	B
25	in	B
26	any	B
27	viral	B
28	strain	B
29	(	B
30	e	B
31	.	I
32	g	I
33	.,	I
34	AGACGTCA	I
35	,	B
36	TGACGGCA	B
37	,	B
38	TGACCTCA	B
39	).	I

1	The	I
2	hatcher	I
3	incubators	I
4	of	B
5	both	B
6	companies	B
7	were	B
8	also	B
9	persistently	B
10	contaminated	B
11	with	B
12	Salmonella	B
13	livingstone	B
14	and	I
15	Salmonella	I
16	thomasville	I
17	in	B
18	company	B
19	A	B
20	and	B
21	with	I
22	Salmonella	I
23	senftenberg	I
24	in	I
25	company	B
26	B	B
27	.	I

1	Binding	B
2	of	B
3	cell	B
4	type	B
5	-	O
6	specific	B
7	nuclear	B
8	proteins	B
9	to	B
10	the	I
11	5	I
12	'-	I
13	flanking	B
14	region	B
15	of	B
16	maize	B
17	C4	B
18	phosphoenolpyruvate	B
19	carboxylase	B
20	gene	B
21	confers	B
22	its	B
23	differential	O
24	transcription	O
25	in	O
26	mesophyll	O
27	cells	B
28	.	I

1	Susceptibility	I
2	to	I
3	ischemia	I
4	-	I
5	induced	I
6	arrhythmias	I
7	was	I
8	lower	B
9	in	B
10	1	B
11	-	B
12	week	B
13	diabetics	B
14	:	I
15	only	I
16	42	B
17	%	B
18	of	B
19	diabetic	I
20	hearts	I
21	exhibited	I
22	ventricular	I
23	tachycardia	I
24	(	B
25	VT	I
26	)	B
27	and	I
28	16	B
29	%	B
30	had	B
31	short	B
32	episodes	B
33	of	I
34	ventricular	I
35	fibrillation	B
36	(	B
37	VF	B
38	)	B
39	as	B
40	compared	B
41	to	I
42	VT	I
43	100	I
44	%	I
45	and	I
46	VF	I
47	70	I
48	%	I
49	(	I
50	including	B
51	sustained	B
52	VF	B
53	36	B
54	%)	B
55	in	B
56	the	B
57	non	B
58	-	I
59	diabetics	B
60	(	B
61	P	I
62	<	I
63	0	B
64	.	I
65	05	I
66	).	B

1	CONCLUSIONS	B
2	:	I
3	The	I
4	methodology	I
5	of	B
6	LHR	B
7	measurement	I
8	significantly	B
9	influences	B
10	the	B
11	clinical	B
12	contribution	B
13	of	B
14	Tl	B
15	-	B
16	201	B
17	lung	B
18	uptake	B
19	evaluation	I
20	.	I

1	The	I
2	authors	I
3	made	I
4	an	I
5	analysis	B
6	of	B
7	social	B
8	-	I
9	economical	I
10	conditions	B
11	limiting	B
12	the	B
13	possibilities	B
14	of	B
15	rendering	B
16	cardiosurgical	I
17	care	I
18	to	I
19	children	I
20	.	I

1	METHODS	B
2	:	I
3	Experiments	I
4	testing	I
5	the	I
6	new	B
7	catheter	B
8	and	I
9	comparing	I
10	it	B
11	to	I
12	the	I
13	existing	I
14	catheter	I
15	included	I
16	:	I
17	(	I
18	1	I
19	)	B
20	measurement	I
21	of	I
22	the	B
23	laser	B
24	output	B
25	beam	B
26	sizes	B
27	and	B
28	divergences	B
29	;	B
30	(	B
31	2	B
32	)	B
33	evaluation	B
34	of	B
35	particulate	B
36	matter	I
37	generation	I
38	during	I
39	ablation	B
40	of	B
41	atherosclerotic	B
42	tissue	B
43	;	B
44	(	B
45	3	I
46	)	I
47	measurement	I
48	of	I
49	ablation	B
50	hole	B
51	sizes	B
52	and	B
53	tissue	I
54	penetration	I
55	rates	I
56	;	I
57	(	B
58	4	B
59	)	B
60	histopathologic	B
61	examination	B
62	of	B
63	laser	B
64	-	B
65	induced	B
66	in	B
67	vivo	B
68	vessel	B
69	wall	B
70	injury	B
71	.	B

1	The	I
2	reproductive	I
3	effects	B
4	of	B
5	the	B
6	administration	B
7	of	B
8	4	B
9	-	B
10	chloro	B
11	-	I
12	2	B
13	-	I
14	methylphenoxyacetic	B
15	acid	B
16	(	B
17	MCPA	B
18	)	B
19	to	I
20	rats	I
21	were	I
22	evaluated	B
23	through	I
24	two	I
25	generations	I
26	,	B
27	from	B
28	prior	I
29	to	I
30	mating	I
31	,	B
32	throughout	B
33	mating	B
34	,	B
35	to	B
36	gestation	I
37	and	I
38	lactation	I
39	.	I

1	Here	I
2	we	I
3	suggest	I
4	that	I
5	uvrA	B
6	and	I
7	the	I
8	nucleotide	B
9	excision	B
10	repair	B
11	pathway	B
12	are	B
13	involved	I
14	in	I
15	the	I
16	repair	I
17	of	B
18	acid	B
19	-	B
20	induced	B
21	DNA	B
22	damage	B
23	and	B
24	are	I
25	associated	B
26	with	B
27	successful	B
28	adaptation	B
29	of	I
30	S	B
31	.	I
32	mutans	I
33	to	I
34	low	I
35	pH	I
36	.	I

1	The	I
2	improved	B
3	CSF	I
4	outflow	I
5	conductance	I
6	may	I
7	increase	I
8	the	I
9	intracranial	I
10	compliance	I
11	and	I
12	thereby	I
13	dampen	B
14	a	B
15	pathological	B
16	ICP	B
17	waveform	B
18	.	B

1	These	B
2	studies	B
3	demonstrate	B
4	that	B
5	site	B
6	-	B
7	specific	B
8	recognition	I
9	of	B
10	the	I
11	bxd	B
12	PRE	B
13	by	I
14	d	B
15	(	B
16	GA	B
17	)(	B
18	n	B
19	)	B
20	repeat	B
21	binding	B
22	activities	B
23	mediates	O
24	PcG	O
25	-	O
26	dependent	O
27	silencing	B
28	.	O

1	The	I
2	gonadotrope	I
3	-	I
4	specific	I
5	and	I
6	regulated	I
7	expression	I
8	of	I
9	the	I
10	GnRH	I
11	receptor	I
12	(	I
13	GnRH	I
14	-	I
15	R	I
16	)	B
17	gene	B
18	is	B
19	dependent	B
20	on	B
21	multiple	B
22	transcription	B
23	factors	B
24	that	B
25	interact	B
26	with	B
27	the	B
28	noncanonical	B
29	GnRH	B
30	-	I
31	R	I
32	activating	B
33	sequence	I
34	(	B
35	GRAS	I
36	),	I
37	the	I
38	activator	B
39	protein	B
40	-	B
41	1	B
42	(	B
43	AP	B
44	-	I
45	1	B
46	)	B
47	element	B
48	,	B
49	and	B
50	the	B
51	steroidogenic	B
52	factor	B
53	-	B
54	1	B
55	(	B
56	SF	B
57	-	B
58	1	B
59	)	B
60	binding	B
61	site	O
62	.	I

1	Before	B
2	PO3	I
3	administration	B
4	,	B
5	more	B
6	than	B
7	half	B
8	(	O
9	57	O
10	.	O
11	4	B
12	%)	B
13	of	B
14	the	B
15	patients	B
16	received	B
17	only	B
18	1	B
19	or	B
20	2	I
21	antituberculous	B
22	drugs	B
23	(	B
24	ethambutole	B
25	and	I
26	ethionamide	I
27	or	I
28	ethambutole	I
29	and	I
30	oprofloxacin	I
31	).	I

1	Using	I
2	the	I
3	presented	I
4	categorical	I
5	structure	B
6	as	I
7	domain	B
8	model	B
9	a	B
10	prototype	B
11	DSS	B
12	for	B
13	dipslide	I
14	urine	I
15	cultures	B
16	has	B
17	been	B
18	developed	B
19	.	I

1	Conclusion	B
2	:	I
3	The	I
4	Lp	I
5	(	I
6	a	B
7	)	B
8	levels	B
9	in	B
10	these	B
11	children	B
12	were	B
13	the	O
14	lower	B
15	ever	O
16	reported	B
17	.	B

1	Foxp1	B
2	and	I
3	Foxp2	I
4	are	I
5	expressed	I
6	at	I
7	high	B
8	levels	B
9	in	B
10	the	B
11	lung	B
12	as	B
13	early	I
14	as	I
15	E12	I
16	.	I
17	5	I
18	of	I
19	mouse	I
20	development	B
21	with	B
22	Foxp2	B
23	expression	B
24	restricted	B
25	to	B
26	the	I
27	airway	I
28	epithelium	I
29	.	I

1	Audiological	B
2	findings	B
3	in	B
4	pregnancy	B
5	.	I

1	Children	I
2	who	I
3	developed	I
4	lower	I
5	respiratory	I
6	tract	I
7	infections	I
8	or	I
9	PCP	I
10	had	I
11	increased	I
12	rates	I
13	of	I
14	decline	I
15	of	B
16	CD4	B
17	cell	B
18	counts	B
19	during	B
20	the	B
21	first	B
22	6	B
23	months	B
24	of	O
25	life	O
26	.	O

1	A	B
2	randomized	B
3	mix	B
4	of	B
5	180	B
6	sections	B
7	(	B
8	10	B
9	samples	B
10	x	O
11	3	I
12	tissues	I
13	x	I
14	3	I
15	stains	I
16	x	I
17	2	I
18	)	I
19	gave	B
20	90	B
21	matched	B
22	pairs	B
23	.	I

1	Sural	B
2	nerve	B
3	biopsy	B
4	showed	I
5	mild	I
6	thickening	B
7	of	B
8	the	B
9	perineurium	B
10	,	B
11	vascular	B
12	alterations	B
13	with	B
14	inflammatory	B
15	cell	B
16	infiltration	O
17	in	I
18	the	I
19	perineurium	B
20	,	B
21	and	B
22	remarkable	I
23	loss	I
24	of	B
25	large	B
26	and	I
27	small	I
28	myelinated	B
29	fibers	I
30	.	I

1	OBJECTIVES	B
2	:	I
3	The	I
4	objective	I
5	of	I
6	this	I
7	review	I
8	was	B
9	to	I
10	assess	I
11	the	I
12	effects	B
13	of	B
14	prophylactic	B
15	prostaglandin	B
16	use	I
17	in	I
18	the	I
19	third	I
20	stage	B
21	of	B
22	labour	B
23	.	I

1	Testing	B
2	was	B
3	associated	B
4	with	B
5	a	B
6	history	B
7	of	B
8	nonsexual	B
9	risk	B
10	behavior	O
11	,	B
12	increased	B
13	knowledge	B
14	of	B
15	the	B
16	hepatitis	I
17	C	B
18	virus	B
19	,	B
20	and	B
21	healthcare	B
22	provider	I
23	communication	I
24	.	I

1	Cytomegalovirus	B
2	,	B
3	Chlamydia	B
4	pneumoniae	B
5	,	B
6	and	B
7	Helicobacter	B
8	pylori	B
9	IgG	B
10	antibodies	B
11	and	B
12	restenosis	B
13	after	B
14	stent	B
15	implantation	B
16	:	O
17	an	B
18	angiographic	B
19	and	B
20	intravascular	B
21	ultrasound	B
22	study	B
23	.	B

1	A	B
2	5	I
3	-	I
4	month	B
5	-	I
6	old	I
7	infant	B
8	with	B
9	persistent	B
10	congenital	B
11	stridor	B
12	and	I
13	acute	I
14	respiratory	I
15	distress	I
16	is	I
17	presented	I
18	.	I

1	OBJECTIVE	B
2	:	I
3	To	I
4	determine	I
5	whether	I
6	RSTD	B
7	predicts	I
8	coronary	I
9	anatomy	I
10	during	B
11	acute	B
12	coronary	I
13	occlusion	I
14	.	I

1	Even	B
2	if	B
3	the	B
4	electrocardiographic	B
5	signs	B
6	are	B
7	subdued	B
8	,	B
9	the	B
10	underlying	B
11	blockade	B
12	of	B
13	I	B
14	(	B
15	Kr	B
16	)	B
17	current	B
18	may	B
19	precipitate	B
20	the	B
21	occurrence	B
22	of	B
23	arrhythmia	B
24	.	B

1	Acetoin	I
2	can	B
3	be	B
4	reused	B
5	by	I
6	the	I
7	bacteria	I
8	during	I
9	stationary	I
10	phase	I
11	when	B
12	other	B
13	carbon	I
14	sources	B
15	have	I
16	been	B
17	depleted	B
18	.	I

1	Analysis	B
2	of	B
3	the	B
4	promoter	B
5	sequence	B
6	revealed	B
7	the	B
8	presence	B
9	of	B
10	a	B
11	major	B
12	transcriptional	B
13	start	B
14	site	O
15	,	B
16	a	B
17	canonical	O
18	TATA	B
19	box	O
20	and	O
21	putative	I
22	cis	I
23	regulatory	I
24	elements	B
25	for	B
26	pituitary	B
27	specific	B
28	expression	B
29	as	I
30	well	I
31	as	I
32	an	I
33	E	B
34	-	B
35	responsive	I
36	element	B
37	.	I

1	IL	I
2	-	I
3	1beta	I
4	was	B
5	significantly	B
6	higher	B
7	in	B
8	endometrioma	B
9	than	B
10	in	B
11	lesions	B
12	of	B
13	other	B
14	localizations	B
15	.	B

1	An	B
2	economic	B
3	analysis	B
4	using	B
5	West	B
6	of	B
7	Scotland	B
8	Coronary	B
9	Prevention	B
10	Study	B
11	(	B
12	WOSCOPS	B
13	)	B
14	findings	B
15	indicates	B
16	that	B
17	statin	B
18	treatment	O
19	would	B
20	have	I
21	prevented	I
22	318	B
23	events	B
24	per	B
25	10	O
26	,	O
27	000	O
28	patients	O
29	in	O
30	a	O
31	population	O
32	similar	O
33	to	O
34	that	I
35	in	I
36	WOSCOPS	I
37	(	B
38	average	B
39	1	B
40	.	B
41	5	I
42	%	I
43	annual	I
44	risk	B
45	of	B
46	a	B
47	cardiovascular	I
48	event	I
49	)	B
50	at	B
51	a	B
52	discounted	B
53	cost	B
54	per	B
55	life	B
56	-	O
57	year	B
58	gained	B
59	of	O
60	20	O
61	,	O
62	375	O
63	pounds	O
64	($	O
65	31	O
66	,	O
67	818	O
68	).	O

1	Hydrogels	B
2	for	B
3	tissue	B
4	engineering	B
5	.	I

1	No	B
2	mutation	B
3	of	B
4	the	B
5	NRL	B
6	gene	B
7	was	B
8	found	B
9	in	B
10	any	B
11	of	B
12	the	B
13	two	B
14	families	B
15	.	O

1	However	B
2	,	B
3	most	B
4	produced	B
5	significant	B
6	alteration	B
7	of	B
8	small	B
9	intestinal	I
10	permeability	I
11	.	I

1	Our	B
2	results	B
3	show	B
4	that	B
5	CVN	I
6	specifically	I
7	recognizes	I
8	with	I
9	nanomolar	I
10	affinity	I
11	Man	B
12	(	B
13	9	B
14	)	B
15	GlcNAc	B
16	(	B
17	2	B
18	)	B
19	and	I
20	the	I
21	D1D3	I
22	isomer	I
23	of	B
24	Man	B
25	(	B
26	8	B
27	)	B
28	GlcNAc	B
29	(	B
30	2	B
31	).	B

1	Saccharomyces	B
2	cerevisiae	B
3	activates	I
4	a	I
5	regulatory	B
6	network	B
7	called	B
8	"	B
9	general	B
10	control	B
11	"	B
12	that	B
13	provides	B
14	the	B
15	cell	B
16	with	B
17	sufficient	B
18	amounts	B
19	of	B
20	protein	B
21	precursors	B
22	during	B
23	amino	B
24	acid	B
25	starvation	B
26	.	I

1	In	B
2	Saccharomyces	B
3	cerevisiae	B
4	,	B
5	entry	B
6	into	B
7	mitosis	B
8	requires	I
9	activation	B
10	of	B
11	the	B
12	cyclin	B
13	-	B
14	dependent	B
15	kinase	B
16	Cdc28	B
17	in	B
18	its	B
19	cyclin	B
20	B	B
21	(	B
22	Clb	B
23	)-	I
24	associated	B
25	form	B
26	.	I

1	Data	B
2	from	I
3	in	I
4	vitro	I
5	splicing	B
6	assays	I
7	,	B
8	UV	B
9	crosslinking	B
10	and	B
11	RNA	I
12	-	I
13	binding	I
14	competition	B
15	experiments	B
16	indicates	B
17	a	B
18	strong	B
19	correlation	B
20	between	B
21	the	B
22	binding	B
23	affinities	B
24	of	B
25	PSI	B
26	for	B
27	the	B
28	SELEX	B
29	sequences	B
30	and	I
31	their	I
32	ability	I
33	to	I
34	modulate	I
35	splicing	I
36	of	B
37	P	I
38	element	I
39	IVS3	B
40	in	B
41	vitro	B
42	.	I

1	The	I
2	sensitivity	I
3	of	B
4	human	B
5	neuroblastoma	B
6	cells	B
7	SK	O
8	-	O
9	N	B
10	-	I
11	SH	I
12	to	I
13	undergo	I
14	apoptosis	B
15	induced	B
16	by	B
17	thapsigargin	I
18	was	B
19	examined	B
20	.	I

1	A	B
2	.,	I
3	Slatkin	I
4	,	B
5	D	B
6	.	I

1	Multiparous	B
2	women	B
3	presented	B
4	higher	B
5	BMI	B
6	(	B
7	P	I
8	=	I
9	0	I
10	.	I
11	01	I
12	)	B
13	and	B
14	PBF	B
15	(	B
16	P	I
17	=	I
18	0	I
19	.	I
20	03	I
21	)	I
22	compared	B
23	with	B
24	primi	B
25	-	B
26	and	I
27	nulliparous	I
28	groups	I
29	.	I

1	CONCLUSIONS	B
2	AND	B
3	CLINICAL	I
4	RELEVANCE	B
5	:	I
6	Increased	I
7	cortical	I
8	thickness	I
9	and	I
10	geometric	I
11	properties	I
12	of	I
13	left	I
14	MCB	B
15	-	I
16	IV	B
17	and	B
18	-	I
19	V	I
20	of	I
21	Greyhounds	B
22	,	B
23	together	B
24	with	B
25	altered	B
26	turnover	B
27	and	B
28	orientation	B
29	of	B
30	osteons	B
31	in	B
32	the	B
33	dorsal	B
34	quadrants	B
35	of	B
36	left	B
37	MCB	B
38	,	B
39	are	B
40	site	B
41	-	I
42	specific	I
43	adaptive	I
44	responses	B
45	associated	B
46	with	B
47	asymmetric	B
48	cyclic	B
49	loading	B
50	as	I
51	a	I
52	result	I
53	of	I
54	racing	I
55	on	B
56	circular	B
57	tracks	B
58	.	B

1	To	I
2	examine	I
3	transcriptional	B
4	regulation	B
5	of	B
6	the	B
7	rat	B
8	eIF4E	I
9	gene	I
10	,	B
11	2	B
12	.	I
13	1	I
14	kB	I
15	of	B
16	the	B
17	rat	B
18	eIF4E	I
19	promoter	I
20	region	B
21	was	B
22	cloned	B
23	and	B
24	the	B
25	contribution	B
26	of	B
27	specific	B
28	elements	B
29	in	B
30	regulating	B
31	transcription	B
32	was	B
33	determined	B
34	in	B
35	primary	B
36	cultures	B
37	of	B
38	rat	B
39	cardiocytes	B
40	and	B
41	in	I
42	a	B
43	murine	B
44	C	B
45	(	B
46	2	B
47	)	B
48	C	B
49	(	B
50	12	B
51	)	B
52	myoblast	B
53	cell	B
54	line	B
55	.	O

1	The	I
2	prevalence	I
3	of	B
4	tobacco	B
5	dependence	B
6	diagnosed	B
7	according	B
8	to	I
9	the	I
10	ICD	I
11	-	I
12	10	I
13	criteria	I
14	was	I
15	higher	B
16	in	B
17	alcohol	I
18	-	I
19	dependent	I
20	individuals	B
21	(	B
22	58	B
23	.	B
24	1	I
25	%)	I
26	than	B
27	in	B
28	nondrinkers	B
29	or	I
30	social	I
31	drinkers	I
32	(	I
33	12	I
34	.	I
35	8	I
36	%).	I

1	Management	B
2	of	B
3	postvitrectomy	B
4	diabetic	B
5	vitreous	B
6	hemorrhage	I
7	with	I
8	tissue	I
9	plasminogen	I
10	activator	B
11	(	B
12	t	B
13	-	I
14	PA	B
15	)	B
16	and	B
17	volume	B
18	homeostatic	B
19	fluid	B
20	-	B
21	fluid	B
22	exchanger	B
23	.	I

1	Transactivation	I
2	of	I
3	oIFNtau	B
4	enhancer	B
5	-	I
6	reporter	I
7	constructs	B
8	was	B
9	primarily	B
10	regulated	B
11	by	I
12	three	I
13	regions	B
14	containing	B
15	AP	B
16	-	I
17	1	I
18	site	I
19	,	B
20	GATA	B
21	like	B
22	sequence	B
23	and	I
24	site	I
25	(	I
26	s	I
27	)	B
28	unidentified	B
29	.	I

1	SELECTION	B
2	CRITERIA	B
3	:	I
4	Randomised	I
5	controlled	B
6	trials	B
7	of	B
8	cabergoline	B
9	versus	B
10	placebo	B
11	in	B
12	patients	B
13	with	B
14	a	B
15	clinical	B
16	diagnosis	B
17	of	B
18	idiopathic	O
19	Parkinson	B
20	'	B
21	s	B
22	disease	O
23	and	O
24	long	B
25	-	O
26	term	I
27	complications	I
28	of	B
29	levodopa	I
30	therapy	I
31	.	I

1	0	B
2	%)	B
3	and	I
4	IL	I
5	-	I
6	12	I
7	(	B
8	42	B
9	.	I
10	6	I
11	%	I
12	vs	B
13	.	I

1	Copyright	B
2	2000	B
3	John	B
4	Wiley	B
5	&	B
6	Sons	B
7	,	B
8	Ltd	B
9	.	B

1	Here	I
2	we	I
3	demonstrate	B
4	that	B
5	native	B
6	MRCK	B
7	exists	B
8	in	B
9	high	B
10	-	O
11	molecular	B
12	-	B
13	weight	I
14	complexes	I
15	.	I

1	METHODS	B
2	:	I
3	This	B
4	retrospective	B
5	review	B
6	comprised	B
7	2711	B
8	eyes	B
9	that	B
10	had	B
11	LASIK	B
12	between	B
13	September	B
14	1996	B
15	and	O
16	September	B
17	1999	B
18	.	I

1	Sixty	B
2	-	B
3	one	B
4	cases	B
5	of	B
6	cholera	B
7	,	B
8	all	B
9	caused	B
10	by	B
11	V	B
12	.	I
13	cholerae	I
14	O1	I
15	,	B
16	were	B
17	reported	B
18	.	B

1	This	B
2	could	B
3	lead	I
4	to	I
5	subsequent	I
6	outbreaks	I
7	if	B
8	Babesia	I
9	carrier	I
10	animals	B
11	were	B
12	to	I
13	be	I
14	introduced	I
15	into	B
16	the	B
17	herd	B
18	.	B

1	Instead	B
2	,	B
3	TRPS1	B
4	potently	B
5	and	B
6	specifically	B
7	represses	B
8	transcriptional	B
9	activation	B
10	mediated	B
11	by	I
12	other	I
13	GATA	I
14	factors	B
15	.	I

1	Eliminating	B
2	any	B
3	subset	B
4	of	B
5	ASCUS	I
6	reduces	B
7	the	B
8	ASCUS	I
9	/	I
10	SIL	I
11	ratio	I
12	but	I
13	also	B
14	significantly	B
15	diminishes	B
16	the	B
17	sensitivity	B
18	of	B
19	the	B
20	Papanicolaou	B
21	test	I
22	.	I

1	In	B
2	order	B
3	to	I
4	overcome	I
5	the	I
6	false	I
7	positive	I
8	readings	B
9	that	B
10	are	B
11	possible	B
12	in	I
13	sphincter	I
14	manometry	I
15	,	B
16	we	B
17	proposed	B
18	to	B
19	use	I
20	secretin	I
21	stimulated	B
22	endoscopic	B
23	ultrasound	I
24	(	I
25	SSEUS	I
26	)	B
27	to	I
28	measure	I
29	pancreatic	I
30	ductal	I
31	response	I
32	as	I
33	an	I
34	adjunctive	B
35	method	B
36	to	B
37	aid	I
38	and	I
39	supplement	I
40	the	I
41	diagnosis	B
42	.	I

1	Endovascular	B
2	aneurysm	B
3	repair	B
4	with	B
5	the	B
6	AneuRx	B
7	stent	B
8	-	O
9	graft	O
10	is	O
11	safe	O
12	,	O
13	but	O
14	is	B
15	it	B
16	effective	B
17	?	O

1	The	I
2	difference	B
3	of	B
4	hardness	B
5	over	B
6	time	B
7	of	B
8	composite	B
9	specimens	B
10	was	B
11	measured	B
12	using	B
13	Knoop	B
14	hardness	B
15	measurements	B
16	taken	B
17	at	B
18	the	B
19	top	B
20	and	B
21	bottom	I
22	surfaces	I
23	of	B
24	resin	I
25	specimens	B
26	made	B
27	in	B
28	a	B
29	Teflon	B
30	mold	B
31	the	B
32	same	B
33	dimensions	B
34	as	B
35	the	I
36	cavity	I
37	prepared	I
38	in	I
39	dentin	B
40	.	I

1	Implications	B
2	in	B
3	biomonitoring	I
4	of	B
5	the	I
6	observed	I
7	accumulation	I
8	patterns	I
9	,	B
10	especially	B
11	in	B
12	the	B
13	different	I
14	tissues	I
15	of	I
16	Posidonia	B
17	oceanica	B
18	,	B
19	are	B
20	discussed	B
21	.	B

1	Based	B
2	on	B
3	mutational	B
4	data	B
5	and	B
6	possible	I
7	mRNA	B
8	structure	B
9	,	B
10	we	B
11	hypothesized	B
12	about	B
13	the	B
14	effect	B
15	of	B
16	mRNA	B
17	structure	B
18	on	B
19	translation	B
20	of	B
21	the	B
22	two	B
23	major	B
24	C	B
25	/	O
26	EBPepsilon	O
27	isoforms	O
28	:	O
29	p32	I
30	and	I
31	p30	I
32	.	I

1	Retinoids	I
2	participate	I
3	in	I
4	the	I
5	onset	B
6	of	B
7	differentiation	B
8	,	B
9	apoptosis	B
10	and	B
11	the	B
12	inhibition	B
13	of	B
14	growth	B
15	in	O
16	a	B
17	wide	O
18	variety	O
19	of	O
20	normal	O
21	and	O
22	cancerous	I
23	cells	I
24	.	I

1	We	B
2	conclude	B
3	that	B
4	RPMS	B
5	acts	B
6	as	B
7	a	B
8	negative	B
9	regulator	B
10	of	B
11	EBNA2	B
12	and	B
13	Notch	I
14	activity	I
15	through	I
16	its	I
17	interactions	I
18	with	B
19	the	B
20	CBF1	B
21	-	B
22	associated	B
23	corepressor	B
24	complex	B
25	.	B

1	Isolated	I
2	Systolic	B
3	Hypertension	B
4	:	I
5	An	B
6	Update	B
7	.	I

1	Transfection	B
2	of	B
3	EGFP	B
4	-	B
5	tagged	B
6	DENTT	B
7	NLS	B
8	deletion	B
9	constructs	B
10	lacking	B
11	the	B
12	bipartite	B
13	NLS	B
14	-	I
15	1	I
16	were	B
17	excluded	B
18	from	I
19	the	I
20	nucleolus	I
21	.	I

1	VE	B
2	-	I
3	DEF	I
4	animals	I
5	had	B
6	significantly	B
7	higher	B
8	(	B
9	p	B
10	<	B
11	0	B
12	.	I
13	05	I
14	)	B
15	levels	B
16	of	B
17	myocardial	B
18	lipid	B
19	peroxidation	B
20	and	O
21	lower	B
22	(	B
23	p	B
24	<	B
25	0	B
26	.	B
27	05	I
28	)	B
29	protein	B
30	thiols	B
31	following	B
32	I	B
33	-	I
34	R	B
35	compared	B
36	to	I
37	the	I
38	CON	I
39	animals	I
40	.	I

1	The	I
2	position	I
3	of	I
4	the	I
5	analyst	B
6	as	I
7	expert	B
8	:	I
9	yesterday	I
10	and	I
11	today	I
12	.	I

1	Furthermore	I
2	,	I
3	we	B
4	showed	B
5	that	B
6	ERSF	B
7	including	B
8	NF	B
9	-	B
10	Y	B
11	and	B
12	ATF6alpha	I
13	and	I
14	/	I
15	or	I
16	beta	B
17	and	B
18	capable	B
19	of	B
20	binding	B
21	to	B
22	ERSE	I
23	is	I
24	indeed	I
25	formed	B
26	when	B
27	the	B
28	cellular	B
29	UPR	B
30	is	I
31	activated	B
32	.	I

1	We	B
2	performed	B
3	the	B
4	present	B
5	study	B
6	to	B
7	clarify	I
8	the	I
9	relationship	I
10	between	B
11	the	B
12	DOX	B
13	binding	B
14	ability	B
15	(%	B
16	DB	B
17	)	I
18	and	I
19	the	I
20	histologic	B
21	response	I
22	,	B
23	rate	I
24	of	I
25	decrease	I
26	in	I
27	tumor	I
28	volume	I
29	of	B
30	malignant	I
31	soft	I
32	tissue	I
33	tumors	I
34	after	I
35	preoperative	I
36	chemotherapy	I
37	and	I
38	prognosis	I
39	.	I

1	We	B
2	have	I
3	also	B
4	isolated	B
5	and	I
6	analyzed	I
7	the	I
8	5	I
9	'	I
10	flanking	B
11	region	B
12	of	B
13	the	B
14	pea	B
15	33RNP	B
16	gene	B
17	.	I

1	We	B
2	have	I
3	previously	B
4	shown	B
5	that	B
6	the	B
7	adenoviral	B
8	12S	B
9	E1A	I
10	protein	B
11	modulates	B
12	the	B
13	phosphorylation	I
14	status	B
15	of	B
16	p130	B
17	and	B
18	p107	B
19	without	I
20	apparent	B
21	changes	B
22	in	B
23	the	B
24	cell	B
25	cycle	B
26	dependent	B
27	phosphorylation	I
28	of	I
29	the	I
30	retinoblastoma	I
31	protein	B
32	.	I

1	Baseline	B
2	MBF	B
3	in	B
4	females	B
5	was	B
6	significantly	B
7	(	B
8	P	I
9	<	I
10	0	B
11	.	I
12	001	I
13	)	I
14	higher	I
15	than	B
16	in	B
17	males	B
18	.	I

1	Only	B
2	nine	B
3	patients	B
4	were	B
5	offered	B
6	surgery	B
7	(	B
8	six	B
9	were	I
10	resected	B
11	and	I
12	three	B
13	were	B
14	found	I
15	inoperable	B
16	).	B

1	The	I
2	deubiquitinating	B
3	enzyme	B
4	DUB	B
5	-	I
6	2	B
7	is	I
8	induced	B
9	in	B
10	response	I
11	to	I
12	IL	I
13	-	I
14	2	I
15	but	I
16	as	I
17	yet	I
18	its	I
19	function	B
20	has	B
21	not	B
22	been	B
23	determined	B
24	.	I

1	A	B
2	split	B
3	motor	I
4	domain	B
5	in	B
6	a	B
7	cytoplasmic	B
8	dynein	B
9	.	I

1	Immunological	B
2	and	I
3	biochemical	B
4	characterization	I
5	of	I
6	streptococcal	I
7	pyrogenic	I
8	exotoxins	B
9	I	I
10	and	I
11	J	B
12	(	B
13	SPE	B
14	-	I
15	I	I
16	and	I
17	SPE	I
18	-	I
19	J	B
20	)	B
21	from	B
22	Streptococcus	B
23	pyogenes	B
24	.	B

1	present	O
2	for	O
3	lifestyle	O
4	modification	O
5	and	O
6	control	B
7	of	O
8	arterial	O
9	blood	O
10	pressure	O
11	elevation	O
12	:	B
13	1	O
14	)	O
15	weight	B
16	reduction	B
17	to	B
18	ideal	O
19	body	O
20	weight	B
21	,	O
22	since	O
23	it	O
24	reduces	O
25	risk	O
26	of	O
27	hypertension	O
28	as	B
29	well	I
30	as	I
31	overall	O
32	cardiovascular	B
33	morbidity	O
34	and	B
35	mortality	O
36	;	O
37	2	O
38	)	O
39	dietary	O
40	sodium	O
41	restriction	B
42	to	B
43	less	I
44	than	O
45	2	O
46	g	O
47	a	O
48	day	O
49	,	O
50	without	O
51	assurance	O
52	that	O
53	it	O
54	will	B
55	normalize	O
56	arterial	O
57	pressure	O
58	although	O
59	it	O
60	may	O
61	help	O
62	reduce	O
63	dosage	O
64	and	B
65	numbers	I
66	of	O
67	prescribed	O
68	antihypertensive	O
69	drugs	O
70	;	O
71	3	B
72	)	O
73	moderation	B
74	of	O
75	alcohol	B
76	consumption	B
77	to	B
78	less	I
79	than	O
80	1	O
81	ounce	O
82	a	O
83	day	O
84	;	O
85	4	O
86	)	O
87	a	O
88	regular	O
89	isotonic	O
90	exercise	O
91	program	O
92	;	O
93	and	O
94	5	O
95	)	O
96	cessation	O
97	of	O
98	tobacco	O
99	consumption	O
100	.	I
1	Descriptions	B
2	of	B
3	this	I
4	locus	B
5	would	B
6	allow	B
7	comparison	B
8	with	B
9	functionally	B
10	relevant	B
11	molecular	B
12	genetic	B
13	features	B
14	of	O
15	other	O
16	species	O
17	'	O
18	homologous	O
19	loci	O
20	including	B
21	the	O
22	single	B
23	-	I
24	copy	I
25	equid	B
26	LH	B
27	/	B
28	CGbeta	B
29	gene	B
30	and	I
31	the	I
32	primate	I
33	LHbeta	B
34	-	B
35	CGbeta	B
36	gene	I
37	cluster	B
38	locus	B
39	.	B

1	METHODS	B
2	:	I
3	One	I
4	hundred	B
5	fourteen	B
6	consecutive	I
7	patients	B
8	(	B
9	mean	B
10	age	B
11	61	B
12	years	B
13	)	B
14	with	B
15	focal	B
16	pancreatic	B
17	masses	B
18	,	B
19	detected	B
20	on	B
21	CT	B
22	,	B
23	underwent	B
24	EUS	B
25	-	B
26	FNA	I
27	by	I
28	using	I
29	a	B
30	linear	I
31	-	I
32	array	I
33	echoendoscope	B
34	and	I
35	22	I
36	-	I
37	gauge	I
38	needles	B
39	.	I

1	The	I
2	effects	B
3	of	B
4	chlordiazepoxide	B
5	(	B
6	2	B
7	.	I
8	5	I
9	-	I
10	15	I
11	.	I
12	0mg	I
13	/	B
14	kg	B
15	),	B
16	a	B
17	full	B
18	benzodiazepine	B
19	receptor	B
20	agonist	B
21	,	B
22	and	B
23	bretazenil	I
24	(	I
25	5	I
26	.	I
27	0	I
28	-	I
29	30	I
30	.	I
31	0mg	I
32	/	B
33	kg	B
34	),	B
35	a	B
36	partial	B
37	benzodiazepine	B
38	receptor	B
39	agonist	B
40	,	B
41	were	B
42	examined	B
43	in	B
44	the	B
45	murine	B
46	elevated	B
47	plus	B
48	-	B
49	maze	B
50	paradigm	B
51	.	I

1	Acute	B
2	effects	B
3	of	B
4	LI	B
5	160	B
6	(	B
7	extract	B
8	of	B
9	Hypericum	B
10	perforatum	B
11	,	B
12	St	B
13	John	B
14	'	B
15	s	B
16	wort	B
17	)	B
18	and	B
19	two	B
20	of	B
21	its	B
22	constituents	O
23	on	B
24	neuroendocrine	B
25	responses	B
26	in	B
27	the	B
28	rat	B
29	.	I

1	Guidelines	B
2	for	B
3	performing	I
4	a	B
5	routine	B
6	spiral	B
7	assay	B
8	are	B
9	presented	I
10	,	B
11	and	B
12	alternative	I
13	test	I
14	methods	I
15	intended	B
16	to	I
17	overcome	I
18	a	I
19	variety	B
20	of	B
21	technical	B
22	difficulties	B
23	(	B
24	such	B
25	as	I
26	restricted	I
27	sample	I
28	availability	I
29	,	B
30	sample	B
31	viscosity	B
32	or	I
33	volatility	I
34	,	I
35	etc	I
36	.)	I
37	are	I
38	recommended	I
39	.	I

1	An	B
2	additional	B
3	9	B
4	patients	B
5	achieved	B
6	normal	B
7	levels	B
8	with	B
9	adjunctive	B
10	drug	B
11	therapy	O
12	.	I

1	Anti	I
2	-	I
3	nucleolin	I
4	mAb	B
5	was	B
6	used	B
7	to	I
8	confirm	I
9	the	I
10	antigenic	B
11	properties	I
12	of	I
13	this	I
14	p95	I
15	component	I
16	.	I

1	Eliminating	B
2	any	B
3	subset	B
4	of	B
5	ASCUS	I
6	reduces	B
7	the	B
8	ASCUS	I
9	/	I
10	SIL	I
11	ratio	I
12	but	I
13	also	B
14	significantly	B
15	diminishes	B
16	the	B
17	sensitivity	B
18	of	B
19	the	B
20	Papanicolaou	B
21	test	I
22	.	I

1	Prrp	B
2	can	B
3	also	B
4	associate	B
5	with	B
6	the	B
7	EVH1	B
8	domain	B
9	of	B
10	Mena	B
11	,	B
12	another	B
13	microfilament	B
14	-	O
15	associated	B
16	protein	B
17	.	B

1	Experience	B
2	with	B
3	xylene	B
4	-	B
5	free	I
6	sections	I
7	since	I
8	1995	B
9	at	B
10	the	B
11	Vrinnevi	B
12	Hospital	I
13	is	I
14	favorable	B
15	.	I

1	Acquired	I
2	antithrombin	B
3	deficiency	B
4	in	B
5	sepsis	B
6	.	I

1	SIP1	B
2	(	B
3	Smad	I
4	interacting	I
5	protein	B
6	1	B
7	)	B
8	and	B
9	deltaEF1	B
10	(	B
11	delta	B
12	-	I
13	crystallin	I
14	enhancer	I
15	binding	B
16	factor	B
17	)	B
18	are	B
19	structurally	I
20	similar	I
21	transcriptional	B
22	repressors	B
23	.	B

1	SERS	B
2	spectra	B
3	were	B
4	obtained	B
5	by	B
6	vacuum	B
7	evaporation	B
8	and	B
9	casting	B
10	of	B
11	p	B
12	-	B
13	NTP	B
14	onto	B
15	silver	B
16	island	B
17	films	B
18	,	B
19	and	B
20	also	B
21	from	I
22	colloidal	I
23	silver	I
24	solutions	I
25	.	I

1	The	I
2	moduli	B
3	of	B
4	elasticity	B
5	of	B
6	the	B
7	gray	B
8	and	B
9	white	B
10	matter	I
11	were	I
12	3	I
13	.	I
14	4	I
15	+/-	I
16	1	B
17	.	I
18	4	I
19	kPa	B
20	(	B
21	mean	B
22	+/-	I
23	standard	I
24	deviation	I
25	)	B
26	and	B
27	3	I
28	.	I
29	4	I
30	+/-	I
31	0	I
32	.	I
33	9	I
34	kPa	B
35	in	B
36	the	B
37	axial	B
38	section	I
39	,	B
40	3	B
41	+/-	I
42	0	I
43	.	I
44	3	I
45	kPa	B
46	and	B
47	3	I
48	.	I
49	5	I
50	+/-	I
51	0	I
52	.	I
53	5	I
54	kPa	B
55	in	B
56	the	I
57	frontal	B
58	section	B
59	,	B
60	and	B
61	3	I
62	.	I
63	5	I
64	+/-	I
65	0	I
66	.	I
67	9	I
68	kPa	B
69	and	B
70	2	I
71	.	I
72	8	I
73	+/-	I
74	0	I
75	.	I
76	4	I
77	kPa	B
78	in	B
79	the	B
80	sagittal	B
81	section	I
82	,	B
83	respectively	B
84	.	I

1	[	I
2	Clinical	B
3	and	I
4	epidemiological	B
5	characteristics	B
6	of	B
7	squamous	B
8	cell	B
9	carcinoma	B
10	of	B
11	the	B
12	oral	B
13	cavity	B
14	in	I
15	women	B
16	]	B
17	BACKGROUND	B
18	:	I
19	Squamous	I
20	cell	B
21	carcinoma	B
22	(	B
23	SCC	B
24	)	B
25	of	B
26	the	B
27	oral	B
28	cavity	B
29	occurs	B
30	mainly	B
31	in	B
32	the	B
33	male	B
34	population	B
35	.	I

1	The	I
2	core	I
3	promoter	B
4	of	B
5	human	B
6	thioredoxin	B
7	reductase	B
8	1	B
9	:	I
10	cloning	I
11	,	B
12	transcriptional	B
13	activity	B
14	,	B
15	and	B
16	Oct	B
17	-	B
18	1	B
19	,	B
20	Sp1	O
21	,	B
22	and	B
23	Sp3	I
24	binding	B
25	reveal	B
26	a	B
27	housekeeping	B
28	-	O
29	type	B
30	promoter	O
31	for	O
32	the	O
33	AU	O
34	-	O
35	rich	B
36	element	B
37	-	O
38	regulated	I
39	gene	I
40	.	I

1	Phase	B
2	II	B
3	trial	B
4	of	B
5	the	B
6	anti	B
7	-	I
8	G	I
9	(	I
10	D2	I
11	)	B
12	monoclonal	B
13	antibody	B
14	3F8	I
15	and	I
16	granulocyte	I
17	-	I
18	macrophage	B
19	colony	B
20	-	B
21	stimulating	B
22	factor	B
23	for	B
24	neuroblastoma	B
25	.	O

1	A	B
2	log	I
3	-	I
4	linear	I
5	dose	I
6	-	I
7	response	I
8	was	B
9	obtained	B
10	for	B
11	the	B
12	average	B
13	increase	B
14	in	I
15	FEV1	B
16	up	B
17	to	I
18	6	I
19	h	I
20	(	I
21	AUC0	B
22	-	I
23	6	I
24	h	B
25	)	B
26	and	B
27	peak	B
28	FEV1	B
29	across	B
30	the	I
31	dose	I
32	range	B
33	administered	B
34	by	B
35	Respimat	I
36	.	I

1	Plasma	I
2	DHE	B
3	concentration	B
4	rose	I
5	promptly	I
6	above	B
7	5	I
8	ng	B
9	/	B
10	ml	B
11	after	B
12	the	B
13	application	B
14	of	B
15	the	B
16	PSA	I
17	tape	I
18	onto	I
19	the	I
20	damaged	I
21	skin	B
22	in	B
23	hairless	B
24	rat	B
25	.	I

1	A	B
2	complete	B
3	drug	B
4	history	B
5	was	B
6	compiled	B
7	,	B
8	specifying	B
9	the	I
10	amount	I
11	and	I
12	duration	B
13	of	B
14	VGB	B
15	medication	B
16	.	B

1	Epithelial	B
2	cytotoxicity	I
3	of	B
4	combined	B
5	antibiotics	B
6	was	B
7	additive	B
8	,	B
9	with	B
10	no	B
11	evidence	B
12	of	B
13	competition	B
14	or	I
15	synergism	I
16	.	I

1	In	B
2	Cd	I
3	-	I
4	spiked	I
5	OECD	I
6	soil	B
7	,	B
8	internal	B
9	Cd	B
10	levels	B
11	were	B
12	linearly	B
13	related	B
14	to	B
15	external	I
16	Cd	I
17	concentrations	I
18	,	B
19	whereas	I
20	the	I
21	springtails	I
22	maintained	I
23	fixed	I
24	internal	B
25	levels	B
26	of	B
27	Cu	B
28	and	B
29	Zn	B
30	regardless	B
31	of	B
32	spiked	B
33	concentrations	B
34	.	I

1	Interestingly	B
2	,	B
3	the	B
4	similarities	B
5	with	B
6	the	I
7	endophilin	I
8	proteins	B
9	cover	B
10	the	B
11	entire	B
12	sequence	B
13	of	B
14	the	B
15	SH3GLB	B
16	family	B
17	,	B
18	suggesting	B
19	a	B
20	common	B
21	fold	B
22	and	B
23	presumably	I
24	a	B
25	common	B
26	mode	I
27	of	B
28	action	B
29	.	B

1	Reovirus	I
2	mRNAs	I
3	are	I
4	efficiently	B
5	translated	I
6	within	B
7	host	B
8	cells	B
9	despite	B
10	the	B
11	absence	B
12	of	B
13	3	B
14	'	B
15	polyadenylated	B
16	tails	B
17	.	B

1	Grippers	B
2	with	B
3	integrated	I
4	piezoresistive	B
5	force	B
6	sensors	B
7	and	B
8	with	I
9	attached	I
10	strain	B
11	gauges	B
12	have	B
13	been	B
14	reported	B
15	.	B

1	Both	B
2	Z	I
3	and	I
4	R	I
5	expression	I
6	resulted	I
7	in	I
8	PML	I
9	dispersion	B
10	in	B
11	EBV	B
12	-	B
13	positive	B
14	cells	B
15	.	B

1	The	I
2	small	I
3	copepod	I
4	Pseudonychocamptus	I
5	proximus	I
6	progressively	B
7	replaced	I
8	the	I
9	large	I
10	Tisbe	I
11	furcata	B
12	in	I
13	sand	B
14	filters	B
15	during	B
16	the	B
17	fall	B
18	of	B
19	1995	B
20	and	B
21	was	B
22	responsible	B
23	for	B
24	the	B
25	large	B
26	increase	I
27	in	I
28	meiofaunal	I
29	biomass	I
30	observed	I
31	after	I
32	spring	I
33	1996	B
34	.	B

1	Evidence	B
2	-	I
3	based	B
4	care	B
5	:	I
6	a	I
7	new	B
8	formula	B
9	for	B
10	an	B
11	old	B
12	problem	I
13	?	I

1	Nrf2	B
2	regulates	B
3	expression	B
4	of	B
5	genes	I
6	encoding	I
7	enzymes	I
8	with	I
9	antioxidant	I
10	(	I
11	e	I
12	.	I
13	g	I
14	.	I
15	heme	I
16	oxygenase	I
17	-	I
18	1	I
19	(	B
20	HO	B
21	-	I
22	1	B
23	))	B
24	or	I
25	xenobiotic	I
26	detoxification	I
27	(	I
28	e	I
29	.	I
30	g	I
31	.	I

1	Workload	B
2	,	B
3	UAPs	B
4	,	B
5	and	B
6	you	B
7	.	I

1	RESULTS	B
2	:	I
3	At	I
4	latest	I
5	examination	I
6	,	B
7	mean	B
8	UPDRS	B
9	II	B
10	and	I
11	III	B
12	scores	B
13	had	B
14	improved	B
15	by	B
16	30	I
17	%	I
18	(	I
19	on	B
20	stimulation	I
21	,	I
22	off	B
23	therapy	I
24	)	I
25	with	I
26	mean	I
27	50	I
28	%	I
29	reduction	I
30	in	I
31	daily	I
32	off	I
33	time	B
34	.	I

1	Perfusion	B
2	technique	I
3	for	B
4	perfusion	I
5	-	I
6	assisted	I
7	direct	B
8	coronary	I
9	artery	I
10	bypass	I
11	(	I
12	PADCAB	B
13	).	B

1	Copyright	B
2	2001	I
3	Academic	I
4	Press	I
5	.	I

1	The	I
2	amount	I
3	of	B
4	drained	I
5	effusion	I
6	was	I
7	measured	B
8	,	B
9	and	B
10	fluid	B
11	was	B
12	sent	B
13	for	B
14	diagnostic	B
15	assessment	B
16	.	B

1		B

